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ABSTRACT
There is mounting evidence that the neuropeptide oxytocin is a possible candidate for 
the treatment of drug addiction. Recently, it has been demonstrated that oxytocin can 
reduce methamphetamine self-administration, conditioned place preference and 
reinstatement of methamphetamine-seeking in rodents. Similarly, it has been shown that 
oxytocin has inhibitory effects on sensitisation, tolerance and self-administration of 
opioids and cocaine. However the mechanisms underlying the action of oxytocin on the 
addictive processes remain unknown.
This work aimed to identify an association between the oxytocinergic system and the 
emergence of emotional impairment (i.e. anxiety- and depressive-like behaviours and 
social deficits) during opioid withdrawal. It also aimed to elucidate whether an acute 
administration of the oxytocin analogue carbetocin is able to reverse this emotional 
impairment. Furthermore, this project investigated the effects of chronic opioid and 
psychostimulant administration and withdrawal on the central oxytocin receptor and 
peptide levels via quantitative receptor autoradiography and/or enzyme-linked 
immunosorbent assay, respectively.
Profound emotional deficits occured following prolonged morphine withdrawal, 
associated with a hypo-oxytocinergic state in the hypothalamus and a rebound up- 
regulation of the oxytocin receptor in the amygdala in a mouse model. Moreover, acute 
administration of carbetocin was able to completely reverse this enhanced depressive- 
like, anxiety-like and impaired social behaviour. Similarly, it was shown that chronic 
administration of cocaine and methamphetamine-induced marked up-regulation of
oxytocin receptor binding in the amygdala, which in the case of cocaine persisted 
following protracted withdrawal.
Collectively, the results described in this thesis highlight a common dysregulation of the 
oxytocinergic system induced by chronic opioid and psychostimulant exposure and 
abstinence. This dysregulation may at least partly underlie the emotional consequences 
of drug addiction. Additionally, this is the first study to support the oxytocinergic 
system as a novel target for the treatment of the emotional consequences of opioid 
abstinence. Since anxiety, mood and social impairment constitute motivational triggers 
to relapse during abstinence it is anticipated that an oxytocin-based pharmacotherapy 
may be able to assist with relapse prevention.
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CHAPTER 1 
General Introduction
1.1 Drug addiction in the United Kingdom
Drug addiction is a chronic relapsing brain disorder which has deleterious consequences 
on an individual’s physical and psychological health. Substance dependence has been 
characterised according to three different criteria: (1) compulsivity to obtain the drug 
despite the negative consequences, (2) loss of control upon drug administration and (3) 
emergence of negative physical and emotional symptoms following drug cessation 
(American Psychiatric Association, 2013).
Addiction to drugs of abuse has serious societal and economic consequences through 
criminality, decreased productivity and increased healthcare costs (see Schumacher et 
al., 2002). It is predominantly observed in the young adult population (16-24 year old) 
in the United Kingdom (U.K.). It has been reported that in 2012, 19.3% of the young 
adults had used an illicit drug (Home office, 2013). Class A drugs (e.g. lysergic acid 
diethylamide (LSD), cocaine, 3,4-methylenedioxy-A- methamphetamine (MDMA), 
methamphetamine (MAP), heroin) are considered to be the most addictive and harmful 
drugs for the user (Smith and Flatley, 2011) while during the last year 6.3% of the youth 
population has abused Class A drugs -  equating to around 0.4 million people in England 
(Home Office, 2013).
A serious consequence of abuse of illicit drugs is criminality (e.g. theft, burglary), with 
an associated annual cost for heroin and cocaine users estimated to reach £15 billion in 
the U.K. (Home Office, 2013). The U.K. government spends almost £15.4 billion per 
year tackling illicit substance use (National Audit Office, 2010). Importantly, the cost of 
healthcare services over the life-span of just one illicit drug user is estimated at £35,000, 
increasing to £480,000 per user when the crime-related cost is included (National 
Institute for Health and Clinical Excellence., 2009).
Drug abuse is also considered as a common cause of premature mortality, with illicit 
drug poisoning (overdose) accounting for approximately 12.5% of total deaths among 
people between 20-40 years old (Office of National Statistics, 2012). In fact, the U.K. 
has the fifth highest drug-related mortality rate in Europe according to the European 
Monitoring Centre for Drugs and Drug Addiction (2012) report.
1.2 Neurobiology of drug addiction
1.2.1 Addiction cycle
Addiction can be characterised as a cycle of neurochemical and psychological changes 
that bring about a shift from the impulsive use of a drug to the compulsive use (see 
Koob and Le Moal, 2008); also see Figure 1.1. Acute administration of all drugs of 
abuse activates the reward pathway of the brain, thus inducing hedonic effects that 
positively reinforce the user to repeat drug administration. Upon repeated use of the 
drug, neuroadaptive tolerance to the rewarding effects of the drug is developed 
therefore, an escalation of the dose is needed in order to achieve the same initial 
pleasurable effects (see Koob and Le Moal, 2001). During this period, positive 
reinforcement associated with acute drug administration is gradually replaced with 
negative reinforcement to prevent the emergence of a negative withdrawal syndrome 
upon drug cessation. Acute withdrawal from drug use causes unpleasant drug-specific 
physical symptoms that are short-lived. Drug users who have abstained from drug 
administration over a long period of time are still vulnerable to relapse to drug-seeking, 
particularly during re-exposure to the drug itself, previously drug-associated 
environmental cues and after stress-related conditions (see Koob and Le Moal, 2008).
Impulsive use Positive Reinforcement
Social Drug use
Euphoria
Tolerance
Escalating Use
Relapse
Acute
withdrawal
Protracted
withdrawal
D ependence ><—
Compulsive use Negative Reinforcement
Figure 1.1: The drug addiction cycle.
Upon administration, drugs o f abuse induce euphoric effects that positively reinforce the user to 
repeat drug use. Following repeated administration tolerance can be developed, meaning that 
increased amount o f a drug is needed to induce the initial pleasurable effects. Acute positive 
reinforcement is gradually replaced with negative reinforcement to prevent the emergence o f 
negative withdrawal symptoms following drug cessation. The acute impulsive use o f the drug 
becomes compulsive use. Even after long-term abstinence individuals are still vulnerable to relapse 
and re-take the drug. Modified from Le Moal and Koob, (2007).
The transition from impulsive (positive reinforcement) to compulsive (negative 
reinforcement) use of drugs of abuse drives the cyclic nature of drug addiction through 
three different stages: (1) binge/intoxication, (2) Avithdrawal/negative affect and (3) 
preocculation/anticipation (see Koob and Le Moal, 2008); also see Figure 1.2.
1.2.L1 Binge/intoxication stage
Upon acute administration all drugs of abuse activate the brain reward systems. The 
concept of an anatomical reward brain circuit emerged from the findings of Olds and 
Milner (1954), who demonstrated that rats would perform a task to acquire an electrical 
stimulation within specific brain regions. This finding was further supported by Phillips 
and Fibiger (1978) who proposed the existence of an intact dopaminergic (DAergic) 
system which is responsible for the rewarding effects of electrical brain stimulation. 
These findings established the basis for the dopamine (DA) theory of addiction.
Two ascending DAergic systems originating from the cell bodies of the ventral 
tegmental area (VTA) have been demonstrated, comprising the mesocorticolimbic 
DAergic system: the mesolimbic DAergic pathway innervates several limbic structures 
including the nucleus accumbens (Acb), ventral pallidum (VP), hippocampus (Hip), 
lateral septum (LS) and amygdala (Amy); and the mesocortical DAergic pathway 
innervating the prefrontal (PFC), the orbitofrontal (OFC) and the anterior cingulate 
cortices (see Feltenstein and See, 2008).
The mesolimbic pathway was postulated as the main pathway of convergence in 
addictive behaviours (see Nestler, 2005a), since both natural rewards, such as food and 
sex, and drug-induced reward acutely increase DA release in the Acb (part of the ventral 
striatum). The reward produced after the acute administration of drugs of abuse is more 
robust than those yielded by natural reinforcers (see Di Chiara and Bassareo, 2007). All 
drugs of abuse induce DA release; however, the mechanism of action of each drug is 
different. For example, psychostimulants, like cocaine and amphetamine, act directly on 
the Acb whereas opioids act on the VTA to disinhibit DA release (see Pierce and 
Kumaresan, 2006). The role of the mesolimbic DAergic pathway in the positive
reinforcing effects of drugs of abuse is further confirmed by microdialysis studies 
having reliably shown that extracellular DA concentrations in the Acb are increased 
during morphine, cocaine and amphetamine self-administration (Pettit and Justice, 
1989, Di Ciano et ah, 1995, Pontieri et al., 1995), and self-administration of a number 
of drugs of abuse is attenuated upon administration of DA receptor antagonists 
(Woolverton, 1986, Rassnick et al., 1992, Richardson et al., 1994) or neurotoxic 6- 
hydroxydopamine (6-OHDA) lesioning of the accumbal DAergic pathways (Roberts et 
al., 1980, Pettit et al., 1984, Zito et al., 1985). In addition to DA, other transmitter 
systems have been identified as key players in acute reinforcement of drugs of abuse, 
including the endogenous opioid system (see Koob and Voikow, 2010).
The ventral striatum (i.e. Acb) is predominantly involved in the acute reinforcing effects 
of drugs of abuse, while in contrast, the dorsal striatum (caudate putamen -  CPu) 
appears to be primarily recruited during the development of compulsive drug-seeking 
(Everitt et al., 2008). It is thus hypothesised that the transition from impulsive use of 
drugs of abuse to compulsive use is mediated by a ventral-to-dorsal striatum shift of 
drug-taking and seeking behaviour (Everitt et al., 2008).
L2.1.2 Withdrawal/negative affect stage
Increases in brain reward thresholds have been revealed after acute withdrawal from all 
drugs of abuse, as measured by direct “brain stimulation reward” (Markou and Koob, 
1991, Schulteis et al., 1995, Schulteis et al., 1994, Epping-Jordan et al., 1998, Gardner 
and Vorel, 1998, Paterson et al., 2000); also see Section 1.3. These findings may 
indicate decreases in the activity of several neurotransmitter systems that are implicated 
in the positive reinforcing effects of drugs. Indeed, not only has DA been implicated in 
the positive reinforcing effects of drugs of abuse but it has also been proposed to be
involved during drug -withdrawal. For example, acute withdrawal leads to disruptions in 
basal DAergic transmission, which has been proposed as a possible mechanism 
underlying drug craving (Weiss et al., 1996, Shen, 2003). Specifically, the opioid 
withdrawal syndrome has been shown to be associated with a remarkable decrease in 
DA release in the limbic forebrain of rats (Druhan et al., 2000). Therefore, the 
mesocorticolimbic DAergic system might also be involved in the negative reinforcing 
effects of the drugs of abuse (i.e. dysphoria, anxiety and stress). However, it has been 
shown that DAergic neurons respond to aversive stimuli either by activation, by not 
responding or by inhibition (Matsumoto and Hikosaka, 2009). For example, accumbal 
DA transmission was significantly increased under the aversive condition of social 
defeat stress in rats (Anstrom et al., 2009). Therefore, the exact role of the 
mesocorticolimbic DAergic system on the withdrawal-associated negative effects 
remains unclear.
The endogenous opioid system has been also implicated during drug abstinence. 
Specifically, enhanced sensitivity of opioid receptor transduction mechanisms was 
observed within the Acb during opioid withdrawal (Stinus et al., 1990). A candidate for 
the negative effects induced by drug abstinence is the opioid peptide dynorphin, an 
endogenous ligand for K-opioid receptors (KOPr) (see Wee and Koob, 2010). 
Dynorphin levels are increased in the Acb and Amy during opioid and cocaine 
withdrawal, and this overactivity of the dynorphin system reduces DAergic function 
which has been shown to induce aversive effects (see Wee and Koob, 2010).
The emotional impairment related to the withdrawal/negative affect stage may also 
involve neurochemical systems other than the ones involved in the positive 
reinforcement effects of addictive substances (Koob and Bloom, 1988). Several
functional observations have provided strong evidence for the existence of a common 
neurocircuitry within the basal forebrain underlying the aversive effects associated with 
drug withdrawal, termed the “extended amygdala” (see Koob, 2009). This circuitry is 
comprised of the central nucleus of the amygdala (CeA), the bed nucleus of the stria 
terminalis (BNST), and a part of the medial Acb (Heimer and Alheid, 1991).
During withdrawal from drug administration, the stress system, including the 
hypothalamic-pituitary-adrenal (HPA) axis and extended amygdala, mediated by the 
corticotropin-releasing factor (CRT), is activated with a common response of increased 
corticosterone and amygdalar CRT levels (Rivier et al., 1984, Merlo Pich et al., 1995, 
Koob et al., 1994, Rasmussen et al., 2000, Olive et al., 2002, Delfs et al., 2000); also see 
Section 1.2.2.1. Acute withdrawal from drugs may also increase the release of 
noradrenaline (NA) in the BNST (Roy and Pandey, 2002). These results suggest that 
during the development of dependence, not only alterations in the function of 
neurotransmitter systems associated with the acute reinforcing effects of drugs such as 
DA and opioid peptides, but also a recruitment of the anti-reward (e.g. dynorphin) and 
stress systems occurs (see Koob and Le Moal, 2001).
1.2.1.3 Preoccupation/anticipation stage
The preoccupation/anticipation stage of the addiction cycle has long been hypothesised 
to be a key element of relapse to drug-taking after abstinence and it is the stage that 
defines addiction as a chronic relapsing disorder. Although often linked to the construct 
of craving, drug craving per se has been difficult to investigate in clinical studies 
(Tiffany et al., 2000) and often does not correlate with relapse. Relapse to drug-seeking 
following abstinence can occur during re-exposure to the drug itself (drug-induced 
reinstatement), exposure to drug-associated environmental stimuli (cue-induced
reinstatement) or under stressful conditions (stress-induced reinstatement). Animal 
models of drug-craving following abstinence have been developed and used to 
investigate the neurobiological and behavioural mechanisms underlying relapse (see 
Section 1.3).
Drug-induced reinstatement has been shown to be localised to the VTA / PFC / Acb / 
VP circuit and to be possibly mediated by glutamate (McFarland and Kalivas, 2001). 
Specifically, neurotransmitter systems involved in drug-induced reinstatement implicate 
a glutamatergic projection firom the PFC to the Acb that is modulated by DAergic 
afférents from the VTA innervating the PFC (Krimer et al., 1997). Indeed, inactivation 
of these structures has been shown to prevent cocaine-primed reinstatement in rodents 
(McFarland and Kalivas, 2001).
In addition, neuropharmacological and neurobiological studies using animal models 
indicate the BLA as a critical substrate underlying cue-induced reinstatement of both 
cocaine- (Ciccocioppo et al., 2001, Kantak et al., 2002, McLaughlin and See, 2003) and 
opioid-seeking (Fuchs and See, 2002). Specifically, cue-induced reinstatement is 
hypothesised to involve DA modulation in the BLA (Berglind et al., 2006) and a 
glutamatergic projection to the Acb from both the BLA and ventral subiculum (Everitt 
and Wolf, 2002, Vorel et al., 2001, Shalev et al., 2002).
Stress-induced reinstatement of drug-related responding in animal models appears to 
depend on the activation of both CRF and NA in the extended amygdala (Shaham et al., 
2003, Shalev et al., 2002). For example, non-selective CRF antagonist injections into 
the BNST blocks footshock-induced reinstatement of cocaine-seeking in the self­
administration paradigm, whereas intra-BNST injections of CRF itself reinstated 
cocaine-seeking (Erb et al., 2001, Erb and Stewart, 1999). Similarly, injection of a CRFi
receptor antagonist into the BNST blocked footshock-induced reinstatement of opioid- 
seeking in rats (Wang et ah, 2006). Moreover, peripheral administration of Ui- 
adrenoceptor agonists, administered in doses sufficient to inhibit NA release, abolished 
footshock-induced reinstatement of cocaine-seeking in rats (Erb et ah, 2000) and 
systemic administration of an ui-adrenoceptor antagonist, yohimbine, reinstated MAP- 
seeking (Shepard et ah, 2004).
Witdrawal/ 
negative affect
Extended Amygdala (CeA, 
BNST)
Binge/
Intoxication
Mesolimbic DAergic oathwav
Preoccupation/
Anticipation
PFC, BLA
Figure 1.2: The three stages of addiction cycle.
Acute administration o f a drug o f abuse which involves the activation o f the mesolimbic DAergic 
pathway, reflects the binge/intoxication component o f the addiction cycle. Repeated administration 
of the drug brings about a shift towards the dorsal striatum. The withdrawal/negative affect stage is 
reflected by the activation o f the brain stress systems, such as CRF within the extended amygdala. 
Reinstatement to drug-seeking following abstinence is associated with the 
preoccupation/anticipation component o f the cycle which is primarily modulated by the PFC and 
BLA. Modified from Koob and Volkow (2010) and Koob and Le Moal (2001).
1 0
1.2.2 Addiction and stress systems
Stress has been defined as a non-specific, physiological response of the body 
characterised by several alterations including the activation of stress systems (Dunn and 
Berridge, 1990, Rivier and Plotsky, 1986). A key element of drug addiction responses 
involves a marked activation of hormonal (HPA axis), and brain (i.e. CRF, NA, 
dynorphin, vasopressin and orexin) stress systems. Brain stress systems are thought to 
be localised in the extended amygdala and to be involved in the modulation of the 
negative emotional state that drives the shift from impulsivity to compulsivity. Since 
part of this thesis investigates the effects of drugs on the HPA axis, the reader is 
directed to reviews by (Koob, 2008; 2009) for further information on the role of the 
brain stress systems in addiction.
L2,2.1 Hypothalamic-pituitaty adrenal axis
Exposure to stress activates the HPA axis (see Figure 1.3) by stimulating a cascade of 
events involving the release of CRF from the paraventricular nucleus (PVN) of the 
hypothalamus (Hyp) (Vale et al., 1981, Rivier and Vale, 1983). CRF acts at the level of 
the anterior pituitary by binding to CRFi receptors on corticotrope cells, thereby 
inducing the synthesis of proopiomelanocortin (POMC). Processing of POMC leads to 
the production of adrenocorticotropic hormone (ACTH), which is released into the 
systemic circulation, and by acting on ACTH receptors into the adrenal cortex 
stimulates glucocorticoid (cortisol in humans and corticosterone in rodents) synthesis 
and release into the circulatory system to modulate physiological events.
The HPA axis is finely tuned via a negative feedback mechanism by which 
glucocorticoids inhibit excessive HPA axis activation by reducing the synthesis and 
release of ACTH and CRF (see Whitnall, 1993). Vasopressin peptide, which is co­
l l
expressed with CRF in neurons of the PVN, is also regulated in response to stress and 
acts synergistieally with CRF to stimulate ACTH release (see Whitnall, 1993). For 
further information on the HPA axis the reader is directed to reviews by Smith and Vale 
(2006) and de Kloet et ah, (2005).
STRESS
Hypothalamus
CRF
AVP
Anterior Pituitary
POMC
ACTH
Adrenal gland
Glucocorticoids
Figure 1.3: Schematic representation of the Hypothalamic-Pitnitary-Adrenal axis.
In response to stress, neural inputs from the central nervous system converge on the paraventricular 
nucleus (PVN) o f the hypothalamus and induce the synthesis and release o f corticotropin-releasing 
factor (CRF), which in turn stimulates the synthesis and release o f adrenocorticotropic hormone 
(ACTH) from the anterior pituitary. ACTH stimulates the synthesis o f glucocorticoids. 
Glucocorticoids negatively feedback to the pituitary and hypothalamus to reduce the synthesis and 
release o f ACTH and CRF, respectively. Modified from Turnbull and Rivier (1999).
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Alteration of HP A axis activity is thought to be a common neurobiological mechanism 
underlying several addiction processes (Heinrichs and Koob, 2004, Marinelli and 
Piazza, 2002, Sinha, 2001). Clinical as well as pre-clinical studies have investigated the 
effects of opioids and psychostimulants on HPA axis activity (see Table 1).
In rodents, acute morphine elevates HPA axis activity (Nikolarakis et al., 1987), while 
acute morphine blocks HPA axis activation induced by stress (Zhou et al., 1999b), 
indicating a counter-regulatory role of opioids on the stress response. Serum cortisol 
levels are significantly decreased in chronic heroin addicts (Rasheed and Tareen, 1995); 
however, basal HPA axis activity is normalised in steady-state methadone-maintained 
patients (Kreek et al., 1984). In rats, chronic administration of morphine (Buckingham 
and Cooper, 1984) as well as steady-state methadone treatment replicated the 
normalisation of the HPA axis response (Zhou et al., 1996, Leri et al., 2012, Leri et al., 
2006, Leri et al., 2009), indicating the development of tolerance to the initial 
stimulatory effects of morphine. Following acute withdrawal from opioid 
administration, HPA axis activity is elevated in both humans (Cami et al., 1992, Beam 
et al., 2001) and animals (Houshyar et al., 2001), and it returns to basal conditions after 
protracted withdrawal (Houshyar et al., 2001, Cami et al., 1992).
In contrast to the inhibitory effects of opioids on HPA axis activity upon acute 
administration, cocaine increases HPA axis activity in humans. After a cocaine 
challenge ACTH levels are lower in cocaine-dependent than in occasional cocaine 
users, suggesting that chronic cocaine abuse induces tolerance to its initial stimulatory 
effects (Mendelson et al., 1998); however, both groups had significantly elevated 
ACTH levels compared to controls. Cocaine-addicted patients show persistent hyper­
activation of the HPA axis following both acute (Contoreggi et al., 2003, Buydens-
13
Branchey et al., 2002) and protracted drug abstinence (Wilkins et al., 2005); animal 
models of cocaine addiction confirmed these clinical data (see Table 1.1).
Similarly to cocaine, acute administration of amphetamine in rats induces a marked 
activation of HPA axis activity (Swerdlow et al., 1993, Knych and Eisenberg, 1979). In 
addition, protracted withdrawal from chronic amphetamine administration is followed 
by increased basal ACTH and corticosterone levels in rodents (Russig et al., 2003).
Acute MAP administration induces activation of the HPA axis in both humans (Fehm et 
al., 1984) and animals (Szumlinski et al., 2001). This hyperesponsiveness of the HPA 
axis persists following repeated administration of MAP in rats (Grace et al., 2008). In 
contrast with the sustained hyper-activation of the HPA axis following protracted 
withdrawal from cocaine and amphetamine, MAP abstinence has not been shown to 
alter basal cortisol and ACTH levels in humans (Zorick et al., 2011). Since the DAergic 
system is considered as a modulator of HPA axis activity (Van Craenenbroeck et al., 
2005, Radley et al., 2009, Asanuma et al., 2003), these discrepancies may be 
attributable to the magnitude of DA release induced by these drugs during withdrawal. 
Although there is evidence for differential influence of abstinence from these drugs of 
abuse on the extracellular DA levels within the striatum in rodents (Zhang et al., 2001), 
the exact mechanism underpinning the differences in HPA axis activity after protracted 
withdrawal from psychostimulants remain unknown and needs further elucidation.
Taken together, these results indicate that opioid and psychostimulant administration 
results in a profound dysregulation of HPA activation, which in the case of 
psychostimulants, persists following protracted withdrawal; thus, it might constitute a 
candidate mechanism to trigger relapse after abstinence.
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1.3 Behavioural paradigms used in drug addiction research
Understanding of the neurobiological alterations that occur during different phases of 
the addiction cycle has been mostly derived from the development of animal models 
(see Koob et ah, 2009); also see Table 1. Each of the three stages of the addiction cycle 
has been assessed in various animal models of drug addiction for the better 
understanding of the underpinning mechanisms by which drugs of abuse exert their 
neurochemical and behavioural effects.
Animal models for the binge/intoxication stage of the addiction cycle can be 
conceptualized as measuring acute drug rewarding effects. Validated models of reward 
and reinforcement include drug self-administration, conditioned place preference, and 
decreases in brain reward thresholds. Animal models for the study of 
the withdrawal/negative affect stage include conditioned place aversion (rather than 
preference), increased brain reward thresholds, and dependence-induced increases in 
drug-seeking. Animal models of drug craving (preoccupation/anticipation stage) involve 
reinstatement of drug-seeking following withdrawal from the drugs, by drug-associated 
or environmental cues linked to the drug, and by exposure to stressors (Shaham et al.,
2003). Since this thesis is focused on the depressive-, anxiety-like and social behaviours 
related to addiction, for further information on the behavioural paradigms used in drug 
addiction research the reader is directed to reviews by Heidbreder, (2011) and Lynch et 
al., (2010).
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Table 1.2: Behavioural paradigms used to study addictive-related behaviours in 
animal models
Stage of the addiction cycle Behavioural paradigms References
Binge / Intoxication
(Acute effects of drugs of 
abuse)
Brain stimulation reward Bain and 
Kometsky, 1989, 
Olds and Milner, 
1954
Conditioned-place preference Sanchis-Segura 
and Spanagel, 2006
Self-administration (intravenous 
or oral)
Collins et al., 1984, 
Hyytia et al., 1996
Drug discrimination Falk and Lau, 
1995, See et al., 
1999
Withdrawal / Negative 
Affect
(Effects of prolonged 
administration of drugs of 
abuse and withdrawal)
Brain stimulation reward Epping-Jordan et 
al., 1998
Conditioned-place aversion Funada and 
Shippenberg, 1996, 
Hand et ak, 1988
Self-administration Roberts et al., 1996
Drug discrimination Brandt and France, 
1998, Emmett- 
Oglesby et al.,
1990
Preoccupation / 
Anticipation
(Reinstatement)
Self-administration Stewart and Wise, 
1992
Conditioned-place preference Mueller and 
Stewart, 2000
Addiction is often characterised by three different stages; the binge/intoxication, 
withdrawal/negative affect and preoccupation/ anticipation stages. To examine the neurobiological 
and behavioural effects o f each o f these stages, several animal models have been developed 
Modified from Koob et al., (2009).
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1.4 Current pharmacotherapies for drug addiction
The hallmark in the treatment of drug addiction is the prevention of relapse following 
abstinence. As this thesis concentrates on opioids and psychostimulant drugs of abuse, 
current pharmacotherapies for nicotine and alcohol addictions will not be discussed.
Despite many years of extensive research, no effective pharmacotherapy currently exists 
for psychostimulant addiction (see Kampman et al., 2005). Indeed, drugs targeting 
DAergic transmission have been widely assessed as possible therapeutic interventions 
for the treatment of addiction to psychostimulant drugs both in pre-clinical and clinical 
trials. However, in humans the suggested treatments were not effective in reducing the 
reinforcing effects of the drugs (Haney et al., 2001).
For opioid addiction, current treatment strategies include substitution therapies that use 
partial opioid agonists including methadone (partial p-opioid receptor (MOPr) agonist), 
buprenorphine (partial MOPr and nociceptin receptor agonist and KOPr antagonist) and 
naltrexone (global opioid receptor antagonist) (see Stein et al., 2012). Methadone is the 
preferred drug for the treatment of opioid dependence due to its high bioavailability 
when taken orally; however, this drug has a substantial addiction liability itself making 
its availability highly controlled, thus reducing compliance (see Connock et al., 2007). 
Buprenorphine provides another possible treatment for opioid abusers with less 
euphoric effects than methadone (see Lintzeris et al., 2009). However, the safety of 
buprenorphine when administered along with other sedative substances such as alcohol 
is still unclear, and may also lead to death (see Lintzeris et al., 2009). Naltrexone is 
another medication used in opioid dependence treatment that does not display abuse 
potential (see Mannelli et al., 2011) and has been shown to reduce opioid use (Giordano 
et al., 1990). Nevertheless, this treatment has been linked with poor treatment retention
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and low patient compliance, mostly due to several side-effects associated with its use 
including depression and dysphoria (Crowley et al., 1985, Hollister et al., 1981). 
Finally, a buprenorphine-naloxone combination (called Suboxone) has been used as 
another strategy for the management of opioid addiction yielding some positive results 
in reducing heroin use (Rothman et al., 2000, McKeganey et al., 2013). Although 
naloxone has been shown to reduce abuse potential of buprenorphine (Alho et al.,
2007), reports of combined buprenorphine/naloxone abuse have been also reported 
(Robinson et al., 1993).
Recent clinical trials on the treatment of drug addiction have started to utilise vaccines 
for opioid and psychostimulant addiction with some promising therapeutic efficacy for 
the reduction of drug craving (see Shen et al., 2012). However, possible side effects and 
ethical implications may prevent these vaccines from being manufactured. Therefore, it 
is clear that novel, more effective pharmacotherapies are needed for the treatment of 
drug addiction, especially substances targeting relapse following abstinence.
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1.5 Comorbidity: drug addiction and other mental disorders
Drugs of abuse can cause users to experience several symptoms of other mental 
disorders, including anxiety, depression and social phobia (see National Institute on 
Drug Abuse, 2010). Comorbidity between mental and substance use disorders is highly 
prevalent worldwide. It has been estimated that 45% of the drug-dependent population 
has a comorbid psychiatric disorder, compared with 12% among the non-dependent 
population (Farrell et al., 2003). Moreover, drug-related mental disorders accounted for 
almost 6,640 hospitalised patients during 2012 in the U.K. (Office of National Statistics, 
2012).
This comorbidity might be caused by overlapping factors such as several 
neurobiological alterations in the brain, or genetic influences; however, the exact 
mechanisms underlying this comorbidity remain poorly understood. Several clinical 
studies have been conducted and a number of animal models have been developed to 
study the underlying neuroanatomical and neurochemical substrates of this comorbidity 
(see Aston-Jones and Harris, 2004, Harris and Gewirtz, 2005, Koob and Le Moal, 
2005). As the focus of this thesis involves co-occuring anxiety, depression and social- 
anxiety behaviours with drug addiction, comorbidity with schizophrenia, bipolar disease 
and other psychiatric disorders will not be discussed. For more information on these 
comorbidities, the reader is directed to reviews on this literature by Brown et al., (2012), 
Batel, (2000), Macdonald and Feifel, (2012) and Altamura, (2007).
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1.5.1 Anxiety
Substance use and anxiety disorders are considered two of the most widely prevalent 
disorders that are often comorbid and poorly treated (DuPont, 1995). This comorbidity 
is associated with negative outcomes and poor prognoses for the treatment of both 
disorders. Several clinical studies observed increased anxiety following chronic 
administration of heroin (Woody et al., 1975), cocaine (Roberts and Horton, 2003, 
Pettinati et al., 1989), amphetamine (Hohoff et al., 2005), MAP (Glasner-Edwards et al.,
2010) and MDMA (Milani et al., 2004). These findings are supported by pre-clinical 
data showing anxiogenic-like effects in animals upon administration of opioids 
(Rezayof et al., 2009), cocaine (Basso et al., 1999, Rogerio and Takahashi, 1992), 
amphetamine (Lin et al., 1999), MAP (Pometlova et al., 2012) and MDMA (Lin et al.,
1999), as measured by using the elevated plus-maze (EPM).
The anxiogenic effect of drugs of abuse has been shown to be associated with changes 
in the release of several brain neurotransmitters. For example, increased glutamate 
release in the brain was observed following administration of cocaine (Shoji et al., 
1997, Reid et al., 1997), amphetamine (Reid et al., 1997), MAP (Abekawa et al., 1994) 
and MDMA (Anneken and Gudelsky, 2012, Anneken et al., 2012) in rodents. Due to the 
ability of glutamate to induce anxiogenic-like behaviours it has been hypothesised that 
this induction of glutamate release may be involved in the anxiogenic effects of drugs of 
abuse (see Bergink et al., 2004). Nonetheless, opioid administration, acute and chronic, 
was shown to decrease the release of glutamate in the brain (Okura et al., 2007, Jin et 
al., 2006, Guo et al., 2005), suggesting that different mechanisms account for the 
anxiogenic mechanisms of each class of drugs of abuse.
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Anxiety profiles have been also observed in individuals abstinent from heroin (Powell 
and Taylor, 1992, Shi et al., 2009) and cocaine (Roberts and Horton, 2003). In animal 
studies, spontaneous withdrawal from opioids (Zhang and Schulteis, 2008, Schulteis et 
al., 1998, Lee et al., 2011), cocaine (El Hage et al., 2012) and MAP (Nawata et al., 
2012) has been shown to be accompanied by enhanced anxiety-like behaviour using the 
EPM (see Table 1.3).
Anxiety-like behaviour during abstinence is considered as a key vulnerability factor for 
relapse to drug-seeking. The most widely used psychological supportive treatment for 
anxiety-related behaviours following cessation of drug use is Relapse Prevention (RP) 
therapy based on Marlatt’s cognitive behavioural model (Marlatt and George, 1984). 
This programme focuses mainly on helping addicts to develop skills to cope with 
putative high-risk situations (such as anxiety-related situations) or cues associated with 
drug administration. However, a meta-analysis on the efficacy of this treatment strategy 
revealed poor effect on reducing substance use, but it showed high effectiveness for 
improvement in overall psychosocial adjustment (Irvin et al., 1999).
1.5.2 Depression
Co-occuring drug addiction and depressive-like symptoms are linked with poor 
treatment prognosis, including high rates of continued substance abuse and mental 
impairment (Alterman et al., 1996, Brooner et al., 1997, Kosten et al., 1986). It has been 
hypothesised that patients with depression may take advantage of the acute rewarding 
effects of the drugs of abuse to relieve their depressive state, which can lead to the 
development of dependence upon chronic administration (Markou et al., 1998). It is also 
known that chronic administration of drugs of abuse trigger neuroadaptational changes
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in the brain that might contribute to mood disturbances potentially leading to 
depression.
In humans, depressive symptoms and a subjective emotional distress state are 
commonly associated with withdrawal from opioids (Ritter, 2002) and cocaine (Dackis 
et al., 1987, Gawin and Kleber, 1986, Kosten and O'Connor, 2003). Animal models of 
addiction have confirmed clinical observations concerning increased depressive-like 
behaviour following withdrawal from drug administration. Specifically, several animal 
studies have reported increase forced-swim test (FST) immobility time during 
withdrawal from opioids (Anraku et al., 2001), cocaine (Filip et al., 2006, Perrine et al.,
2008) and amphetamine (Cryan et al., 2003), also see Table 1.3. The validity of using 
these animal models for the elucidation of the neurobiological changes associated with 
the development of depression during drug abstinence is supported by successful 
reduction of depressive-related behaviours using antidepressant administration during 
withdrawal from cocaine (Frankowska et al., 2010) and MDMA (Thompson et al.,
2004) in rodents.
Anhedonia, a key symptom of clinical depression, is widely modelled in animal models 
by using the sucrose preference and intracranial self-stimulation tests and reflect 
decreased interest in engaging in pleasure-seeking behaviour. Anhedonia-like 
behaviours have been reported in rodents withdrawn from opioids (Schulteis et al., 
1994), cocaine (Markou and Koob, 1992) and MDMA (Galineau et al., 2005, Straiko et 
al., 2007). There is evidence indicating that antidepressant treatments may be effective 
in reversing anhedonic effects induced by cocaine (Markou et al., 1992, Scheggi et al.,
2011). Similarly, amphetamine withdrawal has been shown to induce reward deficits 
(Kitanaka et al., 2008) such as decreased sucrose intake (Orsini et al., 2001, Der-
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Avakian and Markou, 2010) and elevated brain reward thresholds (Paterson et al.,
2000). These impaired behaviours were reversed by treatment with selective 
antidepressants (Harrison et al., 2001, Markou et al., 2005).
A possible mechanism linking depression and substance use disorders is decreased 
serotonergic system activity. Indeed, decreased function of the serotonin (5- 
hydroxytriptamine, 5-HT) system has been implicated in increased vulnerability to the 
development of depression, stress and social impairment (Albert et al., 2012, Kane et 
al., 2012). Similarly, this hypo-activity of the serotonergic system is involved in 
emotional deficits following withdrawal from drugs of abuse; opioid and 
psychostimulant withdrawal were shown to supress 5-HT release in the brain (see Kirby 
et al., 2011). Moreover, social isolation, which has been associated with depressive 
behaviours, has also been repeatedly shown to induce a hypo-serotonergic state 
(Muchimapura et al., 2003, Muchimapura et al., 2002, Bickerdike et al., 1993, Fulford 
and Marsden, 1998). Selective serotonin reuptake inhibitors (SSRIs), which increase 
serotonergic activity in the brain (see Costagliola et al., 2008), have been used in 
clinical trials for the treatment of depressive consequences of addiction. However, 
fluoxetine, an SSRI drug, yielded negative results in the alleviation of the depressive 
symptoms in a tri-morbid population of depressed cocaine/alcohol abusers (Cornelius et 
al., 1998) and depressed methadone-maintained opioid patients (Petrakis et al., 1998). 
Also, several other studies have failed to support the effectiveness of classic 
antidepressants for the treatment of drug-addicted individuals (e.g. Johnson et al., 1996, 
Lima et al., 2001, Nunes et al., 2004).
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1.5.3 Anti-social behaviours
The anti-social consequences of drug addiction are considered important for the 
development of novel pharmacotherapies for drug addiction treatment. Anti-social 
behaviours and drug use are linked and comorbidity between these two is common. It 
has been reported that almost 80% of prisoners have a history of illicit substance use 
and many are imprisoned for anti-social acts under the influence of an addictive 
substance (e.g. Dolan et al., 2007).
Early clinical studies reported that heroin addicts showed social isolation behaviours, 
which persisted following abstinence (Tokar et al., 1975), comprising a motivational 
trigger to relapse and re-take the drug. In parallel, chronic cocaine (Myrick and Brady, 
1997), amphetamine (Williams et al., 2000) or MAP (see Homer et al., 2008) induce 
social phobia in humans. Additionally, cocaine has been found to reduce social 
interaction in both humans (Brower et al., 1988, Resnick and Resnick, 1984, 
Weddington, 1993) and animals (Darmani et al., 1990, Hadfleld et al., 1982).
Social isolation and social withdrawal behaviours have been proposed to be at least 
partially mediated via a hypo-DAergic state in the brain. Indeed, hypo-DAergic activity 
within the striatum has also been observed in social phobia (Schneier et al., 2000). It is 
also well known that chronic administration of drugs of abuse induces the depletion of 
DA levels in the striatum (e.g. Wilson et al., 1996). In addition, positron emission 
tomography (PET) studies in humans have consistently demonstrated decreased striatal 
DA D2 receptor levels in heroin, cocaine and MAP addicts (Volkow et al., 1996, 
Voikow et al., 1997, Wang et al., 1997, Volkow et al., 2001), a finding which has been 
shown to persist following drug detoxification (see Volkow et al., 2004). Also, 
decreased D% receptor levels are observed following chronic cocaine self-administration
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in monkeys (Moore et al., 1998, Nader et al., 2002) and low D2/D3 number in the 
ventral striatum of impulsive rats predicts their vulnerability to escalate cocaine intake 
(Dailey et al., 2007). Taken together, these findings might suggest that chronic illicit 
drug use can lead to the development of social phobia via the disruption of the DAergic 
system and more specifically the D2 receptors. Recently, use of D2 receptor partial 
agonists, such as aripiprazole, have shown some pre-clinical benefit in reducing MAP 
self-administration (Wee et al., 2007) and preventing cocaine reinstatement (Feltenstein 
et al., 2007) in rodents. However, the clinical efficacy of aripiprazole in treating drug 
addiction is currently unclear (Meini et al., 2011, Haney et al., 2011).
1.5.4 Treatment of addiction and comorbid mental disorders
Many drug abusers have been diagnosed with at least one other mental disorder, such as 
schizophrenia, bipolar disease, depression, anxiety and anti-social behaviours. This 
comorbidity has been shown to cause poorer drug treatment outcomes and to increase 
vulnerability to relapse following abstinence from drug use.
It has been shown that medications for the treatment of emotional disorders alone are 
not likely to completely reduce substance use or help abstinence in dually diagnosed 
individuals (see Riggs, 2003). Evidence supports the efficiency of psychosocial support 
in the treatment of drug addiction and the maintenance of abstinence (Koemer, 2010). 
Accumulating evidence shows a strong interaction between neuronal markers of social 
behaviour and those of stress and mood regulation (Dabrowska et al., 2011, Debiec, 
2005, Di Simplicio et al., 2009, Heinrichs and Gaab, 2007, Windle et al., 2004) and of 
drug reward/withdrawal (Liu et al., 2011, Young et al., 2011), suggesting that the 
“social” neuropeptide oxytocin (OT) and its central receptor system may be implicated 
in the modulation of negative emotional aspects of drug addiction. Therefore, the focus
36
of this project will be the effects of oxytocin in opioid and psychostimulant addiction 
processes.
37
1.6 The oxytocin neuropeptide
Oxytocin is a nine amino-acid peptide (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly) 
synthesised within several neuronal populations in the brain and peripheral tissue. The 
OT gene (Figure 1.4) was sequenced in 1984 (Iveil and Richter, 1984b) and was the 
first peptide hormone to be chemically synthesised in biologically active form (Du 
Vigneaud et al., 1953). The mouse OT gene, coding for a prepropeptide, consists of two 
introns and three exons (Kara et al., 1990), similar to those observed in humans 
(Sausville et al., 1985) and rats (Ivell and Richter, 1984b). The first exon encodes for a 
translocator signal, the oxytocin peptide, the tripeptide processing signal (GKR) and the 
first nine residues of neurophysin; the second exon encodes the central part of the 
neurophysin protein; and the third exon encodes the C-terminus of neurophysin (Kara et 
al., 1990).
CHRE
M ouse -174bp GATGACCTTGACC 
Rat -168bp GGTGACCTTGACC 
Human -164bp GGTGACCTTGACC
prornoter
intron 1 intron 2
exon 1 exon 2 exon 3
B
exon 1  exon 2---------  exon 3------ >
NHz- Signal OT GKR Neurophysin -COOH
Figure 1.4: Structure of the oxytocin gene.
(A) Oxytocin gene structure showing exons and introns. The composite hormone response element 
(CHRE) is given for mouse, rat and humans with their relative positions upstream (-). (B) Domain 
organisation o f the prepropeptide o f oxytocin. Enzymes cleave the precursor into fragments, one 
involving a glycyl-lysyl-arginine (GKR) sequence leaving a carboxamide group at the carboxy- 
terminus. Modified from Gimpl and Fahrenholz, (2001).
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OT is enzymatically cleaved from the prepropeptide and has functional signalling 
activity following extracellular release. Neurophysin, a small disulfide-rich protein, is 
essential for the proper targeting, packaging and storage of OT prior to its release into 
the bloodstream (Breslow, 1979).
1.6.1 Oxytocin as a neuromodulator in the central nervous system
The neuropeptide OT is primarily synthesised in the magnocellular neurosecretory cells 
of the supraoptic (SON) and paraventricular (PVN) nuclei of the Hyp (Figure 1.5); it is 
then transported to the posterior pituitary gland where it is stored in vesicles and is 
released into the bloodstream to exert its peripheral effects. Additionally, OT is also 
synthesised in the parvocellular neurons of the PVN which innervates several 
extrahypothalamic regions in the central nervous system (CNS) including the olfactory 
nuclei, frontal and cingulate cortices, Acb, LS, vertical limb of the diagonal band of 
Broca (VDB), Amy, BNST and also the brainstem and spinal cord (Badoer, 2001, Mack 
et al., 2002, Petersson, 2002, Sofroniew and Weindl, 1978, Tang et al., 1998). OT exerts 
several central effects through binding to oxytocin receptors (OTR) in these brain areas 
(Baskerville and Douglas, 2010, Fuxe et al., 2012, Meyer-Lindenberg et al., 2011, 
Rutherford et al., 2011).
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FCx CgCXOB
PA<BNST
CPU :DR
PVN
SolSON
VDB
Amy
Figure 1.5: Prominent oxytocinergic projections in the brain of rodents.
Oxytocin is primarily synthesised in the magnocellular neurosecretory cells in the supraoptic (SON) 
and paraventricular (PVN) nuclei; it is then transported to the posterior pituitary gland where it is 
stored in vesicles and is released into the bloodstream to exert its peripheral effects. Moreover, OT is 
also synthesised in the parvocellular neurons of the PVN, which innervate several extrahypothalamic 
regions in the CNS, including the olfactory nuclei, the nucleus accumbens, the lateral septum, the 
amygdala, bed nucleus of the stria termnalis, and also to the brainstem and spinal cord, to exert its 
local effects. ( * —  magnocellular neurons; 9 parvocellular neurons)
Abbreviations: Acb, nucleus accumbens; Amy, amygdala; BNST, bed nucleus o f stria terminalis; 
CgCx, cingulate cortex; CPu, caudate-putamen; DR, dorsal raphe nucleus; FCx, frontal cortex; LS, 
lateral septum; NT, neural lobe of the pituitary; OB, olfactory bulb; PAG, Periaqueductal gray; PVN, 
paraventricular hypothalamic nucleus; Sol, Solitary tract nucleus; SC, spinal cord; SON, supraoptic 
hypothalamic nucleus; Th, thalamus; Tu, olfactory tubercle; VDB, vertical limb of the diagonal band 
of Broca. Figure founded on Baskerville and Douglas, (2010) , Fuxe et al., (2012), Meyer- 
Lindenberg et al., (2011).
Importantly, OT is released from neuronal dendrites and cell bodies in the PVN and 
SON, where it is considered to impact on a broad network of extra-hypothalamie brain 
regions via volume transmission (see Landgraf and Neumann, 2004). There is evidence 
suggesting that OT can be also locally released in several brain regions including the 
BNST, medial preoptic area (MPOA), and lateral part of the Amy (Young and Gainer, 
2003). However, there is continued disagreement as to whether OT released in these 
extra-hypothalamie brain areas comes from the dendrites of unidentified OT cell bodies 
or from axonal projections-volume transmission from OT-containing neurons in the
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PVN (see Neumann, 2007). There is also some evidence that scattered OT fibers 
projecting from magnocellular hypothalamic neurons lie in diverse brain regions 
including the Hip, cortex, Amy, substantia nigra (SN), VTA, dorsal raphe nucleus (DR), 
locus coeruleus, and densely throughout the brain stem and spinal cord (Sofroniew, 
1983, Sofroniew, 1980).
Oxytocin peptide is known for its peripheral actions, reflecting its release into the 
bloodstream from the pituitary gland. Two of the classical roles assigned to OT is milk 
ejection from the mammary gland and uterine contraction to induce labor (see Gimpl 
and Fahrenholz, 2001). In addition to its peripheral actions, OT exerts several central 
effects by binding to OT receptors (OTR) expressed in the CNS; see Section 1.6.2. 
Indeed, the activation of OT receptors in the brain has been shown to be involved in a 
range of behaviours including autonomic function (Badoer, 2001, Mack et al., 2002, 
Petersson, 2002, Tang et al., 1998), social/sexual (Argiolas, 1999, Argiolas and Melis, 
2004, Insel et al., 1997, Kendrick, 2000, Kendrick, 2004), anxiety-, depressive- and 
psychotic-like behaviours (Baumgartner et al., 2008, Dabrowska et al., 2011, Di 
Simplicio et al., 2009, Kirsch et al., 2005, Rosenfeld et al., 2011, Windle et al., 2004). 
For further elucidation of the functions of the oxytocinergic system, both oxytocin 
peptide knockout and oxytocin receptor knockout mice have been developed (see 
Sections 1.8.4 and 1.8.5, respectively).
1.6.2 Oxytocin receptors
The OTR gene sequence has been identified in several mammalian species including 
human (Kimura et al., 1992), rat (Rozen et al., 1995), sheep (Ivell and Richter, 1984a) 
and mouse (Kubota et al., 1996). Similarly to the human (Inoue et al., 1994) and the rat 
(Rozen et al., 1995), the mouse OT receptor gene contains 3 introns and 4 exons 
(Kubota et al., 1996); also see Figure 1.6. Exons 1-2 correspond to the 5’-prime non­
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coding region. Exon 3 encodes a portion of the 5’-prime non-coding region, the start 
codon ATG, and the first 6 of the 7 transmembrain domains of the OTR. Exon 4 
encodes the seventh transmembrain region, the stop codon TGA, the carboxyl terminal 
and the 3’-prime non-coding region (Kubota et al., 1996).
I n tr o n  In tr o n I n tr o n
3
E xon E x o nE xonE xon
VL TGAv nm JVATG
Figure 1.6: Organisation of the mouse oxytocin receptor gene.
The oxytocin receptor gene consists o f 4 exons and 3 introns. The seven trans-membrain domains (I- 
VII) are indicated as well as the start (ATG) and the stop (TGA) codons o f the gene. Modified from 
Gimpl and Fahrenholz, (2001).
The OTR belongs to the G protein-coupled receptor (GPCR) superfamily and it is 
functionally coupled to Gq/na class GTP binding proteins, stimulating the activity of 
phospholipase C (PEC) (Kimura et al., 1992); also see Figure 1.7. This effect leads to 
the generation of inositol triphosphate (IP3) and 1,2-diacylglycerol (DAG). IP3 diffuses 
into the cytosol and, through its binding to calcium channels on the endoplasmic 
reticulum (ER), allows the release of calcium. In neurosecretory cells, rising calcium 
levels control neuronal excitability, modulate their firing patterns and lead to 
neurotransmitter release (see Berridge, 1998). DAG, in the presence of calcium, directly 
activates protein kinase C (PKC), which then phosphorylates several proteins.
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Figure 1.7: Oxytocin receptor transduction mechanism and second messenger control of 
cellular effector systems.
Activation o f the OTR by OT leads to the activation o f phospholipase C, resulting in the generation 
of phosphatidylinositol biophosphate and 1,2-diacylglycerol. Phosphatidylinositol biphosphate is 
cleaved to activate inositol triphosphate, which releases intracellular calcium from the endoplasmic 
reticulum. 1,2-diacylglycerol stimulates protein kinase C, which in turn is responsible for the 
phosphorylation o f several other proteins in the cell. Abbreviations: Ca^ ,^ calcium; DAG, 1,2- 
diacylglycerol; GDP, guanine diphosphate; GTP, guanine triphosphate; IP3, inositol triphosphate; P, 
phosphate; PIP2, phosphatidylinositol biophosphate; PKC, protein kinase C; PLC, phospholipase C; 
OT, oxytocin; OTR, oxytocin receptor. Modified from Tom and Assinder, (2010).
Primary cell culture experiments indicate that OTRs are localised not only on
hypothalamic neurons but also on astrocytes in rats (Di Seala-Guenot and Strosser,
1992). Concerning the regional distribution of OTR binding sites in the brain, critical
species differences have been observed (see Table 1.4).
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Table 1.4: Distribution of oxytocin receptors in the brain of different species
Brain Regions Human Rat M ouse
Olfactory system
Anterior olfactory nucleus N/R + + + +
Olfactory tubercle N/R + + N/R
Islands o f  Calleja + + + + -
Piriform cortex N/R N/R + + +
Entorhinal/perirhinal area - + N/R
Cortical areas
Peduncular cortex +/- + + + N/R
Insular cortex N/R + N/R
Cingulate cortex N/R - -
Frontal cortex - +/- N/R
Temporal cortex - + N/R
Taenia tecta N/R +/- -
Ventral limb o f  the Diagonal band 
o f Broca
+ N/R N/R
Basal nucleus o f  Meynert + + + - N/R
Basal sanglia
Caudate putamen - + + N/R
Ventral pallidum + + + + + N/R
Glopus pallidus + + - N/R
Nucleus Accumbens - + N/R
Limbic system
Lateral septum + + + + + + +
Bed nucleus o f  stria terminalis - + + + -
Amygdaloid-hippocampal area - + N/R
CAl region o f  Hippocampus N/R N/R -
CA3 region o f  Hippocampus N/R - + + +
Central amygdaloid nucleus - + + + -
Medial amygdaloid nucleus - + +
Basolateral amygdaloid nucleus - + + +
Parasubiculum and presubiculum - + + -
Dorsal subiculum - +/- -
Ventral subiculum - + + + -
Thalamus and hypothalamus
Anteroventral thalamic nucleus - - N/R
Paraventricular thalamic nucleus + + + + +
Ventromedial hypothalamic 
nucleus
- + + +
Anterior medial preoptic area + + - N/R
Supraoptic nucleus - +/- N/R
Paraventricular nucleus - +/- N/R
Medial tuberal nucleus + + + N/R
Posterior hypothalamic area + + - N/R
Supramammillary nucleus - + N/R
Lateral mammillary nucleus + + + N/R
Medial mammillary nucleus + - N/R
Brain stem
Substantia nigra + + + - N/R
Ventral and dorsal tegmental area - - N/R
Central gray + - N/R
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Dorsal raphe nucleus + - N/R
Reticular nuclei - - N/R
Medial vestibular nucleus - - N/R
Hypoglossus nucleus + + - N/R
Nucleus of the solitary tract + + + +/- N/R
Dorsal motor nucleus of the vagus 
nerve
+ + N/R
Inferior olive nucleus +/- + N/R
Substantia gelatinosa of trigeminal 
nucleus
+ + + + N/R
OT receptor binding levels in the brain o f humans, rats and mice. There is a high diversity o f OT 
receptor distribution between different species. The data have been derived from Adan et al., (1995), 
Freund-Mercier et al., (1994), Elands et al., (1988), Freund-Mercier et al., (1987), Gimpl and 
Fahrenholz, (2001), Klein et al., (1995), Kremarik et al., (1993), Loup et al., (1991), Loup et al., 
(1989), Shapiro and Insel, (1989), Tribollet et al., (1990), Tribollet et al., (1997), Tribollet et al., 
(1992a), Tribollet et al., (1988), Tribollet et al., (1992b), Yoshimura et al., (1996), Yoshimura et al., 
(1993), Insel et al., (1993), Jarrett et al., (2006), Curley et al., (2009).
+, low binding; ++, moderate binding; +++, high binding; +/- at the detection limit; -, not detectable; 
N/R, not reported.
The OTR is widely distributed throughout the brain. Species differences exist in the 
OTR distribution and these differences are thought to elucidate several discrepancies in 
behaviour. In rats, OTR are especially prominent in the olfactory system, peduncular 
cortex, ventral pallidum, subiculum, BNST and amygdaloid nuclei (e.g. Jarrett et al., 
2006, Ostrowski, 1998, Tribollet et al., 1992b). In mice, OTR binding is more abundant 
within the olfactory nucleus, LS, Pir, hippocampal formation (especially CAB region) 
and PVN (e.g. Curley et al., 2009, Insel et al., 1991, Insel et al., 1993). In humans, high 
expression is found in the basal nucleus of Meynert, LS, VP, VDB, posterior 
hypothalamic area, SN, Sol and substantia gelatinosa of trigeminal nucleus (Loup et al., 
1991, Loup et al., 1989). In parallel, OTR mRNA was detected in brain areas that 
mostly coincided with the occurrence of OTR binding sites (Yoshimura et al., 1993).
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1.6.3 Oxytocin and the blood-brain barrier
Evidence suggests that central and peripheral OT can be independently regulated, 
meaning that plasma OT may provide a poor proxy for central oxytocinergic tone 
(Neumann et al., 1993a) due to the presence of the blood-brain barrier (BBB). This 
barrier’s limited permeability prevents numerous substances such as many drugs and 
endogenous chemicals from entering the brain. OT, being non-steroid and water 
soluble, is carried freely within the blood circulation; however, peptides have limited 
ability to cross the BBB; -0.1% of systemic OT enters the brain (Jones and Robinson, 
1982).
Nevertheless, there is some evidence suggesting that the OT peptide might cross the 
BBB. It has been shown that peripheral injections of OT can mirror some effects seen 
after central administration of the peptide. For example, in Mongolian gerbils, 
affiliation between monogamous females and their partners was significantly increased 
upon subcutaneous injections of OT (Razzoli et al., 2003). Having a short plasma half- 
life (3-5 minutes), OT’s prolonged effects remain unclear (Uvnas-Moberg, 1998, 
Engstrom et al., 1998). It might be possible that OT can cross the BBB via the 
circumventricular region which allows a less restricted transport of molecules into the 
brain (see Ermisch et al., 1985). Another possible mechanism by which systemically 
administered OT may affect the CNS is via the formation of active fragments that may 
have the cabability to cross the BBB. In fact, fragments of OT have been found to cross 
the BBB and regulate several memory processes (Burbach et al., 1983). Once in the 
brain, OT may bind to OTRs on OT-containing neurons in the PVN and SON; thus, 
even small quantities may stimulate the release of significant quantities of endogenous 
OT to trigger a feed-forward response (Rossoni et al., 2008).
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In addition, OT, when peripherally administered in rats, increased c-Fos expression in a 
number of brain regions including the SON, PVN, Ce A, lateral parabrachial nucleus, and 
the locus coeruleus (Hicks et al., 2012). These are all OTR-dense brain regions which are 
implicated in a number of physiological processes including reproduction, anxiety, water 
balance, blood osmolality, and sleep. A double-labeling approach showed that 
peripherally administered OT increased c-Fos activation within OT-containing neurons 
of the PVN and SON, further supporting previous observations that OT is capable of 
stimulating its own release from central sites (Moos et al., 1984). Moreover, some effects 
of peripheral OT administration were abolished by central administration of OTR 
antagonists (e.g. Kovacs et al., 1998). Finally, intranasal administration of OT decreases 
Amy activation in response to fear in humans (Kirsch et al., 2005).
1.6.4 Oxytocin peptide knockout mice
Currently there are three different versions of the oxytocin deficient mouse (OT' '^): (1) 
Gross et al., (1998) replaced all the three exons of the mouse OT peptide gene, thus 
eliminating the prepropeptide-neurophysin coding sequence. (2) Nishimori et al., (1996) 
deleted the first exon of the OT gene via homologous combination in embryonic stem 
cells. This deletion resulted in the elimination of the initiation ATG codon, the 
processing signal, the OT peptide, and the first few amino acids of neurophysin. (3) 
Young et al., (1996) replaced the second and third exons of the OT gene by using a 
neomyocin resistance cassette, resulting in the deletion of the carrier polypeptide. 
Therefore, although OT is transcribed normally, it is not packaged or transported out of 
the cell. The deletion of the first exon has not been shown to affect arginine vasopressin 
mRNA, while in comparison, deletion of the second exon slightly decreased it. The 
distribution and the concentration of the OTRs were unaffected in these transgenic 
mice. Therefore, pre-synaptic OT is not necessary for the normal neuroanatomical
47
distribution of OTRs and subsequently does not affect the species differences in OTR 
distribution in the brain. OT' '^ mice are phenotypically healthy mice and both male and 
female mice are fertile (see Winslow et ah, 2000). However, these mice appear to have 
differential behaviours compared to wild-types (see Table 2), i.e. deficits in social 
recognition, reduced aggression but normal social interaction behaviours (Winslow et 
al., 2000, Ferguson et al., 2000, Crawley et al., 2007).
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Table 1.5: Oxytocin peptide knockout mice and behaviour
Behavioural
paradigm
Gender, age, 
background
Behavioural
effects
Reference
Social recognition 
test
Male OT^' (Nishimori’s 
model), 129SvEvx 
C57BL/6J, 8-9 weeks old
1 social
recognition
memory
Ferguson et ah, 
2000)
Isolation-induced
aggression
Male OT^' (Nishimori’s 
model), 129SvEvx 
C57BL/6J, 7 weeks old
t  aggression Winslow et ah, 
2000
Resident-intruder
aggression
Male OT'^'(Nishimori’s 
model), 129SvEvx 
C57BL/6J, >7 weeks old
t  aggression Winslow et ah, 
2000
Acoustic startle Male OT'^'(Nishimori’s 
model), 129SvEvx 
C57BL/6J, >7 weeks old
1 acoustic startle 
response
Winslow et ah, 
2000
Elevated plus- 
maze
Male OT’^ '(Nishimori’s 
model) 129SvEvx 
C57BL/6J, >7 weeks old
1 anxiety-related 
behaviour
Winslow et ah, 
2000
Elevated plus- 
maze
Female O T ' (Young’s 
model), C57BL/6J
t  anxiety-related 
behaviour
Amico et ah, 
2004
Open-field test Female and Male OT^' 
(Young’s model), 
C57BL/6J, 11-15 weeks 
old
locomotion Crawley et ah, 
2007
Open-field test Male OT'^'(Nishimori’s 
model), 129SvEvx 
C57BL/6J, 4-5 weeks 
old
1 time in center Crawley et ah, 
2007
Open-field test Female O T'' 
(Nishimori’s model), 
129SvEvxC57BL/6J, 
4-5 weeks old
time in center Crawley et ah, 
2007
Accelerating rota- 
rod test
Male and Female OT' ' 
(Nishimori’s model) 
129SvEvxC57BL/6J, 
4-5 weeks old
motor
coordination
Crawley et ah, 
2007
Social interaction 
and preference for 
novelty tests 
(three-chambered 
box)
Male OT'^'(Young’s 
model), C57BL/6J, 11-15 
weeks old
social 
interaction or 
preference for 
novelty
Crawley et ah, 
2007
Social interaction 
and preference for 
novelty tests 
(three-chambered 
box)
Male and Female OT' ' 
(Nishimori’s model) 
129SvEvxC57BL/6J, 
4-5 weeks old
<-> social 
interaction or 
preference for 
novelty
Crawley et ah, 
2007
Mice with targeted mutation in the OT peptide gene showed deficits in social memory, decreased 
aggression, and normal sociability behaviours
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1.6.5 Oxytocin receptor knockout mice
In order to elucidate the central effects of the oxytocinergic system, two different types 
of OTR knockout (OTR'^‘) have been generated: (1) global OTR knockout mice 
(Takayanagi et ah, 2005, Lee et a l, 2008), and (2) mice lacking the OTR only in the 
forebrain -  conditional OTR^ ®'^ ® mice (Lee et ah, 2008). Male OTR''" mice pups 
generated by (Takayanagi et al., 2005) produced less ultrasonic vocalizations than wild- 
type littermates in response to social isolation (indicating decreased distress following 
social isolation). Adult mice of the latter strain displayed social amnesia and increased 
aggressiveness as measured by the social discrimination and resident-intruder 
aggression tests respectively (Takayanagi et al., 2005). The conditional knockout 
model has been shown to have reduced OTR binding on postnatal day 21 in forebrain 
regions, including the central and medial amygdala, the Hip, the piriform and perirhinal 
cortices (Pagani et al., 2011). Macbeth et al., (2009) investigated the performance of 
both strains of OTR knockout mice in a social discrimination test and showed that 
OTR"'" male mice were unable to discriminate individuals of the same strain but were 
capable to discriminate between females from different strains. This discrimination was 
not replicated in OTR^ ®'^ ® mice. Possible reasons for this difference may rely on the 
spatial or temporal differences in diminished OTR expression between these two types 
of OTR knockout mice, as for instance postnatal delay and incomplete loss of forebrain 
binding in the OTR^ ®'^ ® strain.
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1.7 Oxytocin and emotions
Oxytocin, via its action on the OTRs in the brain, is involved in the regulation of a wide 
variety of CNS behaviours including sexual behaviour, maternal care and aggression, 
pair bonding, social behaviour, stress-related behaviour including anxiety and 
depression, learning and memory (see Neumann, 2008, Gimpl and Fahrenholz, 2001). 
This thesis concentrates on the role of OT in anxiety, depression and social behaviours, 
and the reader is directed to reviews on the central effects of OT by Gimpl and 
Fahrenholz, (2001), Wojciak et al., (2012) and Garrison et al., (2012) for further 
information.
1.7.1 Anxiety
Peripheral and central OT administration has been shown to reduce both hormonal 
stress-response of the HPA axis and anxiety levels (Neumann et al., 2000a). Numerous 
studies in mice and rats have illustrated the anxiol>4ic effects of OT. For instance, 
chronic infusion of synthetic OT into the lateral ventricles of female rats decreased the 
corticosterone response to psychogenic stress and reduced anxiety-related behaviour 
(Windle et al., 1997). Similarly, intracerebroventricular (i.c.v.) OT administration 
attenuated the high anxiety levels of rats selectively bred for high-anxiety behaviour 
(HAB), while infusion of an OT antagonist increased the anxiety levels of rats with 
low-anxiety behaviour (LAB) (Slattery and Neumann, 2010a), suggesting an anxiolytic 
effect of OT. Moreover, central administration of the OT analogue, deamino-1- 
monocarba-(2-0-methyltyrosine)-oxytocin (carbetocin, CBT), had profound anxiolytic 
effects in the rat (Mak et al., 2012). Interestingly, not only does central administration 
of OT exert anxiolytic effects, but peripheral administration of synthetic OT during 
adolescence also induces persistent reductions in the anxiety-like behaviour in rats as 
measured by the EPM (Bowen et al., 2011). Additionally, OT knockout mice showed
51
enhanced anxiety-like behaviours, increased corticosterone levels and higher markers of 
neuronal activity {c-Fos expression) in brain regions related with stress and anxiety (i.e., 
the Amy) after exposure to a stressor (Amico et al., 2004). These effects of OT in 
rodents have been shown to involve the OTR system in the CeA and the hypothalamic 
PVN in the brain since local microinjection of a selective OTR antagonist in these two 
areas was able to reverse anxiety-related behaviours (Neumann et al., 2000b, Neumann, 
2002, Blume et al., 2008, Bale et al., 2001).
Similar to the animal studies, it has been suggested that OT may also decrease stress 
and HPA axis activity in humans. Studies examining OT’s effects on HPA axis activity 
and stress in humans were originally conducted in lactating women. During lactation, a 
time when circulating OT levels are high, women exhibited lower ACTH levels, 
indicating a decreased HPA axis activity, and lower cortisol levels after physical stress 
compared to non-lactating controls (Altemus et al., 1995, Bartz and Hollander, 2006). In 
another study, lactating women were randomly assigned to either hold or breast-feed 
their infant before undergoing psychosocial stress. While cortisol and ACTH were 
significantly increased in both groups in response to stress, women who breast-fed 
before stress had significantly lower post-stress plasma and salivary cortisol levels 
compared to those who only held their infant before stress (Heinrichs et al., 2001). 
These results suggest that the breast-feeding group had higher OT levels, which might 
have reduced cortisol. Similarly, Heinrichs and colleagues (2003) showed that men who 
received OT had lower salivary cortisol levels following a stressful event. Therefore, 
OT may be beneficial in buffering against the negative effects of stress. These results 
support the presence of HPA axis mediated mechanism for OT’s anxiolytic effects. 
However, many factors, including how an individual reacts to a stressful situation, can
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impact the magnitude of the HPA axis activity and subsequent cortisol response (Lupien 
et ah, 2007).
The exact mechanism through which OT affects the HPA axis and anxiety profile of 
both rodents and humans is not fully understood. One hypothesis suggests that OT 
influences the HPA axis by decreasing activity in the sympatho-adrenal system and 
increasing vagal nerve activity (an important part of the calming effect of the 
parasympathetic nervous system) (Higa et al., 2002, Uvnas-Moberg, 1997). 
Specifically, OT terminals in the brain’s solitary vagal complex may modulate reflex 
control of the heart to facilitate vagal activity and slow the heart (Higa et al., 2002). In 
animals, PVN OT neurons project to the vagal nuclei (Buijs et al., 1985), and plasma 
OT increases in response to vagal nerve stimulation (Stock and Uvnas-Moberg, 1988). 
Together, these data provide evidence that OT directly reduces HPA activity by 
promoting positive feedback of vagal reactions.
Another mechanism underpinning the anxiolytic properties of OT involves the 
reduction of fear and/or Amy activation, particularly in response to stress. In a 
functional magnetic resonance imaging (fMRI) study, it has been shown that intranasal 
OT administration decreases Amy activation in response to fearful and angry facial 
expressions (Kirsch et al., 2005). A more recent study suggests that OT reduces 
activation of the CeA, a structure influential in producing physiological responses to 
fear (Knobloch et al., 2012). CeA projects to the rostral ventrolateral medulla, a 
structure which may be essential in regulating cardiovascular responses (e.g., heart rate) 
to fear and anxiety triggered in the Amy. The medulla has also been shown to be 
deactivated in response to OT (Viviani and Stoop, 2008), possibly resulting in lower 
anxiety and increased calmness. However, as OT binds to receptors in many different
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brain areas, this model represents only one possible pathway for OT’s anxiolytic effect. 
Overall, structures governing the fear response may also be responsible for OT’s 
anxiety-reducing properties.
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1.7.2 Depression
Due to the high degree of comorbidity between anxiety and depressive disorders, 
common mediators are likely to underlie both conditions. Indeed, in addition to its 
anxiolytic effect, synthetic OT was shown to shift stress-coping in rodents towards a 
more active coping style, after either central or peripheral administration, indicating 
antidepressant-like effects (see Slattery and Neumann, 2010b).
The first report of an antidepressant-like effect of OT came from Arletti and Bertolini, 
(1987) who demonstrated that intra-peritoneal administration of OT, both acutely and 
chronically, decreased immobility time in the FST in mice. The FST results were 
replicated in rats following peripheral OT (Arletti et al., 1995) and also peripheral or 
central CBT administration (Chaviaras et al., 2010). In addition, subcutaneous OT was 
found to decrease the number of escape failures in the learned helpless test 
(Nowakowska et al., 2002), which is indicative of an antidepressant-like effect (Cryan 
et al., 2002). Recently, a novel non-peptidergic OT agonist, WAY-267464, while 
having an anxiolytic profile, did not show any antidepressant effects in the FST (Ring et 
al., 2010). Nevertheless, the extent to which this drug shows selectivity to OTRs has 
recently been contested (Hicks et al., 2012).
In depressed patients, evidence for an altered oxytocinergic system, as deduced from 
plasma and cerebrospinal fluid (CSF) levels, is limited and inconsistent. Zetzsche et al., 
(1996) reported lower levels of plasma OT in depressed patients compared with non­
depressed controls. Similarly, low levels of plasma oxytocin were reported in depressed 
patients compared with non-depressed ones among fibromyalgia syndrome patients 
(Anderberg and Uvnas-Moberg, 2000). However, van Londen et al., (1997) found no 
significant difference in OT plasma levels between depressed patients and controls, and
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a negative correlation was found between the scored symptoms of depression and 
plasma OT levels (also see Scantamburlo et ah, 2007). Activation of the oxytocinergic 
system has also been reported among depressed patients. For example, in a post-mortem 
study, it has been shown that OT neurons are activated in the PVN in patients with 
depression, which may be associated with activation of the HPA axis activity (Purba et 
ah, 1996). Similarly, increased OT mRNA in the PVN has been reported in patients 
with melancholic depression compared with controls (Meynen et ah, 2007). The 
discrepancies between these studies may be the result of differences between the patient 
populations, between the results interpretation methods (i.e. not considering body mass 
index (BMI) or number of children) or between the kits used. For example, in the study 
by van Londen et ah, (1997), OT levels were assessed without controlling possible 
confounding factors such as food consumption or medication intake (e.g. oral 
contraceptives).
It is therefore clear that oxytocinergic system is highly implicated in depressive-like 
responses. However, several questions remain; for example, whether such alterations in 
the oxytocinergic system represent causes or consequences of depression, and whether 
antidepressant treatment can normalise such changes.
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1.7.3 Social deficits
Animal and human studies indicate a facilitatory role of the neuropeptide OT in a broad 
variety of social-enhancing responses. Following its central release, OT promotes 
important aspects of social behaviour, including social preference (Lukas et al., 2011), 
maternal care and aggression (Numan and Insel, 2003), sexual behaviour (Melis et al.,
2007), pair-bonding in monogamous species (Donaldson and Young, 2008, Carter et al., 
1995), and social cognition (Bielsky and Young, 2004, Gabor et al., 2012)
Intra-cerebral release of OT in specific brain regions was found to be increased in 
response to a variety of social stimuli, including mother-offspring interactions, maternal 
aggression, mating in males and females, and exposure to an adult con-specific during 
social defeat (see Neumann, 2009, Veenema and Neumann, 2008). In the context of 
social stimuli, increased OT release could be identified within the hypothalamic PVN 
(Neumann et al., 1993b, Waldherr and Neumann, 2007), the CeA (Bosch et al., 2005), 
the olfactory bulb (Levy et al., 1995), the mediolateral septum (Ebner et al., 2000), and 
the Acb (Ross et al., 2009). Also, OT has a role in social recognition in both male 
(Popik and van Ree, 1991) and female rats (Engelmann et al., 1998), which has been 
confirmed in OTR receptor knockout mice displaying impaired social memory 
(Ferguson et al., 2000, Choleris et al., 2003, Takayanagi et al., 2005). Furthermore, 
chronic central OT administration increases social interactions between male and 
female rats (Witt and Insel, 1991). Together, these results support the hypothesis that 
stimulation of the brain oxytocinergic system by social cues reinforces appropriate 
social interactions.
Central application of an OTR antagonist was able to attenuate social preference 
between male rats, and dose-dependently caused social avoidance between male mice 
(Lukas et al., 2011). These results provide direct evidence that OT can have a pro-social
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effect on male-male interactions and not only on reproduction-related behaviours such 
as pair-bonding, maternal or sexual behaviours. Consequently, basal and/or social 
stimulus-induced release of OT within the brain and subsequent OTR interactions 
within discrete brain regions may underlie the motivation for social approach.
Human studies confirmed the pro-social effects of OT after intranasal administration in 
healthy subjects, as well as in patients with emotional or social dysfunctions (Meyer- 
Lindenberg et al., 2011, Campbell, 2010, Dai et al., 2012). Intranasal OT administration 
has been shown to affect many aspects of human sociability ranging from social 
perception, increased gazing toward the eye region (Gamer et al., 2010, Guastella et al.,
2008), and improved recognition of emotional facial expressions (Domes et al., 2007b, 
Savaskan et al., 2008), to complex social behaviours like trust, social-risk taking, and 
empathy (Baumgartner et al., 2008, Hurlemann et al., 2010). Finally, OT has been 
shown to have a key role in the regulation of autism spectrum disorders, which are 
characterised by abnormalities in social behaviour and social cognition (see 
Stavropoulos and Carver, 2013). Specifically, children with autism showed to have 
decreased plasma OT levels (Modahl et al., 1998). Moreover, single nucleotide 
polymorphisms in the OTR gene (rs53576G) have been positively correlated with 
autism symptoms (see Brune, 2012). In addition, intravenous OT enhanced the 
performance of individuals with autism spectrum disorders on several social tasks such 
as recognition of affective speech (Hollander et al., 2007) and social cooperation in an 
online computer game (Andari et al., 2010).
Taken together, these findings support the general hypothesis for OT to be the “social” 
molecule as it enhances several social behaviours in humans and in animals. However, a
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minority of human studies showed that OT actually produces anti-social effects under 
particular conditions (Bartz et ah, 2011).
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1.8 Oxytocin and drug addiction
Early evidence suggests that OT might play a role in drug addiction processes (Kovacs, 
1986, Kovacs and Telegdy, 1987). A growing body of evidence has shown that OT is 
implicated in addiction-related behaviours including reinforcement, reward, tolerance, 
withdrawal and reinstatement (see Tables 4-5). In support of this, recent findings 
showed that the pro-social properties of some drugs of abuse induce stimulation of the 
oxytocinergic system (Dumont et al., 2009), and there might be an overlap between the 
neural circuits underlying drug reward and social bonding (Liu et al., 2011, Young et 
al., 2011). The pro-social, anxiolytic and antidepressant effects of OT described in 
Section 1.7, along with the possible interactions between the oxytocinergic and DAergic 
systems in the brain (see Section 1.8.1), have led to the hypothesis that the 
oxytocinergic system might be a novel target for the treatment of addiction. As the 
focus of this thesis involves cocaine, opioid and MAP addiction, the role of OT in 
ethanol and nicotine addictions will not be discussed.
1.8.1 Oxytocin - Dopamine interactions
Classically, most research in the drug addiction field has focussed on DAergic systems 
because both natural rewards, and the ‘reward’ obtained by taking drugs of abuse, 
acutely increases DA release in the Acb (Hernandez and Hoebel, 1988, Carboni et al., 
1989, Mifsud et al., 1989, Rada et al., 1991). The interest for the involvement of the 
oxytocinergic system in drug addiction came from the initial findings that the brain 
systems involved in drug reward interact with systems involved in natural rewards such 
as sexual behaviour and social bonding. Emerging evidence implicates both the 
oxytocinergic and the DAergic systems in the regulation of certain social and affiliative 
behaviours, including pair bonding and sexual behaviour. It has been recently 
demonstrated that common DA- and OT- related brain areas are involved in pair
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bonding and sexual behaviours including the Acb, VTA, SON, PVN, Amy and MPOA, 
regions also known to modulate several reward and addiction processes (Skuse and 
Gallagher, 2009). Early findings from Carmichael et al., (1987) outlined the ability of 
sexual self-stimulation to increase plasma OT levels in male and female humans. In rats, 
the DA agonist apomorphine has been shown to induce penile erection, which was 
reversed by the administration of an OTR antagonist (Argiolas et al., 1987), and OT- 
induced penile erection was inhibited by a DA receptor antagonist (Martino et al., 
2005). Therefore, there is a possibility of a synergistic activation of both oxytocinergic 
and DAergic systems in the mediation of penile erection. In contrast, a recent study 
showed that OT microinjection within the subthalamic nucleus (STh) was able to 
prevent intra-STh DA-induced conditioned-place preference, an effect that was 
prevented by the co-administration of an OTR antagonist in this region (Baracz and 
Cornish, 2013). Taken together, these data suggest that there is a region-specific 
regulation of natural rewards (i.e. sexual behaviour) by the DA and oxytocinergic 
systems in the brain.
Sexual intercourse in prairie voles, a monogamous species, induces lifelong pair bonds 
with evidence for a facilitatory role of OT acting within the DAergic circuitry of the 
Acb (Lim and Young, 2006). The enduring partner preference that is formed by sexual 
intercourse in this species is abolished by both DA antagonists and OT antagonists 
injected into the Acb (Aragona et al., 2006, Lim and Young, 2006). These findings 
might suggest that social attachment and sexual intercourse is a different type of an 
addictive disorder, a hypothesis supported by Insel (2003), and that the same OT 
circuitry that is important in the regulation of “addiction to love” in prairie voles, may 
also regulate some drug addiction processes (Edwards and Self, 2006).
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There is compelling evidence for the existence of direct OT-DA interactions within the 
brain. Early studies showed that intraventricular microinjections of OT into the brain 
were able to increase DA content in the mesencephalon of rats (Schwarzberg et al., 
1981). In addition, Pfister and Muir, (1989) showed significantly increased synaptic DA 
levels in the Hyp following intravenous administration of OT in female rats. These 
findings were extended by Kovacs et al., (1990), who showed that both central and 
peripheral administration of OT acutely increased DA utilisation (i.e. decreased 
intracellular DA levels) within the Acb in mice. However, chronic subcutaneous 
administration of OT (0.2 mg/kg for 8 days) decreased DA utilisation (i.e. increased 
intracellular DA levels) within the basal forebrain (nucleus olfactorius posterior, Acb, 
septum) of mice (Kovacs et al., 1986). These discrepancies may indicate a 
neuroadaptive mechanism within the striatum, which could extend to the receptor level. 
In support of this, blockade of OTRs in the Acb prevented partner preferences induced 
by Dz receptor agonists in prairie voles (Liu and Wang, 2003). Moreover, OTRs 
undergo rapid (5-6 min in humans) desensitisation, clathrin-dependent internalisation 
and subsequently down-regulation following persistent agonist stimulation (e.g. chronic 
administration of OT) (Evans et al., 1997). Therefore, chronic administration of OT 
may have induced a desensitisation of OTRs in the Acb and subsequently caused a 
compensatory increase in the DA release.
In parallel, i.c.v. or peripheral administration of DA or the non-selective agonist 
apomorphine were found to increase hypothalamic and neurohypophysial OT release 
(Melis et al., 1989, Galfî et al., 2001). These data indicate a direct stimulatory effect of 
the DAergic system on the oxytocinergic system at both the hypothalamic and posterior 
pituitary level. Additionally, intra-VTA microinjection of OT induced increases in the
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extracellular DA levels within the Acb and the PVN as measured by microdialysis in 
male rats (Melis et ah, 2007)
In support of this, DA D2 receptors are expressed in hypothalamic SON and PVN OT 
neurons (Baskerville et ah, 2009), which are innervated by DAergic fibers originating 
from the zona incerta (Buijs et ah, 1984, Decavel et ah, 1987), suggesting a possible 
regulation of OT by the DAergic system. Interestingly, it has been recently shown that 
OTR are co-localised and functionally interact with DA D2 in the Acb (Romero- 
Femandez et al., 2012) further supporting a bi-directional regulation between the two 
systems. DA D2 receptors have been found to be expressed in cell bodies and dendrites 
of OT neurons within the MPOA, SON and PVN of male rats (Baskerville et al., 2009). 
This finding suggests that DA may bind to and activate OT cells via a D2 receptor- 
mediated mechanism. Moreover, administration of the D2/D3 agonist quinpirone, but not 
a Di agonist, increased the exitability of OT neuronal populations within the 
hypothalamic SON, which was antagonised by a D2 receptor antagonist (Yang et al., 
1991). These common DAergic and oxytocinergic pathways point toward a possible 
beneficial role of the oxytocinergic system in the treatment of several DA-associated 
disorders including sexual dysfunction, autism, and addiction (see Baskerville and 
Douglas, 2010).
1.8.2 Opioid addiction
Early studies reported a role of the oxytocinergic system in the acute reinforcing effects 
of the opioid, morphine. Acute morphine administration decreased hypothalamic OT 
release in animals (Clarke et al., 1979) and also decreased OT release during suckling 
(Haidar and Sawyer, 1978). However, Kovacs et al. 1987 observed increased OT 
immunoreactivity in extra-hypothalamic regions including Hip, Amy and basal forebrain
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suggesting differential effects of acute opioid administration in different areas of the 
brain.
Chronic morphine administration significantly decreased OT immunoreactivity within 
the Hip, and OT mRNA levels within the SON, ME and arcuate nucleus of the Hyp 
(ARC) (Kovacs et al., 1987a, Laorden et al., 1998). This down-regulation of the 
oxytocinergic system following chronic opioid administration, in comparison with the 
acute stimulatory effects of opioid administration in different brain regions, may be a 
result of several neuroadaptive changes in the oxytocinergic system caused by chronic 
exposure to opioids.
OT has been also shown to play a role during opioid tolerance. In accordance, both 
peripheral and central OT administration dose-dependently attenuated the development 
of rapid and chronic analgesic morphine tolerance in rodents (Kovacs and Telegdy, 
1987, Kovacs et al. 1985; 1998). In support of this, tolerance to the antinociceptive 
effect of y^-endorphin was attenuated by OT in a dose-dependent manner (Kovacs and 
Telegdy, 1987). These results might indicate the existence of an interaction between OT 
and endogenous opioid neuronal systems in the development of opioid tolerance. It is 
remarkable that the effects of OT in opioid tolerance could also be observed with non­
analgesic effects of morphine. Accordingly, OT treatment inhibited the development of 
tolerance to locomotor hyperactivity following the administration of high doses of 
morphine in mice (Kovacs and Telegdy, 1987). Moreover, OT administration reduced 
heroin self-administration in heroin-tolerant rats, while it did not exert any effect in non- 
tolerant rats (Kovacs et al., 1998). The inhibitory effects of OT on the development of 
rapid-morphine tolerance (Samyai et al., 1988), or heroin self-administration (Ibragimov 
et al., 1987) were effectively antagonised by local microinjections of an OTR analogue, 
7V-a-acetyl-[2-0-methyltyrosine]-OT into the limbic brain areas. It is therefore likely
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that endogenous OT, via acting on OTRs in limbic areas of the brain, is able to modulate 
several adaptive mechanisms underlying opioid tolerance.
OT has also been found to play a role during opioid withdrawal. Peripheral OT 
administration decreased naloxone-precipitated morphine withdrawal symptoms: it 
decreased hypothermia and loss in body weight and increased the latency of the onset of 
stereotyped jumping (Kovacs et al., 1985). In parallel, several studies investigated the 
effects of opioid withdrawal on the endogenous oxytocinergic system. Acute 
precipitated morphine withdrawal induced by naloxone has been shown to significantly 
increase plasma OT levels and the firing rate of SON OT neurons in chronically 
morphine-treated lactating rats (Bicknell et al., 1988). Additionally, naloxone has also 
produced a large increase in OT levels within the CSF of opioid dependent rats 
(Coombes et al., 1991). Finally, naloxone-precipitated morphine withdrawal increased 
Fos protein expression within the SON (Murphy et al., 1997, Johnstone et al., 2000) and 
OT mRNA levels within the ME and PVN (Laorden et al., 1998), which may illustrate 
an increase of the biosynthesis of OT within the PVN that travels along the ME to be 
released into the plasma from the posterior pituitary gland.
Several mechanisms have been proposed to explain the hyper-activation of the 
oxytocinergic system following precipitated withdrawal from opioid administration. 
Briefly, the increase in plasma OT levels has been thought to be due to a physiological 
endogenous opioid peptide inhibition of the OT neurons. It is possible that naloxone, by 
blocking opioid receptors (e.g. Oishi et al., 1983, Kitano and Takemori, 1979), was able 
to disinhibit OT neuronal activity. In support of this, opioid peptide neuronal fibers and 
terminals are present in close proximity to OT neurons within the Hyp (Bicknell et al., 
1988). Moreover, MOPr are present in the Hyp, and particularly within the SON and
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PVN nuclei (Atweh and Kuhar, 1983). These findings indicate possible interactions 
between the opioid and oxytocinergic systems. However, there are no studies on co­
localisation of opioid receptors with OTRs, thus further studies are needed to 
demonstrate if there is a functional interaction between these two systems.
1.8.3 Psychostimulant addiction 
1.8.3.1 Cocaine addiction
The effects of OT on cocaine-induced behavioural and neurochemical alterations have 
been extensively studied in rodent models. Kovacs et al. (1990) showed that systemic 
administration of OT was able to block cocaine-induced DA utilisation in the Acb but 
not the CPu and to decrease cocaine-induced hyperactivity in mice (Kovacs et al., 1990). 
In addition, Samyai et al. (1993) demonstrated that systemic administration, i.c.v. or 
microinjections of synthetic OT into the Acb and Tu, but not the CPu or the CeA were 
able to abolish cocaine-induced sniffing. It has been suggested that OT is able to block 
these cocaine-induced behavioural effects due to its inhibitory effects on DA utilisation 
and on postsynaptic DA receptors across a network of limbic and basal forebrain areas of 
the brain (Kovacs et al., 1998). It is also possible that these effects of OT are due to the 
co-localisation and functional interaction of OTRs with DA D% receptors in the Acb 
(Romero-Femandez et al., 2012). It is important to mention that the inhibition of 
cocaine-induced sniffing behaviour by peripherally administered OT was reversed by the 
i.c.v. administration of an OTR antagonist (Kovacs et al., 1998). This finding suggests 
that at least a small amount of peripherally injected OT is able to pass the BBB and exert 
its effects by binding to the wide network of OTRs in the brain.
A large amount of evidence has also indicated profound effects of cocaine on the 
endogenous oxytocinergic system. In fact, OT immunoreactivity levels were decreased
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within the basal forebrain following acute administration of cocaine whilst OT peptide 
levels were increased within the Hyp and Hip (Sarnyai et ah, 1992c). In contrast, plasma 
OT levels as well as OT immunoreactivity levels within the Amy remained unaltered, 
suggesting region-specific effects of cocaine on the oxytocinergic system.
Chronic cocaine administration can lead to either tolerance or sensitisation, depending on 
the dose and route of administration, treatment schedule or environmental effects 
(Hammer et ah, 1997, Johanson and Fischman, 1989). The effect of OT on the 
development of both tolerance and sensitisation to cocaine has also been studied in 
rodents. Repeated administration of cocaine produced a behavioural tolerance to the 
sniffing-inducing effects of cocaine (Samyai et ah, 1992a). The development of 
tolerance was inhibited by the repeated peripheral daily administration of OT prior to 
cocaine injections. However, sub-chronic administration of cocaine-induced behavioural 
locomotor sensitisation (Samyai et ah, 1992b), which was facilitated by the peripheral 
daily injections of OT prior to cocaine administration, suggesting that OT has also a role 
in the modulation of the development of tolerance or sensitisation to cocaine.
Pre-clinical evidence shows that chronic administration of cocaine induces a hypo- 
activity of the oxytocinergic system. For example, Samyai et ah, (1992a) reported 
decreased plasma OT levels and decreased OT immunoreactivity within the Hyp and Hip 
following prolonged administration of cocaine in rats. Accordingly, chronic gestational 
and post-gestational cocaine treatment in rat dams decreased OT levels in the MPOA, 
VTA, and Hip, and OTR binding in the VMH and BNST (Johns et ah, 1997, Johns et ah, 
1998, Johns et ah, 2004, Jarrett et ah, 2006). The detrimental effects of gestational 
cocaine treatment appeared to be long-lasting since young adult female offspring of 
cocaine-treated dams exhibited higher levels of aggression associated with lower levels
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of OT in the Amy (McMurray et ah, 2008). It is highly likely that these effects can be 
attributed to both gestational cocaine exposure in utero and maladaptive rearing 
conditions.
These pre-clinical findings have also been extended to humans. Light et al., 
(2004) provided evidence that mothers who used cocaine during pregnancy showed 
lower plasma OT levels, greater hostility and depressed mood, and less social support 
and adaptive coping strategies for stressful life events compared to cocaine-naiVe 
mothers. Moreover, cocaine exposed mothers maintained higher blood pressure and 
urinary NA levels, while urinary cortisol and adrenaline levels were blunted, suggesting 
a dysregulation of the HPA axis stress system. Together these findings suggest profound 
alterations in the oxytocinergic system following acute and chronic cocaine use which is 
likely to affect behaviour.
1,83.2 Amphetamine addiction
Early research into the role of the adrenergic system in regulating neurohypophysial 
hormones showed that acute administration of amphetamine to rats significantly 
decreased hypothalamic and neurohypophysial OT levels (Guzek et al., 1978). Given 
that this study did not concentrate on the effects of amphetamine on OT, it is possible 
that other neurotransmitters were also involved in the observed down-regulation of the 
oxytocinergic system after amphetamine administration. Consequently, this 
oxytocinergic hypo-activity following acute amphetamine administration needs further 
investigation.
The effects of oxytocin on the behavioural effects of amphetamine were also examined. 
Systemic OT administration prior to amphetamine failed to alter the amphetamine- 
induced hyperlocomotion in mice (Kovacs et al., 1985) and to inhibit amphetamine-
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induced stereotyped behaviour in rats (Samyai, 1993). In contrast, similar doses of OT 
showed inhibitory actions on the behavioural effects of cocaine (see Section 1.8.3.1). 
Differences in the pharmacological action of amphetamine and cocaine might partly 
explain the discrepancies between OT’s effect on the behavioural effects of these dmgs. 
Cocaine, having a relatively short half-life, acts almost selectively to increase synaptic 
DA levels by blocking the action of DA transporters (DAT) for DA reuptake from the 
synaptic cleft (Thomsen et al., 2009). However, amphetamine reverses the DAT pump, 
markedly increasing DA release from the presynaptic terminals (Pifl et al., 1995). 
Furthermore, amphetamine inhibits the metabolism of DA by blocking the action of the 
enzyme monoamine oxidase (see Fowler and Benedetti, 1983). As a result, 
amphetamine has a relatively long half-live, depending on dose (see Cmickshank and 
Dyer, 2009). Therefore, given the prolonged action of amphetamine, it is likely that 
much higher doses of OT and a more proximal time-course of administration might be 
required before an effect can be observed.
The extended action of amphetamine on neuronal DA activity has been linked to a wide 
range of psychotic symptoms associated with schizophrenia in both animal and human 
models (see Hermens et al., 2009). Accumulating evidence suggests that dysregulation 
of the OTergic system may also be associated with the development of symptoms of 
schizophrenia (see MacDonald and Feifel, 2012). In order to investigate a possible role 
for OT as an antipsychotic agent, OT was systemically administered prior to 
amphetamine injection in rats that were tested for deficits in sensorimotor gating by 
using the prepulse inhibition (PPI) task. Briefly, PPI refers to the decrease in the 
magnitude of the startle reflex occuring when a weak sensory stimulus (the prepulse) is 
presented immediately before a startling stimulus (for an extended review on PPI see 
Larrauri and Schmajuk, 2006). Typically, patients with schizophrenia show deficits in
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PPI and this can be modeled in laboratory animals by administration of 
psychostimulants, such as amphetamine (Mansbach et ah, 1988). OT has been shown to 
exert beneficial effects on schizophrenic symptoms with high doses of systemically 
administered OT (1 mg/kg) being able to reverse the amphetamine-induced impaired 
PPI in rats (Feifel and Reza, 1999). These results suggest that OT is capable of 
reversing some of the “psychotomimetic” effects of amphetamine, pointing towards its 
use as an antipsychotic agent. Further investigation may determine how OT achieves 
this effect as PPI is considered to rely on a number of neuronal processes including DA 
and glutamate neurotransmission (see Braff, 2010). However, it should be noted that 
large doses of OT (i.e. 1 mg/kg) delivered systemically have been shown to cause 
sedation and thus attention should be taken in the elucidation of findings such as these 
(Uvnas-Moberg et al., 1994). Moreover, OT has also been found to facilitate the effects 
of sedating anxiolytics such as diazepam (Viviani et al., 2010). Therefore, it is possible 
that systemically administered OT may result in non-specific sedative effects as 
opposed to specifically blocking stimulant-induced behaviours.
Central administration of the OT agonist WAY-267464, has recently been shown to 
reverse the disruption of PPI in the acoustic startle reflex produced by amphetamines 
(Ring et al., 2010). However, as also mentioned in Section 1.7.2, the selectivity of this 
drug for OTRs remains unclear (Hicks et al., 2012).
1.8.3.3 Methamphetamine addiction
Several studies have examined the effects of OT in specific brain regions and 
investigated how OT affects several neurotransmitter systems involved in the formation 
of MAP-induced locomotor hyperactivity in mice. In a recent study, central OT 
administration dose-dependently reduced MAP-induced hyperlocomotion (Qi et al..
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2008). This effect was accompanied by reduced ratios of the DA metabolites 3,4- 
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) to DA in the 
striatum, indicating decreased DA metabolism. Generally, decreased extracellular levels 
of DA are associated with decreased motor activity in rodents (Alexander and Crutcher, 
1990). Therefore, OT, possibly via causing a hypo-DAergic state in the brain, was able 
to reduce MAP-induced hyperlocomotion. Interestingly, central administration of the 
OTR antagonist, atosiban, attenuated these effects, suggesting that OT exerted its 
inhibitory effects on MAP-related behaviours via interaction with OTRs in the brain.
Following the demonstration of the effects of OT on the acute locomotor responses of 
MAP, Qi et al., (2009) examined the effects of OT administration on MAP-induced 
conditioned place preference (CPP). It was shown that centrally administered OT 
significantly inhibited the acquisition of a place preference for MAP, but had no effect 
on the expression of an already acquired CPP for MAP. Moreover, OT was able to 
facilitate the extinction of MAP-induced CPP and to abolish stress-induced but not 
MAP-primed reinstatement of CPP (Qi et al., 2009). The effect of OT in blocking 
stress-induced reinstatement to MAP-seeking has been attributed to the ability of OT to 
prevent increased glutamate levels in the medial prefrontal cortex (mPFC) following 
restraint stress- but not MAP-induced reinstatement of CPP. Evidence suggests that the 
ability of psychostimulants to trigger drug-induced reinstatement following abstinence 
involves their direct ability to activate the mesolimbic DA system, which in turn 
enhances glutamate release in the PFC. In contrast, stress can activate VTA DAergic 
neurons via the activation of an excitatory glutamatergic projection from the PFC 
innervating the VTA (Moghaddam, 1993). The stress-induced increase in glutamate 
levels is thought to be a mechanism underlying reinstatement following exposure to 
stress in rodents. Therefore, OT might differentially regulate glutamate release in the
71
mPFC, thus having a prominent role in stress-induced, but not MAP-primed, induced 
reinstatement.
Although CPP is considered to be a robust model of drug reward-related behaviour, it is 
widely accepted that drug self-administration is a more ethologically valid animal 
model of addiction. Systemic OT administration dose-dependently reduced MAP self­
administration, MAP-induced hyperlocomotion and reinstatement of extinguished 
MAP-seeking behaviour caused by MAP challenge (Carson et al., 2010a). Taken 
together, these findings provide the first evidence that systemically applied OT could 
significantly inhibit MAP-induced addictive-like behaviours. The use of a peripheral 
route of OT administration is an important aspect as it is much more clinically relevant 
than central administration, a delivery that is highly unlikely to find a place in clinical 
practice.
The discrepancies between the findings of the studies carried out by Qi et al. (2009) and 
Carson et al. (2010a) on the blockade of reinstatement of MAP-seeking following a 
MAP challenge (priming-induced reinstatement) may be due to the different protocol of 
drug administration (i.e. contingent v.y non-contingent). In support of this, it has been 
shown that contingent and non-contingent drug administration, including that of 
nicotine (Metaxas et al., 2010) and cocaine (Markou et al., 1999), exerted differential 
neurochemical as well as behavioural responses.
Moreover, peripherally administered OT significantly reduced MAP-induced c-Fos 
expression in the STh and Acb core, two regions highly implicated in impulsivity and 
drug addiction (Eagle and Baunez, 2010). Additionally, peripheral administration or 
microinjections of OT into the STh and Acb core attenuated the formation of MAP- 
induced CPP (Baracz et al., 2012). These findings provide further support for a key role
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of the STh and Acb core in the inhibitory effects of OT on the rewarding properties of 
MAP. Indeed, a single-dose of DA injected directly in the STh of rats resulted in a 
significant acquisition of CPF, while the DA receptor antagonist, fluphenazine, or OT 
administered in to the STh blocked this effect (Baracz and Cornish, 2013). These data 
support the existence of local OTRs in the STh that exert an inhibitory action on 
DAergic reward processes associated with the effects of MAP.
1.8.3.4 MDMA (3y4-methylenedioxy-N-methylamphetamine) addiction
MDMA has repeatedly been shown to induce positive feelings and pro-social effects in 
individuals (Vollenweider et al., 2002), which might be a key factor contributing to the 
escalation of its use. Since OT has been shown to exert similar pro-social effects in 
humans (Lee et al., 2009), it has been postulated that the central oxytocinergic system 
might mediate several MDMA-related effects. A role for OT in MDMA addictive 
processes is further supported by the inhibitory effect of the OTR antagonist atosiban on 
the discrimination between MDMA and placebo as examined by the “drug 
discrimination paradigm” in rats (Broadbear et al., 2011), suggesting that the OTR 
system has a prominent role in MDMA's effects. In addition, acute administration of 
MDMA significantly increases plasma OT levels in humans which are positively 
correlated with OT levels rather than MDMA concentration in the blood (Dumont et al.,
2009). These findings have been replicated in MDMA-positive clubbers who showed 
elevated plasma OT levels, a finding that was associated with changes in plasma 
osmolality and plasma sodium levels (Wolff et al., 2006).
Initial in vitro work by Forsling et al., (2002) showed that MDMA, when applied to 
isolated rat Hyp, resulted in substantial increases in OT release. Similarly, in an attempt 
to uncover the action of MDMA on the brain and behaviour at the neuropeptide level, 
Thompson et al., (2007) showed that acute administration of MDMA in rats induced a
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substantial increase of c-Fos expression in OT-containing neurons in the Hyp as well as 
an increase in plasma OT levels. These results reflect the effects of MDMA in 
increasing social interaction via an oxytocinergic pathway (Clemens et al., 2004). The 
effects of MDMA on the endogenous oxytocinergic system were abolished by pre­
treatment with the 5-HTia receptor agonist, WAY 100,635, and the OTR antagonist, 
tocinoic acid (Thompson et al., 2007). These results suggest that MDMA might exert its 
pro-social effects via an oxytocinergic mechanism involving possible interactions with 
the 5-HT system. In support of this, it has been recently shown that WAY 100,635 was 
able to inhibit MDMA stimulated c-Fos expression in the Hyp but not the striatum, Th 
or CeA (Hunt et al., 2011), further suggesting that MDMA exerts its acute effects on the 
oxytocinergic system via interactions with the serotonergic system.
In order to assess the potential long-term effects of MDMA in rats, van Nieuwenhuijzen 
et al., (2010) showed that a 4-week extinction period following 10 days of chronic 
MDMA administration increased OT mRNA levels in the Hyp, which might act as a 
compensatory mechanism to counteract the negative emotional effects associated with 
prolonged MDMA withdrawal. In humans, long-term abstinence from MDMA 
administration induces anxiety and depression (see Morgan, 2000). However, during 
protracted withdrawal, OTR mRNA levels remained unaltered in the Hyp, suggesting 
that the effects of prolonged withdrawal from MDMA might not be at the receptor level. 
Further research is essential to determine whether the effects of MDMA on the 
endogenous oxytocinergic system during withdrawal reflect counteractive mechanisms 
of the brain to reduce negative emotional withdrawal symptoms.
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1.8.4 The oxytocinergic system in drug addiction: a summary
The neurobiological mechanisms underlying comorbidity of addiction and other mental 
disorders remain unclear and thus this comorbidity is poorly treated. Emotional 
disturbances during abstinence from drugs of abuse are considered as a motivational 
trigger for relapse to drug-seeking; the hallmark for drug addiction treatment. Currently, 
there are no effective pharmacotherapies for the prevention of relapse following long­
term drug cessation. Several neurotransmitter and neuromodulator systems have been 
previously implicated in drug addiction processes. During the last decade, the 
oxytocinergic system has been proposed as a potential mediator and modulator of 
several addiction processes (see Samyai, 2011).
The key role of OT in drug addiction processes has become of great interest following 
several observations including the early evidence showing that OT was able to prevent 
tolerance to opioids and cocaine giving rise to the hypothesis for the involvement of OT 
in mesolimbic and forebrain areas. The oxytocinergic system is generally down- 
regulated as a result of repeated drug use and such adaptations might not only lead to 
tolerance development, but also to increased drug-seeking behaviour and a decreased 
interest in social rewards (McGregor et al., 2008). Recently, the importance of the 
oxytocinergic system has been extended at the level of reinstatement following MAP 
withdrawal. OT, having anxiolytic, antidepressant and social enhancing properties (see 
Section 1.7) may also be a promising candidate for the treatment of comorbidity 
disorders with drug addiction.
However, there are some critical characteristics of OT that might limit its clinical 
therapeutic prospects including its short half-life and its limited (if any) ability to cross
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the BBB, pointing towards the need of using novel OTR agonists or antagonists for the 
treatment of drug addiction.
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1.9 Hypothesis and aims
The role of the oxytocinergic system in the neurochemical and behavioural responses to 
drugs of abuse currently remains unclear. Drug addiction, and more specifically drug 
abstinence, is associated with negative emotional symptoms including social avoidance 
and mood disturbances that trigger relapse. A number of studies have shown that the OT 
peptide has antidepressant, anxiolytic and social enhancing effects, suggesting that it 
might also have beneficial effects in reducing impaired emotional response related to 
drug addiction.
The research in this thesis tests the hypothesis that the oxytocinergic system is involved 
in the modulation of several addiction processes and that administration of oxytocin 
receptor agonists will be beneficial in reducing the negative emotional symptoms 
associated with drug withdrawal.
Chapter 2: The oxytocin analogue carbetocin prevents social deficits and mood 
impairment in long-term abstinent mice.
Obiectives:
• To investigate the effects of protracted morphine withdrawal on emotional- 
like behaviours of mice by using the three-chambered sociability test, the 
elevated plus-maze and the forced-swim test.
• To determine the effects of chronic morphine administration and withdrawal 
on OTR binding in the brain and OT levels in the plasma and brain of mice by 
using quantitative oxytocin receptor autoradiography and ELISA, 
respectively.
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• To elucidate if administration of the oxytocin analogue carbetocin has any 
effect on the modulation of emotional-like behaviour of mice undergoing 
protracted withdrawal from chronic morphine administration.
Chapter 3: Chronic cocaine treatment and withdrawal induces a persistent 
oxytocin receptor up-regulation in the amygdala.
Obiectives;
• To determine the effects of chronic cocaine administration and protracted
withdrawal on stereotypy behaviour in mice.
• To investigate the effects of chronic cocaine administration and withdrawal on
OTR binding by quantitative autoradiography of these receptors in mouse
brains.
Chapter 4: Chronic methamphetamine treatment induces oxytocin receptor up- 
regulation in the amygdala and hypothalamus via an adenosine A2A receptor- 
independent mechanism.
Obiectives:
• To investigate the effects of chronic MAP administration on OTR binding by 
quantitative autoradiography of these receptors in mouse brains.
• To assess the involvement of the adenosine A2A receptors in the modulation of 
MAP-induced neuroadaptations by using quantitative autoradiography of OTR 
in the brains of wild-type and A2A receptor knockout mice.
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CHAPTER 2
The oxytocin analogue carbetocin prevents 
social deficits and mood impairment in 
long-term morphine abstinent mice
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2.1 Introduction
Opioids are a class of drugs derived from the opium poppy, where the biologically 
active alkaloid, morphine, is abundantly found. Opioid drugs such as morphine, codeine 
or the semi-synthetic opiate heroin, act on three opioid receptor subtypes; the MOPr, the 
KOPr and the 6-opioid receptor (DOPr) (Martin et al., 1976, Lord et al., 1977).
Opioids can induce a variety of beneficial pharmacological effects including analgesia, 
primarily by acting at the Gi/o MOPr in the spinal cord and in several areas of the brain 
such as the thalamus (Wang et al., 2009). Even though opioids have been proven to be 
effective in the treatment of pain and are widely used clinically in pain management 
(Corbett et al., 2006), their long-term prescription has been associated with the 
development of dependence (Fields, 2007). This effect of opioids has been at least 
partially attributed to their interactions with the MOPr in the VTA where opioids inhibit 
the y-aminobutyric acid (GABA) release and disinhibit DAergic neurons projecting to 
the Acb (Di Chiara and Imperato, 1988). Increased DA release in the Acb can cause 
euphoric effects (see Sections 1.2.1.1), therefore, opioid drugs are misused for these 
rewarding effects.
Long-term use of opioids can lead to the development of dependence and the emergence 
of physical symptoms upon cessation of drug taking. Several acute physical symptoms 
of opioid withdrawal, which appear after 6-8 hours upon the cessation of use include 
tremor, restlessness, diarrhoea, vomiting and muscle weakness. Moreover, opioid 
addiction is also characterised by the emergence of negative emotional withdrawal 
symptoms (Jaffe, 1990, Martin and Jasinski, 1969, Nunes et al., 2004, Peles et al., 2007) 
which may serve as a motivational trigger to re-administer the drug and to relapse even 
after prolonged abstinence (Le Moal and Koob, 2007).
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The main problem for recovering opioid addicts is the maintenance of the abstinence 
state. Despite the many physical symptoms of withdrawal typically decreasing after a 
short period of time, symptoms associated with emotional distress and dysphoria, such 
as anxiety, irritability, stress, depression, restlessness and anhedonia may linger for 
several months, or in certain instances even up to a year (protracted withdrawal) (Jaffe, 
1990, Martin and Jasinski, 1969). The high prevalence (30%-50%) of major depression 
and anxiety in post-dependent heroin addicts has been well documented (Nunes et al., 
2004, Peles et al., 2007). Moreover the negative impact of impaired social behaviour in 
recovering addicts has been recognised (Heinrichs and Gaab, 2007), especially in light 
of the significant benefits that psychosocial support have in maintaining addicts off the 
drug (Koemer, 2010). In animal studies, impaired emotional-like behaviour has been 
reported following short- or long-term withdrawal from opioids (Anraku et al., 2001, 
Grasing and Ghosh, 1998, Molina et al., 1994) and recently, Goeldner et al., (2011) 
reported an enhancement of despair-like behaviour and a reduction in sociability in 
mice withdrawn for 4 weeks from a chronic morphine administration paradigm.
Although several mechanisms have been suggested (e.g. Goeldner et al., 2011, Koob 
and Kreek, 2007, Koob, 2008), the molecular mechanisms underpinning the emotional 
impairment observed in opioid abstinent individuals remain unclear. Accumulating 
evidence showing a strong interaction between neuronal markers of social behaviour 
and those of stress and mood regulation (Dabrowska et al., 2011, Debiec, 2005, Di 
Simplicio et ah, 2009, Heinrichs and Gaab, 2007, Windle et ah, 2004) and of drug 
reward/withdrawal (Liu et ah, 2011, Young et ah, 2011), suggest that the “social” 
neuropeptide OT and its receptor may be implicated in the modulation of negative 
emotional aspects of protracted abstinence from opioids.
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As discussed in Section 1.7, OT promotes social bonding and social memory (Keveme 
and Curley, 2004) and has a marked anxiolytic and antidepressant effect in humans 
when administered in the form of an intranasal spray (Baumgartner et al., 2008, Kirsch 
et al., 2005, Di Simplicio et al., 2009), or in animal models when administered centrally 
or peripherally (Dabrowska et al., 2011, Windle et al., 2004). This has triggered a 
growing interest in the involvement of OT in psychiatric conditions characterised by 
symptoms associated with increased anxiety and social withdrawal, such as autism and 
schizophrenia (Carter, 2007, Heinrichs and Gaab, 2007). Therefore, it is markedly 
possible for OT to have a key role in addiction processes (see Samyai, 2011); also see 
Section 1.8.
There is emerging evidence supporting the involvement of OT in the effects of a 
number of dmgs of abuse (see Broadbear et al., 2011, McGregor and Bowen, 2012, 
McGregor et ah, 2008, Samyai, 2011). With respect to opioids, peripherally 
administered OT dose-dependently attenuated morphine tolerance, blocked naloxone- 
precipitated morphine withdrawal, inhibited tolerance to the endogenous opioids ^- 
endorphin and met-enkephalin (Kovacs et ah, 1985, Kovacs et ah, 1984) and also 
attenuated the maintenance of heroin self-administration (Kovacs and Van Ree, 1985) 
in animal models. In addition, marked alterations in the endogenous oxytocinergic 
system were observed after acute and chronic opioid administration as well as during 
naloxone-induced withdrawal (see Section 1.8.2). Briefly, OT peptide content and/or 
synthesis were altered in the forebrain. Hip, Amy and Hyp of rodents following acute 
and chronic opioid administration as well as acute precipitated withdrawal (Kovacs et 
ah, 1987a, You et ah, 2000). Although these findings are suggestive of major 
neuroadaptations of the oxytocinergic system by opioid exposure, it is unclear if these 
alterations persist during protracted opioid abstinence and whether they might
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contribute to the emotional behavioural impairment observed in opioid abstinent 
addicts.
As a result, we hypothesised that withdrawal from chronic opioid administration causes 
profound dysregulation of the central oxytocinergic system and that stimulation of 
OTRs may attenuate the emotional impairment observed during protracted opioid 
abstinence. To test this hypothesis, we first established a mouse model for studying 
emotional consequences of protracted opioid abstinence and investigated the effect of 
protracted opioid withdrawal on different components of the endogenous oxytocinergic 
system in plasma and brain tissue of mice. We also examined the effect of the OT 
analogue CBT in preventing this emotional behavioural impairment. This analogue has 
been shown to be protected from aminopeptidase and disulfidase cleavage (Barth et al., 
1974), hence it has much longer elimination half-life than OT; 85-100 min versus 3-4 
min (Engstrom et al., 1998). It has been also suggested to be a potential candidate for 
the treatment of several psychiatric disorders (Quay, 2005).
94
2.2 Methods
2.2.1 Animals
Male C57BL/6J mice (7-week old, 20-25g, Charles River Laboratories, Kingston, UK), 
were housed individually in a temperature-controlled environment with a 12-hour 
light/dark cycle (lights on: 06:00 am). Food and water were available ad-libitum. Mice 
were left to acclimatise in their new environment for seven days prior to the 
experimental start and were handled daily by the experimenter. All experimental 
procedures were conducted in accordance with the U.K. Animal Scientific Procedures 
Act (1986).
2.2.2 Chronic “intermittent” escalating-dose morphine administration paradigm
Mice were randomly divided into chronic saline- and morphine-treated groups. Mice 
were injected (i.p.) with saline (4 ml/kg) or morphine given at the same volume as 
saline (4ml/kg) (Sigma-Aldrich, Poole, UK) with a chronic, “intermittent” escalating- 
dose administration paradigm (20 mg/kg on Day 1, 40 mg/kg on days 2 and 3, 80 mg/kg 
on days 4 and 5 and 100 mg/kg on day 6 and 7) twice per day at 9:00 and 17:00 in 
accordance with Goeldner et al., (2011), Muller and Unterwald, (2004) and Zhou et al., 
(2006), with minor modifications. Both groups of animals were left to spontaneously 
withdraw in their home cages for a period of either 1 and/or 4 weeks. Weight, food and 
water consumption were monitored every day at 7:00am.
2.2.3 Behavioural experiments
2.2,3.1 Locomotor activity
Locomotor activity of each mouse was measured daily (8 o’clock, 2 hours after the start 
of the light cycle) in locomotor chambers (40cm x 20cm x 20cm; Linton 
Instrumentation, Norfolk, U.K.). Each chamber had two lines of 16 photocells located at
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right angles to each other, projecting horizontal infrared beams 2.5. cm apart and 6 cm 
above the cage floor to measure horizontal and vertical activity (rears), respectively. 
Mice were treated with either chronic “intermittent” saline or escalating-dose morphine 
administration paradigm and then left to spontaneously withdraw for 7 days in their 
home cage as described in Section 2.2.2. Mice were habituated in locomotor chambers 
for 1 hour prior to saline/morphine injections in order to assess basal activity every day. 
Subsequently, mice received an i.p. injection of saline or morphine and returned 
immediately to the chamber where horizontal and vertical activity (rearing) was 
measured for 1 hour. Behavioural activity (pre- and post- injection) of each animal was 
monitored daily for the 7-day duration of the treatment (see Figure 2.1) and following 1 
and 7 days withdrawal period after the last treatment injection (basal activity after 7- 
days withdrawal was monitored from 8:00 until 9:00). Horizontal and vertical activities 
were recorded as the number of sequential infrared beam breaks, every 5 mins. The 
average activity of the hourly 5 min bins were calculated daily. Faecal boh production 
was recorded daily after the 2 hours of locomotor testing. Mice were returned to their 
home cages each day following completion of the locomotor test.
Saline/M orphine Injection Saline/M orphine injection
Basal (pre-injection) ^Stim ulated (post-injection)'^Sti l  ; \
“1 I I I  i
8:00 9:00 10:00 17:00
Figure 2.1: Morphine injection timetable
Basal locomotor activity was measured daily from 8:00 until 9:00 during the chronic administration 
paradigm.
2.2.3.2 Physical symptoms of withdrawal
Withdrawal jumps and number of faecal boli were recorded to assess the somatic signs 
of morphine withdrawal. Different cohort of male C57BL/6J mice were treated with an
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identical saline or morphine administration paradigm as described above and were 
placed in locomotor chambers for 120 min following a 24 hr and 7-day withdrawal 
period from this paradigm. Number of jumps and number of faecal boli were recorded 
throughout the 120 min duration of the observation period. This procedure was carried 
out 2 hrs after the start of the light phase of the light/dark cycle (8:00 o’clock).
2.2.33 Emotional impairment testing
For the pilot emotional impairment testing, separate cohorts of C57BL/6J mice were 
treated with an identical chronic saline and morphine administration paradigm followed 
by a 6-8 days withdrawal period and then tested for social interaction preference/social 
novelty preference (6 days withdrawal), anxiety (7 days withdrawal) and depression­
like behaviours (8 days withdrawal) using the 3-chambered social interaction, EPM and 
FST respectively. These three tests were performed 24 h apart in the same animals and 
repeated following a 4-week withdrawal period again in the same animals (28, 29, and 
30 days withdrawal respectively). The order of testing was determined by the degree of 
anxiety inducing properties of each test with the least stressful conducted first and the 
most potentially distressing test last (Clemens et al., 2007).
Social interaction test: The three-chambered box (Figure 2.2) was used to assess social 
interaction behaviours in rodents and was conducted as previously described (Nadler et 
al., 2004). The “experimental” mouse was placed into the middle chamber of an 
interconnected three-chambered box (60cm length x 30cm wide x 30cm high). The test 
consisted of 3 phases. During the habituation phase, the test animal had free access to 
all chambers for 10 min. After this session, two identical small cages (15cm x 8cm x 
10cm), comprised of 1 cm-spaced vertical bars, were placed in each end-chamber and 
secured with a weighted cup. An unfamiliar male C57BL/6J mouse (stranger 1) was
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placed into one of the two smaller cages (“social cage”) while the other cage remained 
empty. The “experimental” mouse was placed back into the centre chamber and was 
allowed to explore the apparatus for 10 mins (social interaction phase). At the end of the 
“social interaction phase” another 10-min session followed, the “preference for social 
novelty” phase, where another unfamiliar male C57BL/6J mouse (stranger 2) was 
placed in the previously empty cage, while the now familiar (stranger 1) mouse 
remained in its original cage. The “experimental” animal was permitted to explore the 
entire apparatus now consisting of a chamber containing a now familiar mouse and 
another chamber containing a novel unfamiliar mouse, for another 10 min. During all of 
the three phases of the test, time spent by the “experimental” animal in each of the three 
chambers was measured by an automated tracking system (EthoVision v.3.0, Noldus 
Information Technology, Wageningen, Netherlands) and validated by an observer blind 
to the treatment groups. Social preference was determined by calculating the time that 
the “experimental” mouse spent in the chamber containing the unfamiliar mouse 
(stranger 1) vs the empty chamber during the social interaction phase of the test. 
Preference for social novelty was determined by calculating the time that the 
“experimental” mouse spent in the chamber containing a novel unfamiliar mouse 
(stranger 2) vj" the chamber containing a now familiar one (stranger 1) during the 
preference for social novelty phase of the test. The test was carried out in dim light 
conditions (lOlux).
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Figure 2.2: Three-chambered sociability apparatus.
The mouse has the choice between staying in the center chamber, spending time in the side chamber 
with an unfamiliar mouse (stranger 1), or spending time in the side chamber with either a novel 
object (empty cage) or a newly introduced mouse (stranger 2). The stranger mice are enclosed into 
the small end-chamber cages.
Elevated plus-maze: The elevated plus-maze (Figure 2.3) was used to measure anxiety­
like behaviour. The apparatus (Linton Instruments, UK) eonsisted of four equal-sized 
lanes (30cm long x 5cm wide) converging at a center square (5cm x 5cm) to form the 
shape of a cross and elevated 40cm off the floor. Of the four arms, two were enclosed 
by a 15cm high solid wall on the long sides of the arms (elosed arms) and the other two 
had no sides (open arms). Each mouse was allowed to habituate in the test room for 1 
hour prior to test session. To assess anxiety-like behaviours, the “experimental” mouse 
was positioned with its head and forelimbs in the eentre square of the apparatus and was 
allowed to explore the whole apparatus for 5 mins. The time spent in each arm was 
measured for each mouse by an automated traeking system (EthoVision v.3.0, Noldus 
Information Technology, Wageningen, Netherlands) and validated by an observer blind 
to the treatment groups. Anxiety-like behaviour was determined by calculating the 
amount of time spent and number of entries each mouse made in the open and closed 
arms and reported as the total time and the percentage number of entries respectively. 
The test was carried out in dim light conditions (lOlux).
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Figure 2.3: Elevated plus-maze apparatus.
The mouse has the choice between staying in the center o f the apparatus, spending time in the open- 
arms, or spending time in the closed-arms. The apparatus is elevated from the floor.
Forced-swim test: The FST measures depressive-like behaviours as previously 
described by Porsolt et al., (1977). Mice were exposed to a 15 min pre-test swim 
followed by a 5 min test, 24 hours after the pre-test as described by Perrine et al., (2008) 
and Lucki, (1997). The pre-test has been shown to facilitate the development of 
immobility during the test session and to increase the sensitivity for detecting 
behavioural effects (Lucki, 1997). Briefly, for the pre-test, mice were placed 
individually into clear glass cylinders (25cm height x 17cm diameter) filled with 2.5 
litres of water at room temperature (23±UC) for 15 min. Animals were removed from 
the water, dried by the experimenter with a paper towel, placed into the recovery 
chambers for 10 minutes (30°C) and placed back in their home cages. Twenty-four 
hours following the pre-test, the animals were placed in the cylinders again for 5 min 
and the session was recorded using a videocamera (Sony Handycam CX-250, Sony, 
Japan). Immobility time, defined as passive floating with no additional activity other 
than that necessary to keep the mice head above water, was scored by two treatment- 
condition blinded observers during the 5-min test session. Latency to the first encounter
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to immobility was also measured. Faecal boli of the animals were counted at the end of 
the FST. The test was carried out in dim light conditions (301ux).
2.2.4 Neurochemical analysis
Separate cohorts of C57BL/6J mice were treated with an identical chronic saline and 
morphine administration paradigm as described above, and were left to spontaneously 
withdraw in their home cage for 7 days following their last treatment injection. Mice 
were killed by decapitation 1 hour post-final injection for the chronic morphine/saline 
administration groups or 7 days post-final injection for the withdrawal groups.
2.2,4.1 Oxytocin receptor autoradiography
Cleaning and subbing o f microscope slides: Microscope slides were left to soak 
overnight in Decon, a water-based detergent. Slides were then rinsed in hot running 
water for 15 minutes followed by a rinse in cold distilled water for a ftirther 15 minutes. 
The slides were then soaked in a 10% hydrochloric acid-90% ethanol solution for 20 
minutes followed by another 15 minute rinse in distilled water. Slides were coated by a 
2-minute immersion in 1% gelatine/chrom-alum solution and left to dry before use.
Tissue preparation: Brains were removed and frozen in -25°C isopentane solution for 
30 seconds and stored at -80°C until use. Prior to sectioning, brains were removed from 
-80°C and placed into a -21 C cryostat apparatus (Zeiss Microm 505E, Hertfordshire, 
U.K.) and coronally aligned by fixing the cerebellum onto a mounting stage using a 
plastic embedding liquid (O.C.T. compound, BDH chemicals, Dorset, U.K.). Adjacent 
20pm coronal brain sections were cut at 300pm distances and thaw-mounted onto 
gelatine-coated ice-cold microscope slides to define receptor binding levels from fore- 
to hind-brain regions. Brain slides were stored at -4°C for 2 hours to prevent the
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formation of ice crystals into the brain structures and then saved into -20°C storage for a 
minimum of 1 week prior to use.
Autoradiographic binding o f  the oxytocin receptor: OTR binding was carried out on 
sections from chronic saline- and morphine-treated and withdrawn mice in accordance 
with previously described methods (Jarrett et al., 2006), with minor modifications. 
Sections were rinsed twice for 10 min in a buffer solution (50mM Tris-HCl, pH 7.4, 
room temperature) to remove endogenous OT. Total binding was determined by 
incubating sections with 50pM [^^^I]-omithine vasotocin (OVTA) in an incubation 
buffer medium (50mM Tris-HCl, lOmM MgClz, ImM ethylenediaminetetraacetic acid 
(EDTA), 0.1 % w/v bovine serum albumin, 0.05 % w/v bacitracin; Sigma-Aldrich, 
Poole, UK, pH 7.4 at room temperature). Adjacent sections were incubated with 
OVTA (50 pM) in the presence of 50pM unlabelled (Thr'^,Gly^)-oxytocin (Bachem, 
Germany), to determine non-specific binding (NSB). Following a radioligand binding 
period of 60 min, slides were rinsed for 3 x 5 min in ice-cold rinse buffer (50 mM Tris- 
HCl, 10 mM MgCli, pH 7.4) followed by a 30 min wash in the ice-cold rinse buffer. 
That was followed by a 2-sec wash in ice-cold distilled water. Slides were then dried 
under a stream of cool air for 2 hours and stored in sealed containers with anhydrous 
calcium sulphate (Drierite-BDH Chemicals, Dorset, U.K.) for 2 days.
Autoradiographic fdm  apposition: Slides were apposed to Kodak MR-1 films (Sigma- 
Aldrich, UK) in Hypercassettes with autoradiographic [^ "^ C] microscales of known 
radioactive concentration (GE Healthcare Life Sciences, Amersham, U.K.) for 3 days 
Sections for all treatment groups were processed in parallel and apposed to the same 
film at the same time.
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Film development: Film development was carried out in the dark under red-filtered 
light. The films were developed in a 50% Kodak D19 developer solution (Sigma- 
Aldrich, Poole, UK) for 3 minutes. The films were then washed in distilled water 
containing glacial acetic acid for 30 seconds to stop the development reaction followed 
by 5 minutes fixation step in a Kodak rapid fix solution (Sigma-Aldrich, Poole, UK). 
Finally, films were rinsed in cold running water for 20 minutes and left to dry in a fume 
hood.
Image analysis (Quantitative autoradiography): Quantitative autoradiographic analysis 
of all structures were carried out by reference to the mouse brain atlas of Frankin and 
Paxinos (1997) and binding was analysed as previously described (Kitchen et al., 
1997), using MCID image analyser (Image Research, Ontario, Canada). Briefly, optical 
density values, which were quantified from autoradiographic [^ "^ C] microscales of 
known radioactive concentration (GE Healthcare, UK), were entered with their 
corresponding radioactivity values into a calibration table, and the relationship between 
radioactivity and optical density was subsequently determined using the MCID 
software. Specific binding was determined by subtracting the NSB from the total 
binding in the images of the brain sections.
2.2.4.2 Oxytocin peptide levels in the brain and plasma
The brains were removed following decapitation and were cut coronally from the 
olfactory bulbs up to the level of cerebellum. Hyp, Amy, septum and Hip were then 
micro-dissected by reference to the mouse brain atlas of Frankin and Paxinos (1997) 
and immediately preserved in dry ice and stored in -80°C until use. Peptides were 
extracted from the brain regions in accordance to previously described protocol by 
Christensson-Nylander et al., (1985), with minor modifications. Briefly, tissues were
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mixed with IM acetic acid, heated to 95°C for 10 min, homogenised and stored in -80°C 
overnight. The following day, the samples were thawed on ice and centrifuged at 9000 x 
g for 20 min (4 °C) and the supernatant was collected and lyophilized.
For plasma oxytocin levels, trunk blood from the mice was collected in tubes containing 
EDTA and aprotinin (500 KlU/ml of blood). The samples were centrifuged at 1600 x g 
for 15 min (4°C) and supernatant stored in -80°C. Solid phase extraction of samples was 
performed using 200mg C l8 Sep-Pak Columns (Phoenix Pharmaceuticals Inc., 
Karlsruhe, Germany). The extraction of the peptide in plasma was followed according 
to the manufacturer’s protocol (Phoenix Pharmaceuticals Inc., Karlsruhe, Germany). 
The eluent from the extraction process was collected and lyophilised.
The oxytocin peptide levels were measured according to the manufacturer’s instructions 
(oxytocin EIA kit, Enzo Life Sciences, Ch). The residues reconstituted in 250pL (for 
the Hyp and septum) or 200pL (for the plasma, Amy and Hip) of EIA assay buffer 
(oxytocin EIA kit, Enzo Life Sciences, Ch). OT levels were determined in duplicate in a 
single assay.
2,2,43 Plasma corticosterone levels
Trunk blood from the mice was collected in EDTA-containing tubes and spun for 15 
min at 2000 x g at 4°C. Blood was collected at 10:00 for all the groups of the 
animals.Plasma was collected and corticosterone levels were measured by using a 
rat/mouse corticosterone [^ ^^ I] kit (MP Biomedicals, New York, NY, USA) according to 
the manufacturer’s instructions. All coricosterone levels were determined in duplicate in 
a single assay.
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2.2.5 Carbetocin effects on morphine-induced behaviour
To assess the effect of the OT analogue CBT on protracted opioid withdrawal- 
associated anxiety, depression and social deficits, different cohorts of C57BL/6J mice 
treated with a chronic saline or “intermittent” escalating-dose morphine administration 
paradigm followed by 7 days withdrawal. Each test was performed on separate group of 
animals and only one test was carried out for each animal.
2.2.5.1 Pilot carbetocin dose-response experiment in prolonged morphine- 
withdrawn mice
The pilot experiment was carried out in order to determine the effective dose of CBT on 
anxiety-like and depressive-like behaviour as well as social interaction and social 
novelty preference deficits in mice undergoing protracted opioid withdrawal. Male 
C57BL/6J mice were treated with either saline or morphine with a 7-day “intermittent” 
morphine escalating-dose paradigm as described in Section 2.2.2 and left to 
spontaneously withdraw for a period of 7 days in their home cages. Seven days after 
their last treatment injection mice were challenged with either saline (4 ml/kg, i.p.) or 
CBT (2 or 6.4 or 20 mg/kg, i.p.) and 15 minutes later they were tested for depressive- 
like behaviour with the use of the FST for 5 min as described in Section 2.2.3.3. The 
mice were exposed to a 15-min pre-test forced-swim test session 24 hrs prior to the test 
session. Immobility time, latency to the first episode of immobility and number of 
faecal boli production were measured during the 5-min duration of the test.
2.2.5.2 Effect o f carbetocin on locomotor activity of naïve mice
To test if the immobility reduction effect of CBT in the FST, at the chosen dose of 6.4 
mg/kg, was due to a possible effect on locomotor activity rather than an antidepressant 
effect, the effect of CBT was tested in naïve C57BL/6J mice in the locomotor chambers. 
Naïve male C57BL/6J mice were placed in the aforementioned locomotor chambers
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equipped with horizontal and vertical photocells (Linton Instrumentation, Norfolk, 
U.K.) for 60 min before they were injected with either saline (4 ml/kg, i.p.) or CBT (6.4 
mg/kg, i.p. -  lowest effective dose in the pilot experiment). Following the injection, the 
mice were immediately placed in the locomotor chambers for a period of 40 min. 
Horizontal and vertical activities were recorded as the number of sequential infrared 
beam breaks every 5 min during the 40 min duration of the experiment. Faecal boli 
production was also measured.
2.2.5.3 Effects o f carbetocin on the social impairment following prolonged 
morphine withdrawal
In order to test the effect of CBT on social deficits following protracted morphine
withdrawal, male C57BL/6J mice were treated with chronic saline or “intermittent”
escalating-dose morphine administration paradigm as described in Section 2.2.2 and
after 7 days of withdrawal mice were administered with either saline (4 ml/kg, i.p.) or
CBT (6.4 mg/kg, i.p.) 5 min prior to testing in the 3-chamber sociability test for social
preference and preference for social novelty. The sociability test was conducted as
described in Section 2.2.3.3.
2.2.5.4 Effects of carbetocin on the anxiety-like behaviour following prolonged 
morphine withdrawal
In order to test the effect of CBT on anxiety-like behaviours following protracted
morphine withdrawal, male C57BL/6J mice were treated with chronic saline or
escalating-dose morphine administration paradigm as described in Section 2.2.2 and
after 7 days of withdrawal mice were administered with either saline (4 ml/kg, i.p.) or
CBT (6.4 mg/kg, i.p.) 10 min prior to testing in the EPM. The test was conducted as
described in Section 2.2.3.3
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2.2.5.5 Effects o f carbetocin on the depressive-like behaviour following prolonged 
morphine withdrawal
In order to test the effect of CBT on depressive-like behaviours following protracted
morphine withdrawal, male C57BL/6J mice were treated with chronic saline or
escalating-dose morphine administration paradigm as described in Section 2.2.2 and
after 7 days of withdrawal mice were administered with either saline (4 ml/kg, i.p.) or
CBT (6.4 mg/kg, i.p.) 10 min prior to testing in the FST. The test was conducted as
described in Section 2.2.3.3
2.2.5.6 Effects o f carbetocin on the hypolocomotion following prolonged morphine 
withdrawal
In order to investigate the effects of CBT on hypolocomotion following protracted 
morphine withdrawal male C57BL/6J mice were treated with a chronic saline or 
escalating-dose morphine paradigm (see Section 2.2.2) and left to spontaneously 
withdraw for 7 days. At this time point, mice were pre-injected with either saline (4 
ml/kg, i.p.) or CBT (6.4 mg/kg, i.p.) and tested in the locomotor chambers for a period 
of 60 min.
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2.2.6 Statistical Analysis
Body weight, food and water intake differences in morphine administered and 
withdrawn animals were analysed using two-way repeated measures ANOVA for 
factors ‘treatment’ and ‘day (repeated factor)’. Social interaction behavioural data were 
analysed using repeated measures two-way ANOVA for factors ‘treatment’ and 
‘chamber (repeated factor)’. Basal locomotor activity data during the chronic 
saline/morphine administration paradigm were analysed using repeated measures two- 
way ANOVA for factors ‘treatment’ and ‘day (repeated factor)’. Locomotor data 
following the 7 day withdrawal period was analysed with an unpaired Student t-test. 
CBT effects on locomotor activity was analysed using repeated measures two-way 
ANOVA for factors ‘pre-treatment (saline/CBT)’ x ‘time (repeated factor)’. Faecal boli 
production in the FST was analysed with non-parametric Mann-Whitney U-test. For the 
analysis of the effect of morphine withdrawal on anxiety and depressive-like behaviour, 
an unpaired t-test was used. The effect of CBT on anxiety and depressive-like behaviour 
in opioid abstinent mice was analysed by two-way ANOVA for factors ‘treatment 
(saline/morphine)’ x ‘CBT effect’. The effect of CBT on social preference and social 
novelty preference data were analysed using repeated measures three-way ANOVA for 
factors ‘treatment (saline/morphine)’ x ‘chamber’ (repeated factor) x ‘CBT effect’. For 
analysis of the OT levels and OTR binding two-way ANOVA was performed in each 
individual brain region or plasma for factors ‘treatment (saline/morphine)’ and 
‘withdrawal effect’. Corticosterone levels were analysed using two-way ANOVA for 
factors ‘treatment (saline/morphine)’ and ‘withdrawal effect’. All statistical analyses 
were performed using Statistica 8.0 analysis program (StatSoft Inc., France). Where 
ANOVA revealed a significant factor or interaction effect (p<0.05), a Bonferroni post- 
hoc test was carried out. All the values were expressed as mean ± SEM
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2.3 Results
2.3.1 Chronic morphine administration and withdrawal induced marked 
alterations in hody weight, food and water intake
Morphine treatment reduced body weight (F[i34]=12.20, p<0.001), food consumption
(F[i,24]=1 87.66, p<0.001) and water consumption (F[i,24]=15.54, p<0.001) over time
(f{i,2z%]=52.16, p<0.001\ F[7J68]=38.01,/><6.6>67 and F[7j 68]=2 .86,/><(?.67 respectively)
(Figure 2.4). However, withdrawal from morphine significantly increased body weight,
food and water consumption over time (F[6,204]=76.01,/><6.667; F[6,i9g]=38.01,/><6.667
and F[6,204]=9.31,/?<6.667 respectively). After 7 days of withdrawal (i.e. day 14), mice
recovered body weight, food intake and water consumption similar to saline-treated
animals {p>0.05, Figure 2.4).
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Figure 2.4: Effects of chronic morphine administration and withdrawal on body weight, food 
and water consumption.
(A) Daily alterations in body weight, (B) food consumption, and (C) water intake during chronic 
morphine or saline administration and withdrawal period. Data are expressed as mean ± SEM (n=13-
18 per group). *p<0.05, **p<0.01, ***p<0.001 vs saline control; ”p<0.05, ^^^p<0.001 vs day 7 
(repeated measures two-way ANOVA followed by Bonferroni post-hoc test). Dashed lines indicate 
the start o f withdrawal period.
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2.3.3 Chronic morphine administration induced marked increase in horizontal 
but not vertical locomotor activity
Morphine treatment increased horizontal activity (F[i,34]=59.46, p<0.001) over time
(F[6,204]=12.98, p <0.001) during the chronic administration paradigm (Figure 2.5A).
Following 5 days of morphine administration, tolerance to the hyperlocomotion was
developed as indicated with a significant decrease in morphine-stimulated horizontal
activity V5 the first day of morphine administration (time effect: (F[6,204]=19.71,
p<0.001)). Chronic morphine treatment did not induce any significant alterations in the
vertical locomotor activity compared to saline controls (F[i^34]=0.36, p>0.05) (Figure
2.5B). Saline animals showed decreased vertical locomotor activity over time
(F[6,204]=3.01,/><(?.07) due to habituation with the locomotor chambers.
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Figure 2.5: Chronic morphine administration increases horizontal but not vertical locomotor 
activity.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm (2 x 20-100 mg/kg, i.p. per day). Stimulated (A) horizontal and (B) 
vertical activity (representing rearing) were measured daily in 5 min bins for 1 hour post- morphine 
or saline injection during the 7-day “intermittent” saline or escalating-dose morphine administration 
paradigm. The average activity o f the hourly 5-min bins was calculated daily. Chronic morphine 
administration increased horizontal activity compared to saline. Tolerance to the locomotor 
hyperactivity has been developed following chronic administration of morphine. Data are expressed 
as mean ± SEM (n=18 per group). ***p<0.001 Saline; *^*p<0.001 vs Morphine Day 1; 
^'\'\p<O.OOJ Saline Day 1 (repeated measures two-way ANOVA followed by Bonferroni post-hoc 
test).
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2.3.4 Absence of physical withdrawal symptoms but reduction of basal locomotor 
activity following protracted morphine abstinence
Mice withdrawn from morphine for 1 day exhibited higher number of withdrawal 
jumping (40 ± 13 V5 0 ± 0; p<0.001) and showed higher numbers of faecal boli (13 ± 1 
vj" 3 ± 1 ; p<0.001) compared to saline-withdrawn animals. However, following a 7-day 
withdrawal from morphine, mice did not show any withdrawal jumping and faecal boli 
production was identical to saline-withdrawn mice (4 ± 1 V5 4 ± 1; p>0.05) 
demonstrating an absence of physical withdrawal symptoms following a 7-day 
morphine abstinence period.
Morphine treatment reduced basal horizontal activity (F[i,204]=16.84, p<0.001) over 
time (F[6,204]=6. 15,/><(?. 007) during the chronic administration paradigm (Figure 2.6A), 
which persisted following 7 days of withdrawal (p<0.001). This reduction was also 
observed in vertical basal activity but only following 7 days of withdrawal (p<0.01) 
(Figure 2.6B).
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Figure 2.6: Chronic morphine administration reduces basal locomotor activity which persists 
after a 7-day withdrawal period.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm (2 x 20-100 mg/kg, i.p. per day) and left to spontaneously withdraw for a 
period o f 7 days (i.e. day 14). Basal (A) horizontal and (B) vertical activity (representing rearing) 
were measured daily in 5 min bins for 1 hour prior- to morphine or saline injection (basal) during the 
7-day “intermittent” saline or escalating-dose morphine administration paradigm. Basal activity was 
also measured for a period o f 60 min, 7 days after the last treatment injection (day 14: withdrawal 
period). The average activity o f the hourly 5-min bins were calculated daily. Chronic morphine 
administration decreased basal horizontal activity which persisted following 7-days o f morphine 
withdrawal. Data are expressed as mean ± SEM (n=9-18 per group). *p<0.05, **p<0.01 vs Saline
(repeated measures two-way ANOVA followed by Bonferroni post-hoc test); **p<0.01, ””^ p<0.001 
vs Saline withdrawal (unpaired t-test).
m#
114
2.3.5 Protracted abstinence from chronic morphine administration abolished 
social preference in mice
We assessed social preference and social novelty preference in chronically saline and 
morphine-withdrawn mice with the use of the 3-chambered sociability test following 1- 
and 4-weeks withdrawal.
1-week withdrawal (Figure 2.7): Repeated measures two-way ANOVA showed a 
significant main effect of ‘side’ (F[ijo]=42.63, p<0.001) and significant ‘side’ x 
‘treatment’ interaction (F[ijo]=28.79,/?<(?.(?(?/) during the “social interaction” phase of 
the three-chambered sociability test (Figure 2.7A). Saline-withdrawn mice exhibited a 
significant preference for the chamber containing stranger 1 mouse vs the empty 
chamber (social preference) (p<0.001). However, morphine-withdrawn animals did not 
show any preference between the chamber containing stranger 1 mouse and the empty 
chamber (p>0.05), demonstrating a lack of social preference. Although there was a 
trend of increased amount of time that saline-withdrawn animals spent in the chamber 
containing the stranger 2 mouse compared to the amount of time spent in the chamber 
containing the stranger 1 mouse, repeated measures two-way ANOVA did not indicate 
any significant effects of chamber side (F[no]=2.72, p>0.05) or significant chamber side 
X  treatment interaction (F[ijo]=0.75, p>0.05) during the social novelty phase of the 
three-chambered sociability test (Figure 2.7B). However, this is probably due to power 
issues since by increasing the n numbers to n=10 in the studies with CBT, saline control 
animals showed preference for social novelty (see Section 2.3.12 and Figure 2.17B). 
Morphine-withdrawn animals did not show any preference between the chamber 
containing stranger 2 mouse and that containing stranger 1 demonstrating a lack of 
social novelty preference.
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4-weeks withdrawal (Figure 2.8): Repeated measures two-way ANOVA showed a 
significant main effect of ‘side’ (F[i,io]=5.30, p<0.05) and significant ‘side’ x 
‘treatment’ interaction (Figure 2.8A, F[i^io]=4.99, p<0.05) during the “social 
interaction” phase of the three-chambered sociability test (Figure 2.8A). Saline- 
withdrawn mice exhibited a significant preference for the chamber containing stranger 1 
mouse vs the empty chamber (social preference) (p<0.05). However, morphine- 
withdrawn animals did not show any preference between the chamber containing 
stranger 1 mouse and the empty chamber (p>0.05), demonstrating a lack of social 
preference. Although there was a trend of increased amount of time that saline- 
withdrawn animals spent in the chamber containing the stranger 2 mouse compared to 
the amount of time spent in the chamber containing the stranger 1 mouse, repeated 
measures two-way ANOVA did not indicate any significant effects of chamber side 
(F[i,io]=2.63, p>0.05) or significant chamber side x treatment interaction (F[i,io]=2.26, 
p>0.05) during the social novelty phase of the three-chambered sociability test (Figure 
2.8B). Morphine-withdrawn animals did not show any preference between the chamber 
containing stranger 2 mouse and that containing stranger 1 demonstrating a lack of 
social novelty preference.
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Figure 2.7: Abolition of social preference following 1-week withdrawal from chronic morphine 
administration.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm (2 x 20-100 mg/kg, i.p. per day) and left to spontaneously withdraw for a 
period o f 6 days. Mice were tested for (A) social preference, as defined by the time spent in the 
chamber containing the unfamiliar mouse (stranger 1) vs the empty chamber, during the 10 min 
“social interaction phase” o f the three-chambered sociability test and (B) social novelty preference, 
as defined by the time spent in the chamber containing a novel unfamiliar mouse (stranger 2) vs the 
chamber containing a now familiar one (stranger 1) during the 10-min “preference for novelty” 
phase o f the three-chambered sociability test. Mice chronically withdrawn from morphine exhibited 
a lack o f social preference. Data are expressed as mean ± SEM (n=6 per group). ***p<0.001 v^ ’ 
Saline withdrawal (Stranger 1 Side), (repeated measures two-way ANOVA followed by Bonferroni 
post-hoc test).
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Figure 2.8: Abolition o f social preference following 4-week withdrawal from chronic morphine 
administration.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm (2 x 20-100 mg/kg, i.p. per day) and left to spontaneously withdraw for a 
period o f 28 days. Mice were tested for (A) social preference, as defined by the time spent in the 
chamber containing the unfamiliar mouse (stranger 1) vs the empty chamber, during the 10 min 
“social interaction phase” o f the three-chambered sociability test and (B) social novelty preference, 
as defined by the time spent in the chamber containing a novel unfamiliar mouse (stranger 2) vs the 
chamber containing a now familiar one (stranger 1) during the 10-min “preference for novelty” 
phase o f the three-chambered sociability test. Mice chronically withdrawn from morphine exhibited 
a lack o f social preference. Data are expressed as mean ± SEM (n=6 per group). *p<0.05 V5 Saline 4 
weeks withdrawal (Stranger 1 Side), (repeated measures two-way ANOVA followed by Bonferroni 
post-hoc test).
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2.3.6 Protracted abstinence from chronic morphine administration enhanced 
anxiety-like behaviour in mice
Anxiety-related behaviour in saline and morphine -withdrawn mice was assessed with 
the use of the EPM following 1- and 4-weeks withdrawal.
1-week withdrawal (Figure 2.9): Morphine-withdrawn animals spent significantly less 
time in the open arms compared to saline-withdrawn animals (Figure 2.9A, p<0.01). In 
addition, morphine-withdrawn mice showed significantly less % of entries in the open 
arms compared to saline-withdrawn controls (Figure 2.9B,p<0.05).
4-weeks withdrawal (Figure 2.10): Morphine-withdrawn animals spent significantly less 
time in the open arms compared to saline-withdrawn animals (Figure 2.10A, p<0.01). 
In addition, morphine-withdrawn mice showed significantly less % of entries in the 
open arms compared to saline-withdrawn controls (Figure 2.1GB, p<0.05). These data 
clearly show that protracted withdrawal from morphine increases both measures of 
anxiety-like behaviour. The time spent by the 4-weeks withdrawn animals in the open 
arms showed a marked reduction compared with the time spent in the open arms of the 
EPM during the 1-week withdrawal. This reduction is due to the prior experience of the 
animals with the EPM that has been shown to cause a shift of the emotional state of the 
anims and to induce a phobic state instead of an ancoditioned anxiety response (File et 
al., 1993).
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Figure 2.9: Increase in anxiety-like behaviour following 1-week abstinence from chronic 
morphine administration.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm (2 x 20-100 mg/kg, i.p. per day) and left to spontaneously withdraw for a 
period o f 7 days. (A) Time in open-arm and (B) open-arm entries (%) were measured in saline and 
morphine-withdrawn animals during the 5 min duration o f the elevated plus-maze test. Mice 
chronically withdrawn from morphine demonstrated increased anxiety-like behaviour. Data are 
expressed as mean ± SEM (n=6 per group). *p<0.(95, **p<0.01 (unpaired t-test).
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Figure 2.10: Increase in anxiety-like behaviour following 4-weeks abstinence from chronic 
morphine administration.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm (2 x 20-100 mg/kg, i.p. per day) and left to spontaneously withdraw for a 
period o f 29 days. (A) Time in open-arm and (B) open-arm entries (%) were measured in saline and 
morphine-withdrawn animals during the 5 min duration o f the elevated plus-maze test. Mice 
chronically withdrawn from morphine demonstrated increased anxiety-like behaviour. Data are 
expressed as mean ± SEM (n=6 per group). *p<0.05, **p<0.01 (unpaired t-test).
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2.3.7 Protracted abstinence from chronic morphine administration enhanced 
depressive-like behaviour in mice
Depression-like behaviour in saline and morphine-withdrawn mice was assessed with
the use of the FST following 1- and 4-weeks withdrawal.
1-week withdrawal (Figure 2.11): Morphine-withdrawn animals showed significantly 
increased immobility time compared to saline-withdrawn animals (Figure 2.11 A, 
p<0.05). Morphine-withdrawn mice also took significantly less time to reach 
immobility (latency to immobility) for the first time compared to saline-withdrawn mice 
ip<0.01) (Figure 2.1 IB). Number of faecal boli production of each mouse were also 
measured during the forced-swim session. Morphine-withdrawn mice produced 
significantly more faecal boli compared to saline-withdrawn mice (Figure 2.11C,
4-weeks withdrawal (Figure 2.12): Morphine-withdrawn animals showed significantly 
increased immobility time compared to saline-withdrawn animals (Figure 2.12A, 
p<0.01). Morphine-withdrawn mice produced significantly more faecal boli compared 
to saline-withdrawn mice (Figure 2.12B, p<0.01). These data clearly show that 
protracted withdrawal from morphine increases depressive-like behaviour.
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Figure 2.11: Increase in depressive-like behaviour following 1-week abstinence from chronic 
morphine administration.
Male C57BL/6J mice were treated either with saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm (2 x 20-100 mg/kg, i.p. per day) and left to spontaneously withdraw for a 
period o f 8 days. (A) Immobility time, (B) latency to the first episode o f immobility and (C) number 
of faecal boli production were measured in saline and morphine-withdrawn animals during the 5-min 
duration o f the forced-swim test. Mice chronically withdrawn from morphine demonstrated 
increased depressive-like behaviour. Data are expressed as mean ± SEM (n=6 per group). *p<0.05,
'p<0.01 (unpaired t-test); p<0.05 (Mann-Whitney non-parametric t-tesf).
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Figure 2.12: Increase in depressive-like behaviour following 4-weeks abstinence from chronic 
morphine administration.
Male C57BL/6J mice were treated either with saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm (2 x 20-100 mg/kg, i.p. per day) and left to spontaneously withdraw for a 
period o f 4 weeks. (A) Immobility time and (B) number o f faecal boli production were measured in 
saline and morphine-withdrawn animals during the 5-min duration o f the forced-swim test. Mice 
chronically withdrawn from morphine demonstrated increased depressive-like behaviour. Data are 
expressed as mean ± SEM (n=6 per group). **p<0.01 (unpaired t-test); ^^p<0.01 (Mann-Whitney 
non-parametric U-test).
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2.3.8 Carbetocin reversed depressive-like behaviour in 7-day morphine- 
withdrawn mice in a dose-dependent manner (pilot experiment)
This dose-response study was conducted to determine the optimal dose of CBT in 
reducing the emotional impairment during protracted morphine withdrawal in mice. 
Withdrawal from morphine significantly increased immobility time (Figure 2.13A, 
F[i,36]=15.63, p<0.001; Sal-Sal vs Mor-Sal, p<0.001), decreased latency to the first 
episode of immobility (Figure 2.13B, F[i,36]=25.58, p<0.001; Sal-Sal vs Mor-Sal, 
p<0.001) and increased faecal boli production (Figure 2.13C, F[i,36]=9.38,/><0.(?(?7; Sal- 
Sal vs Mor-Sal,/7< 0.(7/), indicating an enhancement of depression-like behaviour. Pre­
treatment with CBT dose-dependently decreased immobility time ((F[i,36]=4.88, p<0.01 
Mor-Sal vs Mor-CBT (6.4 or 20 mg/kg),/><0.0/)), increased latency to the first episode 
of immobility (F[i36]=3.86, p<0.05; Mor-Sal vs Mor-CBT (20 mg/kg), p<0.05), and 
decreased faecal boli production (F[i^36]=3.69, j9<0.05 Mor-Sal vs Mor-CBT (6.4 or 20 
mg/kg), p<0.01) in 7-day morphine-withdrawn animals. Saline-withdrawn mice pre­
treated with CBT (2, 6.4 or 20 mg/kg) showed no significant change in immobility time, 
latency to immobility or faecal boli production (Figure 2.13, p>0.05). According to the 
results, the chosen dose for CBT was 6.4mg/kg since it is the lowest effective dose 
reducing depressive-like behaviour of morphine withdrawan animals in the FST.
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Figure 2.13: Pilot dose-response carbetocin reversal of depressive-like behaviour in long-term 
morphine abstinent mice.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm and left to spontaneously withdraw for a period o f 7 days. Seven days after 
their last treatment injection, mice were challenged with either saline or CBT (2 or 6.4 or 20 mg/kg, 
i.p) and 15 minutes later they were tested for depressive-like behaviour with the use o f the forced- 
swim test. (A) Immobility time, (B) latency to the first episode o f immobility and (C) number of 
faecal boli production were measured during the 5-min duration o f the test. Withdrawal from chronic 
morphine administration induced depressive-like behaviour that was reversed by pre-treatment with 
CBT in a dose-response manner. Data are expressed as mean ± SEM (n=3-10 per group). **p<0.01, 
***p<0.001 Sal - Sal; ^p<0.05, **p<0.01, *^*p<0.001 vs Mor - Sal (two-way ANOVA for factors 
‘treatment (saline/morphine)’ x ‘CBT effect’ followed by Bonferroni post-hoc test).
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2.3.9 Carbetocin effects on locomotor activity in naive mice
Separate cohort of male C57BL/6J were randomly assigned to two treatment groups 
(saline or CBT 6.4mg/kg) and tested in the locomotor chambers to investigate the 
effects of the CBT on motor activity. There was no significant difference in basal 
horizontal (Figure 2.14A) or vertical activity (Figure 2.14B) of the animals (unpaired t- 
test, p>0.05). Two-way repeated measures ANOVA revealed no significant differences 
in either horizontal (Figure 2.14C, F[i,no]=1.10, p>0.05) or vertical (Figure 2.14D, 
F[i,iio]=l .80, ^ >0. OJ) locomotor activities following saline or CBT 6.4mg/kg injections.
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Figure 2.14: Carbetocin administration did not alter locomotor activity in naive mice.
Naïve male C57BL/6J mice were placed in locomotor chambers for 60 min before (pre-CBT 
injection) they were injected with either saline (4 ml/kg, i.p.) or CBT (6.4 mg/kg, i.p.) and average
(A) horizontal and (B) vertical activities were measured for 1 hour. Following the injection (post- 
CBT injection), the mice were immediately placed in the locomotor chambers for a period o f 60 min 
and (C) horizontal and (D) vertical activities were measured throughout the 60 min post-injection 
period. Data are expressed as mean ± SEM (n=6 per group).
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2.3.10 Carbetocin reversed the enhancement of depressive-like behaviour in 
protracted morphine abstinent mice
Withdrawal from morphine significantly increased immobility time in the forced-swim
test (Figure 2.15A, F[i,28]=24.67, p<0.001; Sal-Sal vs Mor-Sal, p<0.001), decreased
latency to the first episode of immobility (Figure 2.15B, F[i,28]=17.36,/><0.007; Sal-Sal
vs Mor-Sal, p<0.001) and increased faecal boli production (Figure 2.15C, F[i,28]=17.30,
p<0.01; Sal-Sal v.s Mor-Sal, p<0.01), indicating an enhancement of depressive-like
behaviours. Pre-treatment with CBT decreased immobility time (Figure 2.15A,
F[i,28]=16.34, p <0.001; Mor-Sal vs Mor-CBT p<0.001) and decreased faecal boli
production (Figure 2.15C, ¥[i2Sf=H-2l, p<0.01; Mor-Sal vs Mor-CBTp<0.01) only in
morphine-withdrawn animals (morphine x CBT interaction: F[i^28]=19.11, p<0.001).
CBT pre-treatment showed a trend to increase the latency to the first episode of
immobility only in the morphine-withdrawn animals (interaction: ¥\\;i %ÿ=5 3 1  , p<0.05),
however, this effect did not reach statistical significance (Figure 2.15B, Mor-Sal vs
Mor-CBT,p=0.08). Saline-withdrawn mice pre-treated with CBT showed no significant
changes in immobility time, latency to immobility and faecal boli production (Figure
2.15, Sal-Sal v.y Sal-CBT,p>O.OJ).
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Figure 2.15: Carbetocin pre-treatment prevented the enhancement of depressive-like 
behaviour during protracted morphine abstinence.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm. Seven days after their last treatment injection, mice were challenged with 
either saline or CBT (6.4 mg/kg i.p.), and 15 minutes later they were tested for depressive-like 
behaviour with the use o f the forced-swim test. (A) Immobility time, (B) latency to the first episode 
of immobility and (C) number of faecal boli production were measured during the 5 min duration o f 
the test. Pre-treatment with CBT reversed the enhancement o f immobility time, the decrease in 
latency to the first episode o f immobility and increased the number o f faecal boli production in 7- 
days morphine-withdrawn animals. Data are expressed as mean ± SEM (n=6-10 per group). 
**p<0^01, ***p<0.001 V5 Sal - Sal; ^^p<0.01, ^*^p<0.001 Mor - Sal (two-way ANOVA followed 
by Bonferroni post-hoc test).
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2.3.11 Carbetocin reversed the enhancement of anxiety-like behaviour in 
protracted morphine abstinent mice
Withdrawal from morphine significantly decreased time spent in the open-arms of the
elevated plus-maze (Figure 2.16A, F[i,29]=6.80, p<0.05; Sal-Sal vj Mor-Sal, p<0.05),
which is an indication of increased anxiety-like behaviour in rodents. Pre-treatment with
CBT (6.4 mg/kg, i.p.) increased the time spent in the open-arms only in morphine-
withdrawn mice (F[i,29]=5.67,/?<(?.05; Mor-Sal Mor-CBT,/?<(?. (?5). In addition, CBT
pre-treatment significantly increased the % of open-arm entries in morphine-withdrawn
animals (Figure 2.16B, F[i,29]=7.5455, p<0.05; Mor-Sal vs Mor-CBT, p<0.05). Mice
undergoing withdrawal from saline and pre-treated with CBT showed no significant
changes in time spent in open-arms or % of open-arm entries (Figure 2.16, Sal-Sal vs
Sa\-CBT, p>0.05).
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Figure 2.16: Carbetocin pre-treatment prevented the enhancement of anxiety-like behaviour 
during protracted morphine abstinence.
Carbetocin pre-treatment prevented the enhancement o f anxiety-like behaviour during protracted 
morphine abstinence. Male C57BL/6J mice were treated with either saline or morphine with an 
“intermittent” 7-day escalating-dose paradigm. Seven days after their last treatment injection mice 
were challenged with either saline or CBT (6.4mg/kg, i.p.) and 15 minutes later they were tested for 
anxiety-like behaviour with the use o f the elevated plus-maze. (A) Time spent in the open arms and
(B) open-arm entries (%) were measured during the 5 min duration o f the test. Pre-treatment with 
CBT reversed the decrease o f open-arm time and open-arm entries following 7-days morphine 
withdrawal. Data are expressed as mean ± SEM (n=6-10 per group). *p<0.05 Sal - Sal; ^p<0.05 
vs Mor - Sal (two-way ANOVA followed by Bonferroni post-hoc test).
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2.3.12 Carbetocin restored social preference in protracted morphine abstinent 
mice
In the social preference test, three-way repeated measures ANOVA for factors 
‘treatment (morphine/saline)’ x ‘CBT effect’ x ‘side (stranger 1/empty cage)’ revealed a 
significant interaction between all three factors (Figure 2.17A, F[i,25]=11.16, p<0.01). 
While saline-withdrawn animals showed significant preference to the chamber 
containing the stranger 1 mouse (p<0.05), morphine-withdrawn animals did not show 
any preference between these two chambers (p>0.05), indicating a lack of social 
preference. Pre-treatment with CBT significantly increased the time that morphine- 
withdrawn animals spent in the chamber containing the stranger 1 mouse (Figure 2.17A, 
Mor-Sal vs Mor-CBT, p<0.001; stranger 1 vf empty cage, p<0.001), indicating a 
restoration of social preference. CBT pre-treatment had no effect on social preference in 
mice undergoing withdrawal from saline (Figure 2.17A, Sal-Sal Sal-CBT stranger 1 
side, p>0.05).
For social novelty, three-way repeated measures ANOVA showed a significant ‘side’ x 
“CBT effect” interaction p<0.001) and a significant ‘side’ x ‘treatment’
interaction (Figure 2.17B, F[i^25]=12.14, p<0.001). While saline-withdrawn animals 
showed significant preference for the chamber containing the novel stranger 2 mouse 
(i.e., unfamiliar animal) the chamber containing stranger 1 (i.e., familiar animal) 
(p<0.05), morphine-withdrawn mice did not show any preference between the two 
chambers (p>0.05), indicating a lack of social novelty preference. Pre-treatment with 
CBT increased the time that morphine-withdrawn mice spent in the chamber containing 
the unknown stranger 2 mouse compared to the chamber containing the familiar 
stranger 1 mouse, although this effect did not reach statistical significance (p>0.05).
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CBT pre-treatment had no significant effect on preference to social novelty in mice 
undergoing withdrawal from saline (Figure 2AlB,p<0.05).
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Figure 2.17: Carbetocin pre-treatment restored social preference during protracted morphine 
abstinence.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm. Seven days after their last treatment injection, mice were challenged with 
either saline or CBT (6.4 mg/kg, i.p.) and 25 minutes later they were tested for (A) social interaction 
as defined by the time spent in the chamber containing the unfamiliar mouse (stranger 1) vs the 
empty chamber during the 10-min “social interaction phase” o f the three-chambered sociability test 
and (B) preference for social novelty as defined by the time spent in the chamber containing a novel 
unfamiliar mouse (stranger 2) the chamber containing a now familiar one (stranger 1) during the 
10-min “preference for novelty” phase o f the three-chambered sociability test. Withdrawal from 
chronic morphine administration abolished social preference which was restored by pre-treatment 
with CBT. Data are expressed as mean ± SEM (n=6-10 per group). *p<0.05, ***p<0.001 V5. 
stranger 1 side in the same treatment group; ^^^p<0.001 vs Mor - Sal stranger 1 side (repeated 
measures three-way ANOVA followed by Bonferroni post-hoc test).
133
2.3.13 Carbetocin increased hypolocomotion induced by morphine withdrawal in 
mice
Horizontal locomotor activity: Withdrawal from morphine significantly decreased 
horizontal locomotor activity (Figure 2.ISA, F[i46p33.79, j9<0.001; Sal-Sal vs Mor-Sal, 
p<0.001). Pre-treatment with CBT (6.4 mg/kg, i.p.) showed a trend to increase 
horizontal activity only in morphine-withdrawn mice, however this effect did not reach 
statistical significance (F[ij6]=5.67, p<0.05; Mor-Sal vs Mor-CBT, p=0.07). Mice 
undergoing withdrawal from saline and pre-treated with CBT showed no significant 
changes in horizontal activity (Figure 2.18A, Sal-Sal vj- Sal-CBT, p>0.05).
Vertical locomotor activity: Withdrawal from morphine significantly decreased vertical 
locomotor activity (Figure 2.18B, F[i,i6]=29.03,/?<(?.001; Sal-Sal vj Mor-Sal, ^ <0.007). 
Pre-treatment with CBT did not show any significant effect in mice undergoing 
withdrawal from either saline or morphine (Figure 2.18B, Sal-Sal vs Sal-CBT, Mor-Sal 
Mor-CBT p>0.05).
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Figure 2.18: Carbetocin pre-treatment increased hypolocomotion induced by protracted 
morphine abstinence.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm. Seven days after their last treatment injection mice were challenged with 
either saline or CBT (6.4mg/kg, i.p.) and 15 minutes later they were tested for locomotion activity. 
(A) Horizontal and (B) vertical activities were monitored for 1 hour. Morphine withdrawal 
significantly decreased both horizontal and vertical activities. Data are expressed as mean ± SEM 
(n=6-10 per group). **p<0.01, **p<0.01 vs Sal - Sal (two-way ANOVA followed by Bonferroni 
post-hoc test).
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2.3.14 Protracted abstinence from morphine induced marked alterations in the 
oxytocin receptor binding in the brain of mice
A significant ‘treatment’ effect was found in the Fir (F[ij6]=19.88, p<0.001), medial 
septum (MS) (F[i,i6]=10.06, p<0.01), ventral limb of the diagonal band (F[i,i6]=6.40, 
p<0.05), LS (F[i,i6]=13.72,/?<(?.(?7) and Amy {F[\ i^e]=63.S6, p<0.001). A  significant 
withdrawal effect was observed in the Fir {¥[i^ie]=ll.S9,p<0.001), the LS (F[ij6]=9.60, 
p<0.01) and Amy (F[ij6]=29.00, p<0.001) and a significant treatment x withdrawal 
interaction was identified in the Amy (F[i,i6]=4.75, p<0.05). Chronic morphine 
administration increased OTR binding in the Amy compared with saline control 
(p<0.001) which persisted following a 7-day withdrawal period (p<0.001) (Figure 
2.19). Seven-day withdrawal from chronic morphine administration induced a 
significant increase in OTR binding in the Fir (p<0.05), MS (p<0.05) and LS (p<0.001) 
compared with saline-withdrawn animals (Figure 2.19).
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Figure 2.19: Region-specific alterations of [ I] OVTA binding following protracted withdrawal 
from morphine administration.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm (2 x 20-100 mg/kg, i.p. per day) and left to spontaneously withdraw for a 
period o f 7 days. (A) Computer-enhanced representative autoradiograms o f adjacent coronal brain 
sections from chronic saline-, morphine-treated, saline-withdrawn and morphine-withdrawn mice at 
the level o f the olfactory nuclei (Bregma 2.46mm, first row), the caudate putamen (Bregma 0.86mm, 
second row), the septum (Bregma 0.14mm, third row) and the thalamus (Bregma -2.06mm, fourth 
row). OTRs were labelled with ['^^1]-0VTA (50pM). The colour bar illustrates a pseudo-colour 
interpretation o f black and white film images in fmol/mg tissue equivalent. Representative images for 
the non-specific binding (50pM ['"^1]-0VTA in the presence o f 50pM un label led oxytocin) are shown 
for all the treatment groups. (B) Quantitative oxytocin receptor autoradiographic binding and in brain 
regions o f mice treated with a chronic “intermittent” escalating-dose morphine administration 
paradigm and in mice-withdrawn for 7 days from this paradigm. Data are expressed as mean ± SEM 
(n=5) specific [ '“^1]-0VTA binding (fmol/mg tissue equivalent). ***p<0.001 v.s’ saline control; 
^p<0.05; *^^p<0.001 vs saline 7 days withdrawal (two-way ANOVA followed by Bonferroni post-hoc 
test). Abbreviations: Acb, nucleus accumbens; Amy, amygdala; AGE, anterior olfactory nucleus- 
lateral; ACM, anterior olfactory nucleus-medial; AOV, anterior olfactory nucleus-ventral; CgCx, 
cingulate cortex; CPu, caudate-putamen; Hip, hippocampus; Hyp, hypothalamus; LS, lateral septum; 
MS, medial septum; Fir, piriform cortex; PV Th, paraventricular nucleus o f thalamus; Th, thalamus; 
Tu, olfactory tubercle; VDB, vertical limb of the diagonal band of Broca.
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2.3.15 Protracted abstinence from morphine induced alterations in the oxytocin 
peptide levels in the brain of mice
A significant ‘treatment’ effect (F[p22]~15.81, p<0.001) was observed on oxytocin
levels in the Hyp. A 43% decrease in OT levels was observed in the Hyp of mice
undergoing 7-day withdrawal from morphine vj 7-day saline-withdrawn animals
(Figure 2.20, p<0.05). No ‘treatment’ or ‘withdrawal’ effects were observed in the
septum (p>0.05), and OT content in the Hip and Amy were mostly below detection
levels (<11.7 pg/ml, i.e. 1.4 pg/mg of tissue).
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Figure 2.20: Brain region-specific alterations of oxytocin peptide levels following ptrotracted 
withdrawal from morphine administration.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm (2 x 20-100 mg/kg, i.p. per day) and left to spontaneously withdraw for a 
period o f 7 days. Data are expressed as mean ± SEM (n=5-7) OT peptide levels (pg/mg o f tissue). 
*p<0.05; vs saline 7 days withdrawal (two-way ANOVA followed by Bonferroni post-hoc test). 
Abbreviations: Amy, amygdala; Hyp, hypothalamus.
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2.3.16 Chronic administration and protracted withdrawal from morphine induced 
profound alterations in the plasma corticosterone and oxytocin levels
Plasma corticosterone levels: Two-way ANOVA showed a significant ‘treatment’
(F[i,43]=10.81, ‘withdrawal’ (F[i 43]=8.79, and interaction ‘treatment’
X  ‘withdrawal’ effect (F[i^43]=21.34, Chronic morphine treatment increased
plasma corticosterone levels (Figure 2.21,p<0.001), but levels were comparable to the
control group following a 7-day morphine withdrawal period (Saline withdrawal vs
Morphine withdrawal, ^ >0.0J).
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Figure 2.21: Normalisation of corticosterone levels following protracted withdrawal from 
morphine administration.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm (2 x 20-100 mg/kg, i.p. per day) and left to spontaneously withdraw for a 
period o f 7 days. Plasma corticosterone levels were measured in chronic saline-treated, morphine- 
treated, saline-withdrawn and morphine-withdrawn mice. Data are expressed as mean ±  SEM (n=l 1- 
12 per group) ***p<0.001 V5 saline control; ^**p<0.001 V5 morphine (two-way ANOVA followed by 
Bonferroni post-hoc test).
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Plasma oxytocin levels: Two-way ANOVA showed a significant ‘treatment’ effect 
(F[i,19]=30.91, p<0.001). A decrease in OT plasma levels was observed in chronic 
morphine-treated (p<0.05) and 7-day withdravm (p<0.001) mice compared to their 
respective saline controls (Figure 2.22).
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Figure 2.22; Persistent decrease in plasma OT levels following chronic morphine 
administration and withdrawal.
Male C57BL/6J mice were treated with either saline or morphine with an “intermittent” 7-day 
escalating-dose paradigm (2 x 20-100 mg/kg, i.p. per day) and left to spontaneously withdraw for a 
period o f 7 days. Plasma OT levels were measured in chronic saline-treated, morphine-treated, 
saline-withdrawn and morphine-withdrawn mice. Data are expressed as mean ± SEM (n=5-6 per 
group) *p<0.05 vs saline control; ^^^p<0.001 vs saline 7-day withdrawal (two-way ANOVA 
followed by Bonferroni post-hoc test).
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2.4 Discussion
The aim of this study was to investigate if protracted abstinence from chronic morphine 
causes dysregulation of the endogenous oxytocinergic system and if this is associated 
with the emergence of emotional impairment, characteristic for recovering abstinent 
opioid addicts. Moreover, we investigated the effects of CBT administration in 
reversing the emotional deficits induced following 1-week withdrawal firom chronic 
morphine administration.
A mouse model of protracted opioid abstinence was established which mimicked the 
physical and emotional alterations taking place during long-term withdrawal in human 
opioid abstinent addicts. The significant reduction in food and water consumption as 
well as weight loss following chronic morphine administration, followed by the rebound 
over-eating, over-drinking and weight gain observed during acute abstinence from 
chronic morphine exposure in our model, is in line with the nutritional and weight 
changes observed in heroin addicts chronically exposed to the drug and during drug 
withdrawal periods (Mohs et al., 1990). These findings, along with the behavioural 
observations of this study, indicate the translational validity of the mouse model used in 
this study.
In addition, we demonstrated that acute (1 day) withdrawal from chronic morphine 
exposure triggered severe physical withdrawal symptoms including jumps and increased 
defecation which disappeared after 7 days of abstinence. This is in agreement with 
Goeldner et al., (2011) who observed a decrease in physical withdrawal symptoms 
following naloxone precipitation with increasing abstinence duration from morphine in 
the same strain of mice.
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Despite the disappearance of the acute physical withdrawal symptoms and the 
normalisation in food, water consumption and weight changes following 7 days of 
morphine abstinence, 7-day morphine-withdrawn mice exhibited higher levels of 
anxiety, depression and abolished social preference, which persisted following 4 weeks 
of withdrawal. These observations are consistent with the typical decrease of physical 
withdrawal symptoms following a short period of drug free detoxification in human 
heroin addicts (Nunes et al., 2004, Peles et al., 2007, Martin and Jasinski, 1969) and in 
line with the persistence of symptoms associated with emotional distress, dysphoria and 
social withdrawal lingering for months in recovering heroin addicts (Jaffe, 1990, Martin 
and Jasinski, 1969, McGregor et al., 2008). In support of this, the persistent reduction of 
basal horizontal activity during and following chronic morphine administration is likely 
to be a representation of anhedonia in these mice. Indeed, impaired locomotor activity 
has been associated with anhedonia and a loss of interest in exploration in rodents 
(Rygula et al., 2005), implying a deficit in motivation. The hypolocomotion observed 
during protracted morphine withdrawal might be associated with a decreased DAergic 
activity. Opioid withdrawal has been largely associated with a long-lasting reduction of 
mesolimbic DAergic neuronal activity (Diana et ah, 1995) and a marked decrease in 
extracellular DA levels in the Acb (Pothos et ah, 1991, Rossetti et ah, 1992, Acquas et 
ah, 1991), which have been associated with decreased locomotor activity in rats (Hooks 
et ah, 1991)
This study demonstrated a clear causal link between opioid abstinence and the 
emergence of a negative emotional state and social deficits in mice. This is particularly 
important for the understanding the mechanisms underpinning the high comorbidity 
(30-50%) between heroin addiction and major depression and anxiety disorders (Nunes 
et ah, 2004, Peles et ah, 2007) as well as social withdrawal and self-isolation (Heinrichs
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and Gaab, 2007). There is a considerable body of literature suggesting that dyregulation 
of the HP A axis activity in opioid abstinent individuals might be involved in the 
mechanisms underlining at least some aspects of physical and emotional symptoms of 
withdrawal observed in opioid abstinent individuals (Koob and Kreek, 2007, Koob, 
2008, Li et al., 2008, Zhang et al., 2008); also see Section 1.2.2.1. The results presented 
here indicate that although dysregulation of the HP A axis activity might be the case for 
the manifestation of acute physical withdrawal symptoms which is associated with a 
significant elevation of plasma corticosterone, this is unlikely to be the case for the 
manifestation of emotional behavioural impairment. This is supported by the 
normalisation of both physical withdrawal symptoms (jumping and increased 
defecation) as well as corticosterone levels following long-term morphine withdrawal 
in our animal model which is in accordance with Goeldner et ah, (2011) and Zhou et ah, 
(2008) who also reported normalisation of the HP A response following prolonged 
opioid abstinence in mice and rats respectively. All together, these data indicate the 
neuroadaptational alterations in other extra-hypothalamic stress circuitries and 
monoamine systems which might be also involved in the manifestation of the emotional 
deficits following chronic morphine withdrawal.
Additionally, this is the first study to demonstrate a dysregulation of the oxytocinergic 
system following protracted opioid withdrawal. Indeed, a marked decrease of OT levels 
in plasma of chronically morphine-treated mice that persisted following 7 days of 
withdrawal was observed. Lower levels of OT were also detected in the Hyp of 
morphine-withdrawn mice, clearly indicating a hypo-oxytocinergic state during this 
protracted opioid withdrawal period. This is coupled with an up-regulation of the OTR 
in the Amy, septum and Pir, where oxytocinergic neurons project (Gimpl and 
Fahrenholz, 2001), possibly as a compensatory consequence of a reduced oxytocinergic
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activity. Generally, an increase in OT peptide or administration of an OTR agonist is 
concomitant with rapid OTR desensitisation, clathrin-dependend internalisation and 
subsequent down-regulation (Evans et ah, 1997). Therefore, it is likely that the up- 
regulation of the OTR in the Amy, septum and Pir is the result of decreased OT levels 
in the brain. These findings are in agreement with deficits in plasma OT levels reported 
in mothers who were exposed to cocaine during pregnancy (Light et ah, 2004) and they 
are also consistent with studies in rodents showing a decrease in OT content, synthesis 
or mRNA expression in several brain regions following chronic exposure to other drugs 
of abuse (see McGregor and Bowen, 2012), including morphine (Kovacs et ah, 1987a, 
You et ah, 2000). Considering the ability of the oxytocin analogue CBT to prevent the 
enhancement of anxiety- and depressive-like behaviour and to restore social preference 
in protracted opioid abstinent mice, this oxytocinergic dysfunction is likely to be at least 
partly responsible for the emotionally impaired behaviours observed in our mouse 
model. Interestingly, the up-regulation of OTR was observed in the Amy and septum, 
regions known to be responsible for the antidepressant, anxiolytic and/or pro-social 
effects of OT (Curley et ah, 2012, Debiec, 2005, Domes et ah, 2007a, Lukas et ah, 
2012). As there is considerable evidence demonstrating abnormalities of both these 
regions following chronic drug use (Cornish et ah, 2012, Okvist et ah, 2011), it is 
possible that the compensatory region-specific up-regulation of OTRs might represent a 
homeostatic mechanism to oppose the anxiogenic, depressive and anti-social 
consequences of chronic opioid use and withdrawal. In support of this, OTR binding has 
also been shovm to be increased in the brain following chronic stress in rats (Liberzon 
and Young, 1997). Although the up-regulation of the OTR binding alone is unlikely to 
explain the effects of CBT in preventing the emotional impairment, the hypo-
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oxytocinergic state observed in the Hyp supports the hypothesis that CBT may increase 
the OT levels in the Hyp by acting on the central OTR.
In contrast with our results showing a decrease in OT peptide levels in the Hyp and a 
concomitant up-regulation of the OTR in the brain, Curley et ah, 2012, found up- 
regulation of the OTR in the lateral septum, dorsal endopiriform nucleus and the dorsal 
BNST under communal rearing in lactating female Balb/c mice with their pups, a period 
that has been widely associated with elevated hypothalamic and plasma OT levels. The 
discrepancy here may be due to sex-differences in mice (male mice in our study vs 
female mice in Curley’s study), different strains (C57BL/6J vs Balb/c) and the fact that 
during lactation and pup suckling hormonal differences might affect the oxytocinergic 
system. Indeed, oxytocin release has been shovm to increase during milk ejection and 
suckling (see Gimpl and Fahrenholz, 2001).
At a molecular level, these findings may also suggest the presence of close interactions 
between the opioid and oxytocinergic system in the brain. In fact, we showed that 
manipulation of the opioid system by chronic administration of morphine or by 
withdrawal induced profound alterations of OT levels in the brain of mice. This 
interaction could also take place at the receptor level as persistent alteration of OTR 
were observed following chronic opioid stimulation and following withdrawal. The 
presence of a MOPr-OTR interaction is supported from data from our laboratory 
showing significantly higher levels of OTR binding in the brains of MOPr knockout vs 
WT mice (unpublished data). Interestingly, the up-regulation is localised in the Amy of 
MOPr knockout mice which is supportive of a MOPr-OTR interaction in a region of 
high MOPr (Kitchen et ah, 1997) and OTR expression. The significance of this receptor 
interaction in the modulation of mood, pain and addictive disorders remains to be 
determined.
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The results of this study provide strong evidence that the endogenous central 
oxytocinergic system might be a novel target for the effective prevention of the 
emotional deficits during opioid withdrawal. Indeed, the oxytocin analogue CBT 
completely abolished the anxiety- and despair-like behaviour observed following 
prolonged morphine abstinence highlighting the potential of oxytocinergic-based 
pharmacotherapy to assist with the prolongation of an abstinent state by attenuating the 
persistent emotional withdrawal symptoms. This is particularly important given the high 
prevalence of depression even in heroin addicts treated with methadone maintenance 
treatment (Peles et ah, 2007) and the ambiguous efficacy of classic antidepressants in 
treating these symptoms in that population (Nunes et ah, 2004). The effect of CBT on 
social withdrawal in morphine abstinent mice is of particular interest as it represents the 
first attempt to modulate the social consequence of opioid abstinence with a specific 
pharmacotherapy. Social enhancing effect of intra-amygdalar administration of OT was 
similarly observed in animals made socially withdrawn by repeated exposure to 
phencyclidine (PCP) (Lee et ah, 2005). Considering the therapeutic success of social 
support programs (e.g. Alcoholics Anonymous; see Loder, (2009)) and the benefits of 
social rehabilitation and social reintegration (see McGregor and Bowen, 2012) in 
keeping addicts abstinent, the use of OT agents may prove an important tool to assist in 
relapse prevention by promoting pro-social behaviour.
Previous studies have shown that centrally but not peripherally administered CBT 
produces anxiolytic effects (Mak et ah, 2012) and i.c.v., i.p. and i.v. administration of 
this compound exhibits antidepressant-like effect (Chaviaras et ah, 2010) in naïve rats 
as measured in the EPM and FST respectively. However, in the present study CBT did 
not show a significant anxiolytic or antidepressant effect in control animals that were 
injected with saline for 7 days, at least at the dose of 6.4 mg/kg. This is likely to be due
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to the already reduced baseline anxiety and aversive mood tone that the mice experience 
following repeated handling and injections over the 7-day injection period, which would 
make the detection of anxiolytic and antidepressant effect challenging. Nonetheless, our 
results indicate that the anxiolytic and antidepressant effect of CBT is specific for 
opioid withdrawal-induced symptoms, at least at the low dose of 6.4 mg/kg used. CBT, 
at this dose, did not alter the locomotor activity in naïve (Figure 2.14) and chronically 
saline-treated animals (Figure 2.18) suggesting that the decreased immobility measured 
in the FST in this study was not due to a stimulatory effect of CBT on motor activity but 
rather to an antidepressant effect, which is in complete accordance to similar 
observations in the rat (Chaviaras et al., 2010). The antidepressant-nature of the effects 
of CBT on the FST is further supported by its potent effect in reducing faecal boli 
production during the 5-min testing period. Indeed, antidepressant drugs were shown to 
significantly decrease defecation during the FST (Craft et ah, 2010, Eissa Ahmed and 
Al-Rasheed, 2009).
Although activation of the oxytocinergic system is known to have a marked anxiolytic, 
anti-aggressive and antidepressant effect, primarily by inhibiting CRF release in the 
Hyp (Baumgartner et al., 2008, Kirsch et al., 2005, Di Simplicio et al., 2009, 
Dabrowska et al., 2011, Windle et al., 2004, Neumann et al., 2000b), this is unlikely to 
reflect the mechanism by which CBT exerts its antidepressant and anxiolytic effect 
during opioid abstinence, as basal HP A activity is normalised at that prolonged stage of 
abstinence in our animal model. However, it is likely that CBT may exert these effects 
as well as its pro-social effects, by modulating extra-hypothalamic activity (primarily in 
the Amy and septum). Indeed, the growing body of evidence demonstrating that the 
stress-regulating and pro-social behavioural enhancing properties of OT are partly due 
to its action in the Amy (Domes et al., 2007a) and the septum (Curley et al., 2012,
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Lukas et al., 2012), strongly support our suggestion. The region-specific up-regulation 
of OTRs in the Amy and septum following long-term opioid withdrawal, which reflects 
an increase in sensitivity of the OTR system, may indeed assist with the high efficacy of 
CBT to reduce emotional impaired behaviour during abstinence, even at the relative low 
dose of 6.4 mg/kg.
The effects of CBT in our study are likely to be a consequence of OTR activation in the 
CNS. Indeed, the antidepressant effect of systemic CBT in the FST was shown to be 
blocked by i.c.v. administration of the selective OTR antagonist atosiban (Chaviaras et 
al., 2010) indicating a central OTR mediated effect of CBT. The normalisation of 
emotional impairment behaviour by CBT during protracted opioid abstinence suggests 
that oxytocinergic enhancing pharmacotherapy may be effective in assisting relapse 
prevention to opioid se lf administration. This is indeed the case for MAP addiction, as 
OT facilitated extinction of MAP-induced CPP and prevented its stress-induced 
reinstatement in mice (see Section 1.8.3.3).
It is also highly likely that the pro-social enhancing effect of CBT in morphine abstinent 
mice may be due its effect on the mesolimbic DAergic system, given the strong 
interaction between the OT and DA system (see Section 1.8.1) which are common 
neuronal substrates for both social and addictive related behaviours (Baskerville and 
Douglas, 2010, McGregor and Bowen, 2012, McGregor et al., 2008). Nonetheless, it is 
unlikely that CBT itself is rewarding as intranasal OT is not euphorogenic in humans 
despite modulating social cognition (MacDonald et al., 2011, McGregor and Bowen, 
2012) and only extremely high doses of systemically administered OT can induce CPP 
in rats (Liberzon et al., 1997, McGregor and Bowen, 2012). In accordance, it has been
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recently shown that CBT 6.4mg/kg, i.p. is neither rewarding, nor aversive, as measured 
by the conditioned place preference paradigm (unpublished data).
In conclusion, we provide the first evidence that OTR analogues attenuate emotional 
impairment behaviour during protracted opioid abstinence in mice. We also demonstrate 
that long-term opioid abstinence induce profound neuroadaptations of the endogenous 
oxytocinergic system which are likely to modulate at least in part withdrawal-induced 
emotional impaired behaviour. These findings strongly suggest that the oxytocinergic 
system might emerge as a novel target for assisting long-term opioid detoxification and 
as a consequence might increase the chances of opioid addicts remaining in a long-term 
drug free abstinent state. OT itself is commercially available in an intranasal spray 
format, it is not euphorogenic itself (MacDonald et al., 2011) and is currently used as a 
treatment strategy for autistic spectrum disorder, social anxiety and obsessive 
compulsive disorders (OCD). Preliminary results from the first trial with intranasal OT 
treatment for acutely withdrawn alcoholics have revealed promising results in 
preventing withdrawal symptoms (Pedersen et al., 2013).
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CHAPTER 3
Chronic cocaine treatment and withdrawal 
induces persistent oxytocin receptor up- 
regulation in the amygdala
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3.1 Introduction
Cocaine is purified from the leaves of the Erythroxylum coca plant originally grown in 
South America, Mexico, Indonesia, and the West Indies (see Goldstein et ah, 2009). 
Cocaine is a widely abused Class A psychostimulant drug acting on monoamine 
transporters in the brain to block the re-uptake of DA, NA and 5-HT, thus increasing 
their synaptic concentrations. The pre-synaptic blockade of the DA transporter in the 
DAergic neurons projecting from the VTA to the Acb causes increased DA levels in the 
synaptic cleft, which by binding to the DA receptors in the Acb cause euphoric effects 
(see Nestler, 2005b). Cocaine can be administered via several routes, including 
intravenous injection, intranasal administration of cocaine hydrochloride and smoking 
of cocaine base (“crack” cocaine) (Hatsukami and Fischman, 1996).
Administration of cocaine results in elevated motor responses and the emergence of 
stereotypic-like behaviours which are believed to be mediated by DAergic transmission 
in the mesolimbic system (see Kalivas and Stewart, 1991, Kalivas and Duffy, 1993, 
Robinson and Berridge, 1993). In animal models, psychostimulant-induced behaviour 
often manifests as escalated locomotor and/or stereotyped repetitive responses, such as 
rearing, grooming, biting or circling (see Creese and Iversen, 1972, Scheel-Krüger, 
1972). Although the neural mechanisms underlying stereotypic behaviours are not fully 
elucidated, it is thought to be related with the psychostimulant-induced increased striatal 
DAergic transmission (Costall et al., 1977). Specifically, stereotypic responses to 
cocaine have been associated with increased DAergic transmission in the dorsal 
striatum (Staton and Solomon, 1984) and it has been shown that persistent vertical 
activity (rearing), a characteristic high-level stereotypic response to cocaine observed in 
C57BL/6J mice (Schlussman et al., 2003, Bailey et al., 2008), was correlated with high 
DAergic stimulation in the CPu (al-Khatib et al., 1995).
151
The major problem for cocaine addicts who are recovering from their addiction is as for 
opioids, the maintenance of a drug-free state since relapse is common. Cocaine 
withdrawal is not characterised by the substantial physical symptoms associated with 
opioid withdrawal (Gawin, 1991). Rather, acute cocaine withdrawal involves a 
spectrum of psychological side effects including dysphoria, anhedonia, anxiety, 
depression, sleep and appetite disturbances and craving (Gawin, 1991, Kampman et al., 
2001, Malin et al., 2000, Montoya and Vocci, 2008, Mulvaney et al., 1999). These 
emotional effects associated with cocaine withdrawal are particularly crucial in terms of 
the treatment of cocaine addicts, as the expression of these symptoms has been shown to 
play a key role even after long-term abstinence, which often leads to relapse (Gawin and 
Kleber, 1986). Individuals crave the rewarding properties of cocaine and re-administer 
the drug to ameliorate the negative psychological effects associated with withdrawal 
(see Adinoff, 2004).
Several mechanisms have been proposed for the neurobiology underlying cocaine 
withdrawal negative emotional symptoms; however the exact mechanisms underpinning 
these affective behaviours remain unclear. Both pre-clinical and clinical studies 
demonstrated profound alterations in the HPA axis activity during acute as well as 
chronic cocaine administration and withdrawal. Both acute and chronic cocaine use 
induced hyper-activation of the HPA axis activity (see Section 1.2.2.1). Moreover, 
persistent elevations of plasma ACTH and corticosterone levels have also been 
observed following acute and prolonged spontaneous withdrawal from chronic 
escalating-dose cocaine administration in rodents (Mantsch et al., 2007, Zhou et al., 
2011). In addition, Samyai and colleagues (1995) showed that during cocaine 
withdrawal, hypothalamic CRF-like immunoreactivity levels are decreased indicating 
increased CRF release. In contrast, POMC mRNA levels remain unchanged in the
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pituitary (Zhou et al., 2003b). Cocaine abstinent individuals exhibit profound alterations 
in the HPA axis activity leading to stress-induced cravings of the drug as well as 
negative emotions (Fox et al., 2008, S inha et al., 2003, Zhou et al., 2003a). Some 
human studies found that cocaine-addicted patients have higher basal plasma ACTH 
and cortisol levels persisting even up to three months of abstinence (e.g. Wilkins et al., 
2005). Therefore, dysregulation of the HPA axis has been hypothesised to at least 
partially underlie the negative mood state during cocaine abstinence. Although CRF 
antagonists have been proved to be beneficial in reversing stress-induced reinstatement 
in drug-seeking after withdrawal and attenuating acute negative physical symptoms of 
drug withdrawal in rodents (Iredale et al., 2000, Lu et al., 2000), several clinical trials 
that investigated the effects of CRF antagonists on stress-related responses and anxiety 
in humans, yielded negative results in their treatment potential (Steckler and 
Dautzenberg, 2006, Binneman et al., 2008, Zorrilla and Koob, 2004, Holsboer and 
Ising, 2008). Given these negative results, prospects for the efficacy of CRF antagonists 
in the treatment of addiction and prevention of relapse after abstinence are not clear.
There is some evidence indicating a possible beneficial role of OT in the modulation of 
several negative emotional symptoms of prolonged withdrawal from cocaine. As it has 
been discussed in Section 1.7, OT has antidepressant and anxiolytic effects both in 
humans (Baumgartner et al., 2008, Kirsch et al., 2005, Di Simplicio et al., 2009) and in 
animals (Dabrowska et al., 2011, Windle et al., 2004). As a result, it is possible that 
some of the negative emotional effects associated with cocaine addiction and 
withdrawal may be at least partly modulated by the oxytocinergic system and that 
exogenous administration of OT might prove beneficial for the alleviation of these 
negative symptoms.
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A number of pre-clinical as well as clinical studies have demonstrated profound 
dysregulation of the oxytocinergic system following chronic cocaine exposure and a 
possible role for exogenous administered OT in treating the behavioural and 
neurochemical consequences of chronic cocaine use (see Section 1.8.3.1). Briefly, both 
central and peripheral administration of OT have been found to decrease cocaine- 
induced hyperlocomotion (Kovacs et al., 1990), exploratory hyperactivity (Samyai et 
al., 1990), stereotypic behaviour -  e.g. sniffing (Samyai et al., 1991), tolerance (Samyai 
et al., 1992a) and intravenous se lf administration (Samyai and Kovacs, 1994).
Additionally, several studies reported profound effects of cocaine on the oxytocinergic 
system. For example, acute cocaine administration increased OT peptide levels within 
the Hyp and Hip (Samyai et al., 1992c), while chronic administration of cocaine 
decreased both plasma levels as well as OT immunoreactivity within the Hyp and Hip 
(Samyai et al., 1992a), and increased OTR binding in the Amy of rat dams (Johns et al.,
2004). In accordance to these pre-clinical findings, mothers who used cocaine during 
pregnancy showed lower plasma OT levels (Light et al., 2004). The exact mechanisms 
underlying the interactions of the oxytocinergic system and cocaine remain unclear. The 
DAergic innervation of the hypothalamic OT-synthesising neurons might be a putative 
link between cocaine and oxytocinergic system since DAergic neurotransmission is 
activated following cocaine administration (see Section 1.2.1.1). In support of this, it 
has been observed that DA and DA agonists are able to increase OT hypothalamic 
secretion in vitro (Bridges et al., 1976). It has been also shown that OT administration 
was able to block cocaine-induced DA release in the Acb (Kovacs et al., 1990).
Although there is strong evidence for the involvement of the oxytocinergic system in 
cocaine addiction, it is currently not clear if chronic cocaine administration can 
dysregulate the OTR system and if this persists following prolonged periods of
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abstinence. As a result, we hypothesised that chronic cocaine administration can cause 
alterations in the central OTR system, which persist following long-term withdrawal. To 
test this hypothesis, male mice were administered with a chronic escalating-dose 
“binge” cocaine paradigm to mimic escalating pattern of cocaine administration in 
humans (Mantsch et al., 2004, Picetti et al., 2012, Tsukada et al., 1996) and/or left to 
spontaneously withdraw for 14 days from this paradigm. Alterations of the OTR density 
in the brains of these animals were measured by means of quantitative [^^^I]-OVTA 
autoradiography.
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3.2 Methods
3.2.1 Animals
Male 7-week old C57BL/6J mice (20-25g, Charles River Laboratories, Kingston, UK), 
were single-housed in a temperature-controlled environment with a 12-hour light/dark 
cycle (lights on: 06:00 am). Whilst in home cages, mice had access to food and water 
ad-libitum. Mice were left to acclimatise in their new environment for 7 days prior to 
the start of experimental procedures and were handled daily by the experimenter. All 
procedures were conducted in accordance with the U.K. Animal Scientific Procedures 
Act (1986).
3.2.2 Chronic “binge” escalating-dose cocaine administration paradigm
Mice were randomly divided into 4 different treatment groups: (1) chronic saline, (2) 
chronic cocaine, (3) saline 14-days withdrawal, (4) cocaine 14-days withdrawal. Mice 
were injected (i.p.) with saline (4 ml/kg) or cocaine (Sigma-Aldrich, Poole, UK) in an 
escalating-dose “binge” paradigm as described by Bailey et al., (2005, 2007) to mimic a 
common pattern of self-administration in human cocaine abusers (Mantsch et al., 2004, 
Picetti et al., 2012, Tsukada et al., 1996). Three i.p. injections of saline or cocaine (Ih 
apart) were administered daily, with the first injection given 4 hours after the start of the 
light cycle (i.e. 10:00am). The cocaine-treated animals received 3 x 15 mg/kg/day on 
days 1-4, 3 x 20 mg/kg/day on days 5-8, 3 x 25 mg/kg/day on days 9-12, and 3 x 30 
mg/kg/day on days 13 and 14 (Figure 3.1). One hour (chronic treatment groups) or 14 
days (protracted withdrawal groups) after their last treatment injection, animals were 
killed by decapitation after a 30-sec exposure to carbon dioxide (CO2). Brains were 
rapidly removed, frozen in -25°C isopentane solution for 30 seconds, and stored at - 
80°C until use. Trunk blood was also collected in EDTA-containing tubes. Weight and 
food consumption of the animals were monitored during the whole drug-administration
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period at 8:00am. Weight of the animals was also recorded during the withdrawal 
period.
3 X Saline or 3 x Saline or 3 x Saline or 3 x Saline or
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Figure 3.1: Chronic cocaine administration and withdrawal protocol.
Male C57BL/6J mice were treated with chronic saline or “binge” escalating-dose (3 injections x 15- 
30 mg/kg, i.p./day) cocaine for 14 days and sacrificed (chronic administration groups). Another
cohort o f mice were treated with the same administration paradigm and left to spontaneously
withdraw for 14 days (Day 28; 14-day withdrawal groups).
3.2.3 Behavioural experiments
3.2.3.1 Locomotor activity
Horizontal and vertical motor activities (basal and stimulated) were recorded everyday 
during the administration period, and 14 days following withdrawal (Day 28) as detailed 
in Section 2.2.3.1. The only difference being that motor activity was recorded for 60 
minutes immediately following each of the three injections. Mice were returned to their 
home cages each day following completion of the locomotor activity measurement. 
Average activity from the Ih basal activity and average from the three daily injections 
were calculated.
3.2.3.2 Cocaine-induced stereotypy
All mice were scored for stereotypy behaviour 30 min after each injection for a period 
of 30 seconds. The rating was based on a slight modification of the scale used by 
Schlussman et al., (2003), Bailey et al., (2007), Schlussman et al., (2005) and Metaxas 
et al., (2012) and consists of a graded scale of behaviours, see Table 3.1. Stereotypy 
behaviour of each mouse was recorded during the saline/cocaine administration period 
(Days 1-14). Mice were also behaviourally assessed for stereotypy following 1, 8, 12
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and 14 days of withdrawal (Days 15, 22, 26 and 28 respectively) at the same time 
points. The median stereotypy score of the three injections on each day was calculated 
for each treatment group.
Table 3.1: Cocaine stereotypy score
Score Predominant behaviour
1 Asleep, inactive
2 Alert, actively grooming
3 Increased sniffing (occasional light sniffing, often while exploring the cage)
4 Intermittent rearing and sniffing (two or three rears in a 20 sec period, with sniffing frequently at the apex of the rear)
5 Increased locomotion
6
Intense sniffing in one location (rapid sniffing, often with head down is the 
predominant behaviour displayed)
7 Continuous pivoting and sniffing with locomotion (no rearing)
8
Intermittent rearing and sniffing with locomotion (intermittent up and down 
rearing behaviour)
9
Maintained rearing and sniffing (animal remains up on hind legs throughout 
most of the observation period)
10 Splayed limbs
Mice were scored daily for saline- or cocaine- induced stereotypy behaviour for a period o f 30 
seconds, 30 min after each o f the three administration injections and at specific days during 
withdrawal.
3.2.4 Neurochemical analysis
3.2.4.1 OTR autoradiography
Tissue preparation, quantitative autoradiographic binding of the OTR and subsequent 
autoradiographic procedures were carried out as detailed in Section 2.2.4.1.
3.2.4.2 Plasma corticosterone levels
Trunk blood from the mice was collected in EDTA-containing tubes and spun for 15 
min at 2000 x g at 4°C. Plasma was collected and corticosterone levels were measured 
as detailed in Section 2.2.4.3.
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3.2.5 Statistical Analysis
Body weight and food consumption changes were analysed using two-way repeated 
measures ANOVA for factors ‘treatment’ and ‘day (repeated factor)’. Basal and 
stimulated locomotor activity data during the chronic saline/cocaine administration 
paradigm were analysed using repeated measures two-way ANOVA for factors 
‘treatment’ and ‘day (repeated factor)’. Basal locomotor data following the 14-day 
withdrawal period was analysed with an unpaired t-test. For the stereotypy behaviour 
repeated measures two-way ANOVA for factors ‘treatment’ and ‘day’ (repeated factor) 
was used. Because the expression of behavioural stereotypy was measured with a 
behavioural rating scale, non-parametric Mann Whitney U-test was used on individual 
test days to confirm ANOVA results. During withdrawal, stereotypy behaviour was 
analysed using Mann Whitney U-test,
For analysis of OTR binding and corticosterone levels, two-way ANOVA was 
performed in each individual brain region for factors ‘treatment (saline/cocaine)’ and 
‘withdrawal effect’. All statistical analyses were performed using Statistica 8.0 analysis 
program (StatSoft Inc., France). Where ANOVA revealed a significant factor or 
interaction effect (p<0.05), a Bonferroni post-hoc test was carried out. All the values 
were expressed as mean ± SEM.
159
3.3 Results
3.3.1 Chronic cocaine administration and withdrawal induced marked 
alterations in body weight of mice
Cocaine administration reduced body weight (Figure 3.2, F[i,io]=14.477, p<0.01) over
time (Figure 3.2, F[i4j4oj=2.02, p<0.05). This reduction in body weight persisted 1-day
following withdrawal from chronic cocaine administration compared to saline controls
(p<0.001). However, after 14 days withdrawal from cocaine (i.e. day 28) cocaine-
withdrawn mice increased their body weight (Day 28 vs Day 14, p<0.05) and they did
not show any significant differences compared to saline-treated animals (Figure 3.2,
p>0.05).
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Figure 3.2: Effects of chronic cocaine administration and withdrawal on body weight of mice.
Daily alterations in body weight during chronic cocaine or saline administration and withdrawal 
period. Cocaine administration significantly decreased body weight compared to saline controls 
which persistent 1-day following withdrawal (Day 15). No significant differences in body weight o f  
cocaine withdrawan animals compared to controls were observed on Days 22, 26 and 28). Data are 
expressed as mean ± SEM (n=6 per group). *p<0.05 va Saline control; *^p<0.01 va Saline 1-day 
withdrawal (Day 15); ^p<0.05 vs Cocaine Day 14 (repeated measures two-way ANOVA followed 
by Bonferroni post-hoc test). Dashed line indicates the start o f withdrawal period.
160
3.3.2 Chronic cocaine administration significantly decreased food intake of mice
In order to investigate whether the decrease in body weight of animals following 
chronic cocaine administration was due to cocaine-induced hyperlocomotion or 
alterations in food intake, food consumption was recorded daily during the 
saline/cocaine administration paradigm. Cocaine administration reduced food intake 
(Figure 3.3, Y[\ \^qÿ=\2 \.91,p<0.001) over time (Figure 3.3, Y[u^m]=\52\,p<0.001).
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Figure 3.3: Effects of chronic cocaine administration on food intake of mice.
Daily alterations in food intake during chronic cocaine or saline administration. Cocaine 
administration significantly decreased body weight compared to saline controls. Data are expressed 
as mean ± SEM (n=6 per group). **p<0.01, ***p<0.001 V5 Saline control (repeated measures two- 
way ANOVA followed by Bonferroni post-hoc test).
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3.3.3 Chronic cocaine administration increased locomotor activity of mice
Cocaine treatment increased horizontal activity (F[i,9]=88.74, p<0.001) over time 
(F[13,ii7]=12.98, p <0.001) during the chronic administration paradigm (Figure 3.3A). 
Cocaine-treated animals had increased locomotor activity compared to saline controls 
on days 2-14. Following 3 days of cocaine administration, there was a significant 
increase in cocaine-stimulated horizontal activity compared with that of Day 1 
ip<0.001), indicating the aquisition of behavioural sensitisation to the locomotor- 
stimulating effect of cocaine. This increase in horizontal activity persisted following 14 
days of withdrawal from this administration paradigm.
Chronic cocaine treatment significantly increased vertical locomotor activity compared 
to saline controls on all treatment days (Figure 3.3B, F[i,9]=10.69, p<0.05). No 
‘treatment’ x ‘time (day)’ interaction effect was observed (p>0.05) indicating a lack of 
sensitisation for that behaviour.
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Figure 3.4; Chronic cocaine administration increased horizontal and vertical locomotor 
activity.
Male C57BL/6J mice were treated with either saline or cocaine with a “binge” 14-day escalating- 
dose paradigm (3 x 15-30 mg/kg, i.p. per day). Stimulated (A) horizontal and (B) vertical motor 
activity (representing rearing) were measured daily in 5 min bins for 1 hour post- each saline or 
cocaine injection during the administration period. The average activity o f the hourly 5-min bins (for 
all the three injections) was calculated daily. Chronic cocaine administration increased horizontal 
activity compared to saline. Data are expressed as mean ± SEM (n=6 per group). ***p<0.001, 
*p<0.05 vs Saline; ^^p<0.01, vs Cocaine Day 1 (repeated measures two-way ANOVA followed by 
Bonferroni post-hoc test).
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3.3.4 Increase of basal locomotor activity following chronic cocaine pre­
treatment and following protracted abstinence
Cocaine pre-treatment increased basal horizontal activity (F[i,io]=8.00, p<0.05) over
time (Figure 3.5A, ¥[13^ i3Q]=3.S0, p<0.001). Cocaine pre-treatment also increased basal
vertical (rearing) activity (F[i,io]=17.31, p<0.01) during the chronic administration
paradigm (Figure 3.5B). The increased basal horizontal (p<0.05) and vertical (p<0.001)
activity persisted following 14-days withdrawal compared to saline-withdrawn animals
(Day 28) (Figure 3.5).
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Figure 3.5: Chronic cocaine pre-treatment increased basal horizontal and vertical locomotor 
activity which persisted following a 14-day withdrawal period.
Male C57BL/6J mice were treated with either saline or cocaine with a “binge” 14-day escalating- 
dose paradigm (3 x 15-30 mg/kg, i.p. per day) and left to spontaneously withdraw for a period o f 14 
days (i.e. day 28). Basal (A) horizontal and (B) vertical motor activity (representing rearing) were 
measured daily in 5-min bins for 1 hour prior to saline or cocaine injection during the 14 days of 
administration paradigm. Basal activity was also measured for a period o f 60 min, 14 days after the 
last treatment injection (Day 28). The average activity o f the hourly 5-min bins was calculated daily. 
Chronic cocaine administration increased basal horizontal and vertical activity which persisted 
following 14-days o f cocaine withdrawal. Data are expressed as mean ± SEM (n=6 per group). 
*p<0.05, p<0.001 vs Saline (repeated measures two-way ANOVA followed by Bonferroni post-hoc 
test);  ^p<0.05, ^^^p<0.001 vs Saline withdrawal (unpaired t-test). Dashed line indicates the start o f  
withdrawal period.
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3.3.5 Chronic cocaine induced stereotypic behaviours which did not persist 
following withdrawal in mice
Cocaine administration significantly increased stereotypy behaviours in mice. Two-way
repeated measures ANOVA for factors ‘treatment’ and ‘day (repeated factor)’ revealed
that cocaine administration increased stereotypy behaviours (Figure 3.6) of mice
(F[i,io]=1713.42, p<0.001) over time (F[i3j30]=7.40, p<0.001). Following 3 days of
cocaine administration, there was a significant increase in cocaine-induced stereotypy
behaviour compared with Day 1 (p<0.001), indicating the presence of sensitisation to
the stereotypy behaviour induced by cocaine. This increase did not persist following 1,
8, 12 and 14 days of withdrawal from the cocaine administration (i.e. Days 15, 22, 26
and 28 respectively), where stereotypic behaviour observations were similar to saline-
withdrawn animals (Figure 3.6,p>0.05, non-parametric Mann-Whitney U-test).
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Figure 3.6: Effects of chronic cocaine administration and withdrawal on stereotypy behaviour 
of mice.
Cocaine treatment resulted in a significant increase in stereotypy scores and acute sensitisation. 
Cocaine-induced stereotypy behaviour was absent in 1-, 8-, 12- and 14-day withdrawn mice (i.e. 
Days 15, 22, 26 and 28 respectively). Data are expressed as mean ± SEM (n=6 per group). 
***p<0.001 Saline; *^^p<0.001 vs Cocaine Day 1 (repeated measures two-way ANOVA followed 
by Bonferroni post-hoc test). Dashed line indicates the start o f withdrawal period.
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3.3.6 Chronic administration and protracted withdrawal from cocaine induced 
profound alterations in the plasma corticosterone levels
Two-way ANOVA showed a significant ‘treatment’ effect (F[i,35]=15.88, p<0.001) on
the plasma corticosterone levels. Chronic cocaine treatment increased plasma
corticosterone levels (Figure 3.6, p<0.05), which persisted following a 14-day
withdrawal period (Saline withdrawal Cocaine withdrawal,/><0.05).
350
ffl ~  200
5  150
0 
Ü 
re
1
CL
100
Saline Cocaine Saline withdrawal Cocaine withdrawal
Figure 3.7: Increased corticosterone levels following chronic administration and withdrawal 
from cocaine in mice.
Male C57BL/6J mice were treated with either saline or cocaine with a “binge” 14-day escalating- 
dose paradigm (3 x 15-30 mg/kg, i.p. per day) or left to spontaneously withdraw for a period o f 14 
days. Plasma corticosterone levels were measured in chronic saline-treated, cocaine-treated, saline- 
withdrawn and cocaine-withdrawn mice. Data are expressed as mean ± SEM (n=6-12 per group) 
*p<0.05 vs Saline control; *p<0.001 V5 Saline withdrawal (two-way ANOVA followed by 
Bonferroni post-hoc test).
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3.3.7 Chronic administration and protracted abstinence from cocaine induced 
marked region-specific alterations in oxytocin receptor binding in the brain 
of mice
Quantitative autoradiographic binding of [^^^I]-OVTA was performed in coronal brain 
sections of chronic saline-treated, cocaine-treated and protracted saline-withdrawn and 
cocaine-withdrawn mice. Regional 2-way ANOVA for factors ‘treatment’ x 
‘withdrawal’ showed a significant ‘treatment’ effect on the OTR binding in the Pir 
(F[i.i8rll-86, p<0.01), LS (F[i,i6rl5.54, p<0.01) and the Amy (F[i,ig]=29.11, 
p<0.001). A significant ‘withdrawal’ effect was observed in the MS (F[i,ig]=11.26, 
p<0.01) and the VDB (¥[ns]=6.3^,p<0.05) and a significant ‘treatment’ x ‘withdrawal’ 
interaction was identified in the MS ( ¥ 0 7 ,  p<0.05) and the VDB (F[ijg]=16.13, 
p<0.001). Chronic cocaine administration increased OTR binding in the Amy compared 
with saline control (p<0.01), which persisted following a 7-day withdrawal period 
(p<0.05) (Figure 3.7). Fourteen days withdrawal from chronic cocaine administration 
induced a significant increase in OTR binding in the MS (p<0.05), VDB (p<0.01) and 
the LS ip<0.05) compared with saline-withdrawn animals (Figure 3.7).
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withdrawal from cocaine administration.
Male C57BL/6J mice were treated with either saline or cocaine with a “binge” 14-day escalating- 
dose paradigm (3 x 15-30 mg/kg, i.p. per day) or left to spontaneously withdraw for a period o f 14 
days. (A) Computer-enhanced representative autoradiograms of adjacent coronal brain sections from 
chronic saline-treated, cocaine-treated, saline-withdrawn and cocaine-withdrawn mice at the level o f 
the olfactory nuclei (Bregma 2.46mm, first row), the caudate putamen (Bregma 0.86mm. second 
row), the septum (Bregma 0.14mm, third row) and the thalamus (Bregma -2.06mm, fourth row). 
OTRs were labelled with [’"^l]-OVTA (50pM). The colour bar illustrates a pseudo-colour 
interpretation of black and white film images in fmol/mg tissue equivalent. Representative images 
for the non-specific binding (50pM ['^^1]-0VTA in the presence o f 50pM unlabelled oxytocin) are 
shown for all the treatment groups. (B) Quantitative OTR binding in brain regions o f mice treated 
with a chronic “binge” escalating-dose cocaine administration paradigm and in mice-withdrawn for 
14 days from this paradigm. Data are expressed as mean ± SEM (n=5-6) specific [ '“'^IJ-OV'fA 
binding (fmol/mg tissue). **p<0.01 V5 Saline control; ^p<0.05; *^p<().()l v.v Saline 14 days 
withdrawal (two-way ANOVA followed by Bonferroni post-hoc test). Abbreviations: Acb, nucleus 
accumbens; Amy, amygdala; AOL, anterior olfactory nucleus-lateral; AOM, anterior olfactory 
nucleus-medial; AOV, anterior olfactory nucleus-ventral; CgCx, cingulate cortex; CPu, caudate- 
putamen; Hip, hippocampus; LS, lateral septum; MS, medial septum; Pir, piriform cortex; PV Th, 
paraventricular nucleus o f thalamus; Th, thalamus; Tu, olfactory tubercle; VDB, vertical limb o f the 
diagonal band of Broca.
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3.4 Discussion
The aim of this study was to determine the effects of chronic administration and 
protracted withdrawal from cocaine on the OTR system in the brain. This is the first 
study showing that prolonged abstinence from chronic cocaine administration induces 
marked up-regulation of the OTR binding in the Amy and septum of mice.
Food intake and weight changes that chronic cocaine addicts experience were mimicked 
in a mouse model (Brewer et al., 2008, Lynch et al., 2008, Williamson et al., 1997), 
with a significant decrease in food intake and body weight in mice chronically treated 
with cocaine and a rebound increase in weight gain following withdrawal. Indeed, 
cocaine abusers have repeatedly reported decreased appetite during cocaine use which 
returned to normal after cessation of drug taking (Lynch et al., 2008, Williamson et al.,
1997). However, the nutritional effects of cocaine is beyond the scope of this thesis; 
thus, for further information the reader is directed to an extended review by Mohs et al., 
(1990).
Chronic “binge” escalating-dose cocaine administration increased both horizontal and 
vertical locomotor activities of mice. These findings are in line with previous findings 
showing increased locomotor activity following both steady-dose (e.g. Koff et al., 1994, 
Schlussman et al., 2003, Tolliver and Carney, 1994, Bailey et al., 2008, Bailey et al., 
2007, Metaxas et al., 2012) and escalating-dose (Bailey et al., 2008, Schlussman et al.,
2005) cocaine administration. Horizontal activity of cocaine-treated animals was 
significantly higher on Day 3 (15 mg/kg) compared to Day 1 (15 mg/kg) indicating the 
acquisition of rapid sensitisation to the locomotor activity which reached a plateau after 
the Day 4 of administration. Bailey et al., (2008) and Metaxas et al., (2012) observed a
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similar pattern of cocaine-induced locomotor sensitisation by using a steady-dose 
“binge” cocaine administration paradigm in the same strain of mice.
Additionally, this is the first study to show increased basal horizontal and vertical 
locomotor activities following previous exposure to cocaine by using an escalating-dose 
“binge” administration paradigm, an effect which persisted following 14 days of 
spontaneous withdrawal. This finding shows a persistent cocaine-induced contextual 
sensitisation (i.e. the animals show behavioural sensitisation in an environment paired 
with the drug injection). The environment associated with drug administration has been 
shown to modulate both the development as well as the expression of behavioural 
sensitisation (Badiani and Robinson, 2004). Generally, in rodents, behavioural 
sensitisation is measured in terms of locomotor or stereotypic (including rearing) 
activity, although it is thought that locomotor sensitisation may only represent indirect 
evidence of hypersensitivity of the motivation circuit, which contributes to the addictive 
‘wanting’ (see Robinson and Berridge, 2008). Locomotor sensitisation in the drug- 
paired environment has been linked with drug craving (see Robinson and Berridge, 
2008), which might contribute to relapse following abstinence. Indeed, a low dose 
“challenge” with a previously paired drug during long-term abstinence from the 
administration paradigm induces the expression of behavioural sensitisation (see Pierce 
and Kalivas, 1997). The observed baseline sensitisation following cocaine pre-treatment 
is in contrast with the hypolocomotion induced by morphine in basal activity of the 
mice (see Chapter 2, Figure 2.6). This discrepancy is due to the anhedonic effects 
induced by chronic morphine administration and withdrawal and consequently the 
decrease in basal locomotor activity compared to the contextual sensitisation induced by 
cocaine administration. Opioids and psychostimulant drugs have been shown to exert
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differential effects after chronic administration as well as during withdrawal, which 
affects their behavioural phenotype (Kreek et ak, 2012).
We hypothesised that the oxytocinergic system may be involved in the observed 
expression of behavioural sensitisation in withdrawn mice since the oxytocinergic 
system interacts with the DA system (see Section 1.8.1) and DAergic neurotransmission 
in the striatum is involved in the modulation of cocaine-induced sensitisation (see 
Narendran and Martinez, 2008) and stereotypy behaviour (Staton and Solomon, 1984, 
Kuczenski et al., 1991, Segal and Kuczenski, 1992). Moreover, cocaine withdrawal has 
been found to induce a marked desensitisation of the DA D% autoreceptors (Jones et al., 
1996, Pierce et al., 1995), an effect which is at least partly responsible for the 
expression of behavioural sensitisation (Antelman and Chiodo, 1981, Dwoskin and 
Zahniser, 1986). Since OTR is co-localised and facilitates allosteric functional 
interactions with D2 receptors in the Acb (Romero-Femandez et al., 2012), it is possible 
that OTR system is involved in the regulation of the basal hyperlocomotor activity 
observed during chronic protracted withdrawal from cocaine. Indeed, OT administration 
has been shown to facilitate cocaine-induced behavioural locomotor sensitisation in 
rodents possibly via interacting with the DAergic system within the striatum (Samyai et 
al., 1992b). Although the present study showed an up-regulation of OTR in the Amy 
and not the striatum following chronic administration of cocaine and withdrawal, it is 
important to highlight the possibility of OTR dysregulation taking place in the Amy, to 
influence DAergic neurotransmission in the Acb and thus modulating the observed 
basal hyperlocomotion and motivation to dmg-taking. A clear connection between the 
Acb and the Amy has been proposed to control limbic function and motivation. For 
instance, it has been suggested that the Ce A affects basal DAergic tone in the VTA,
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thereby regulating DAergic tone in the Acb and modulating the incentive value of 
environmental stimuli (Phillips et ah, 2003).
The dysregulation of the oxytocinergic system during cocaine withdrawal was localised 
in the septum and Amy. Considering the role of the Amy and septum in the 
antidepressant, anxiolytic and/or pro-social actions of OT (Curley et al., 2012, Debiec, 
2005, Domes et al., 2007a, Lukas et al., 2012), the up-regulation of the OTR binding in 
these regions might be a neuroadaptive response of the oxytocinergic system to 
counteract the negative consequences of cocaine withdrawal. Indeed, comorbidity of 
cocaine addiction and depression has been reported (Schmitz et al., 2001) and early 
clinical observations demonstrated that cocaine use and abstinence are able to induce 
anxiety (Mackler and O'Brien, 1992, O'Brien, 1996); also see Section 1.5. These 
findings are supported by several pre-clinical evidence showing that withdrawal from 
cocaine can cause anxiety-and depressive- like behaviour in rodents (Paine et al., 2002, 
Blanchard and Blanchard, 1999, Basso et al., 1999, Ambrose-Lanci et al., 2010, Perrine 
et al., 2008). Therefore, the up-regulation of the OTR density following prolonged 
withdrawal may be a compensatory mechanism to counteract depressive- and anxiety­
like behaviours that serve as motivational trigger to re-take the drug and relapse. Indeed, 
like the case of morphine withdrawal, OTR up-regulation in the Amy and septum was 
associated with emotional impairment (see Chapter 2).
The exact mechanism underlying the persistent central oxytocinergic system 
dysregulation following chronic administration of cocaine needs further investigation. 
However, it can be postulated that the OTR up-regulation may possibly be a 
compensatory consequence of a hypo-oxytocinergic state. In support of this, Samyai et 
al., (1992c) found decreased hypothalamic OT synthesis and reduced plasma OT levels 
in rats chronically treated with cocaine indicating a hypo-oxytocinergic state. Deficits in
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plasma OT levels were also reported in mothers who were exposed to cocaine during 
pregnancy (Light et ah, 2004). In fact, this is in accordance with the morphine data (see 
Chapter 2) where we observed hypo-oxytocinergic activity following chronic morphine 
administration and withdrawal. Generally, an increase in OT peptide or administration 
of an OTR agonist is concomitant with rapid OTR desensitisation, clathrindependend 
internalisation and subsequent downregulation (Evans et al., 1997). Therefore, it is 
likely that the up-regulation of the OTR in the Amy and septum is the result of 
decreased OT levels in the brain, and this mechanism to be at least partly responsible 
for the emotional deficits induced by cocaine abstinence.
Another possible mechanism by which chronic cocaine administration and withdrawal 
induced up-regulation of the OTR binding in stress-related regions of the brain is via the 
hyper-activation of the HP A axis. Indeed, in the present study, we found increased 
corticosterone levels following 14 days of escalating-dose “binge” cocaine 
administration which persisted after 14 days of withdrawal in mice. This finding is 
consistent with Zhou et al., (1999a) who showed that 14-day “binge” cocaine 
administration increased plasma corticosterone and ACTH levels in rats, indicating an 
activation of the HP A axis. Dysregulation of the HP A axis has been associated with 
emotional impairment including depression (see Pariante and Lightman, 2008), anxiety 
(see Graeff, 2007) and social phobia (Condren et al., 2002), which are all consequences 
of cocaine addiction and withdrawal (see Sections 1.5). There is ample evidence 
showing that activation of the oxytocinergic system has a marked anxiolytic, anti- 
aggressive and antidepressant effect, partly by inhibiting CRF release in the Hyp 
(Baumgartner et al., 2008, Kirsch et al., 2005, Di Simplicio et al., 2009, Dabrowska et 
al., 2011, Windle et al., 2004, Neumann et al., 2000b). Therefore, the dysregulation of 
the OTR following cocaine administration and withdrawal may be a cause or a
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consequence of a dysregulated HP A axis. However, this hypothesis needs further 
investigation.
In conclusion, this is the first study to demonstrate profound alterations in the 
oxytocinergic system following chronic cocaine administration and withdrawal in 
specific brain regions. It is also shown that this cocaine-induced up-regulation of OTR 
in the Amy and septum is accompanied by a dysregulation of the HP A axis. This may 
have implications in the understanding of the role of the oxytocinergic system in 
modulating a number of neurochemical and behavioural effects of cocaine including 
behavioural sensitisation, anxiety and depression. Understanding the role of OT may 
prove important for the development of drugs targeting the OTR as useful targets for 
treatment of cocaine addiction and the prevention of relapse.
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CHAPTER 4
Chronic methamphetamine treatment 
induces oxytocin receptor up-regulation 
in the amygdala and hypothalamus via an 
adenosine A2A receptor-independent
mechanism
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4.1 Introduction
Methamphetamine, or methylamphetamine, is the A-methylated analogue of the 
psychostimulant amphetamine sharing common pharmacological properties (Melega et 
al., 1995). MAP is a widely abused drug and its use has become of public health 
concern in many parts of the world. The relatively easy clandestine manufacture and 
consequently low street cost of MAP has meant that its use has reached near-epidemic 
proportions in the United States (see Gonzales et al., 2010) and multiple cases of 
epidemic MAP use in Japan have been also reported (see Wada, 2011). MAP is a highly 
addictive psychostimulant drug (Woolverton et al., 1984) that acutely stimulates DA, 
NA and 5-HT release via either amine redistribution from synaptic vesicles to the 
cytoplasm, or by reversing the action of monoamine transporters (Krasnova and Cadet, 
2009, see Sulzer et al., 2005). Actions of MAP on striatal DAergic nerve terminals are 
hypothesised to account for its acute rewarding effects (Vollm et al., 2004).
Chronic use of MAP leads to neurotoxic effects by either damaging the striatal DAergic 
neurons (Wagner et al., 1980), or by the formation of reactive oxygen species (O'Dell et 
al., 1991, Cubells et al., 1994, Yamamoto and Zhu, 1998, LaVoie and Hastings, 1999), 
or even via glutamate excitotoxicity as a consequence of MAP-induced glutamate 
release in the striatum (Nash and Yamamoto, 1992, Abekawa et al., 1994, Stephans and 
Yamamoto, 1994). Repeated administration of MAP has also been shown to induce 
emotional impairments including social avoidance and isolation, aggressiveness, 
depression and anxiety and can also induce psychotic behaviour in humans (Grant et al., 
2012, McKetin et al., 2011). Currently, pharmacotherapy for addiction to 
psychostimulant drugs, including MAP, is limited (Ciccarone, 2011).
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Although several mechanisms have been suggested, the molecular mechanism 
underpinning the addictive properties of chronic MAP use and its behavioural and 
emotional consequences remain unclear. More recently, centrally administered OT has 
been shown to reduce both MAP-induced hyperlocomotion and DA release in the Acb 
in mice (Qi et al., 2008), demonstrating a key role for OT in the modulation of 
behavioural effects of MAP, possibly via a DAergic-dependent mechanism. Moreover,
i.c.v. OT treatment attenuated MAP-induced CPP and abolished stress-induced 
reinstatement to MAP-seeking in mice (Qi et al., 2009). In rats, peripheral treatment 
with OT reduced MAP self-administration and MAP-induced reinstatement (Carson et 
al., 2010a), providing further evidence for its “antireward/anticraving” and relapse 
prevention potential for MAP addiction. Interestingly, OT also reduced MAP-induced 
Fos neuronal activation within the STh and the Acb core of rats (Carson et al., 2010b), 
which are part of the basal ganglia. Given the prominent role of the basal ganglia in the 
rewarding, motivational, motor, compulsive and stereotypic behavioural effects of MAP 
(Bergman et al., 1990, Canales and Graybiel, 2000, Chiang et al., 2009, Klavir et al., 
2009, Lardeux and Baunez, 2008, Smith-Roe and Kelley, 2000, Winter et al., 2008), 
these results provide further insight into the way in which OT might moderate 
rewarding and compulsive behavioural effects of MAP. Nonetheless, the mechanism by 
which the oxytocinergic system modulates these addictive processes remains unclear.
A mechanism underlying the beneficial effect of OT on modulating MAP’s behavioural 
effects may involve an interaction with adenosine A2A receptors. There is emerging 
evidence suggesting an involvement of central adenosine A2A receptors on endogenous 
oxytocinergic function in the brain. Indeed, the ubiquitous neuromodulator adenosine 
has been shown to play an integral role in the neuroendocrine function of SON neurons 
(vasopressin and oxytocin containing), via its action on Ai and A2A receptors. While Ai
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activation suppresses neurons of the SON (Ponzio and Hatton, 2005), activation of A2A 
receptors located on post-synaptic SON neurons and astrocytes causes depolarisation 
and excitation of those neurons (Ponzio et al., 2006). Although yet unknown, it is likely 
that A2A receptors may facilitate the excitation of other oxytocinergic neuronal sub­
populations (e.g. PVN projections to the reward centers of the brain). Similarly to the 
effect of OT, activation of A2A receptors has a prominent role in modulating MAP 
behavioural effects including attenuation of MAP-induced hyperactivity (Shimazoe et 
al., 2000) and stimulus discrimination (Munzar et al., 2002), at least partly by inhibiting 
MAP-induced elevation in DA output in the striatum (Golembiowska and Zylewska, 
1998, Yoshimatsu et al., 2001).
As a result, it is likely that OT might exert its modulatory effect on MAP-induced 
behaviours via an A2A receptor-dependent mechanism. At the receptor level, while 
structural interactions between OTR and A2A receptors have yet to be identified, A2A 
receptors are well known to be co-localised and form opposing functional interactions 
with DA D2 receptors in the striatum (Ferre et al., 2007, Ferre et al., 2008). DA D2 
receptors are strongly associated with addictive processes and are consistently decreased 
in human drug addicts (Voikow et al., 2009) including MAP abusers (Volkow et al., 
2001, Hume et al., 1996) and in animal models of MAP addiction (Kokoshka et al.,
1998). As OTR and D2 receptors have recently been shown to co-localise and facilitate 
allosteric functional interactions in the Acb (Romero-Femandez et al., 2012), it is 
tempting to speculate that OTR may also co-localise and/or functionally interact (i.e. 
form heterodimers) with A2A in the striatum and this interaction might be involved in 
the modulatory effect of OT on MAP-induced behavioural effects.
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Based on the above, it has been hypothesised that chronic MAP use induces profound 
alterations in the oxytocinergic system, which may be involved in the modulation of 
various behavioural and neurochemical effects of the drug. To test this hypothesis, this 
study aimed firstly to investigate whether chronic MAP administration induces 
alterations in the central OTR system in the mouse brain with the use of quantitative 
receptor autoradiographic binding. Further, autoradiographic OTR binding in brain 
sections of wild-type (WT) and A ia  receptor knockout (AiaR'^') mice treated with a 
chronic steady-dose MAP administration paradigm was carried out to demonstrate 
whether possible MAP-induced alterations in the OTR system are mediated via an A ja 
receptor-dependent mechanism.
180
4.2 Methods
4.2.1 Maintenance and genotyping of the adenosine A2A receptor knockout mouse 
colony
The CD-I adenosine A2aR' '^ mice were originally created by Ledent et a l (1997) and 
generously supplied in order to maintain a breeding colony within the University of 
Surrey. The mice were bred from heterozygote breeding pairs which originated from the 
original crossing of a number of heterozygote males from the existing colony each with 
a WT female from an external supplier (Charles River, Margate, Kent, UK). The male 
and female heterozygotes from the litters of the newly created breeding pairs were 
paired and these formed the main breeding colonies which were maintained for 
approximately one year before new breeding pairs were created. The mice were housed 
in groups of approximately 4-5 mice per cage in a temperature-controlled environment 
on a 12 hour light-dark cycle (lights on: 06:00am) and were fed a standard diet with 
water available ad libitum. All experimental procedures were conducted in accordance 
with the UK Animal Scientific Procedures Act (1986).
A polymerase chain reaction (PCR) based method was used to genotype the mice at 
weaning (three weeks old). Tail tip samples of no more than 3 mm were taken from 
each mouse and deoxyribonucleic acid (DNA) was extracted using the DNeasy tissue 
kit (Qiagen, Hilden, Germany), following the manufacturer’s protocol. In brief, all 
samples were incubated in a water bath at 55°C with proteinase K (Sigma-Aldrich, 
Dorset, UK) overnight. The following day cells in the sample were lysed with ethanol 
and transferred to individual spin columns, composed of a silica-gel membrane allowing 
DNA to selectively bind. Two centrifugation steps with washes followed, removing any 
contaminants and binding the DNA to the column. The spin columns were transferred to 
collection tubes and the DNA extracted upon the addition of a buffer, releasing the
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DNA from the membrane. The extracted DNA was then subjected to PCR amplification 
using puReTaq Ready-To-Go PCR beads (GE Healthcare, Buckinghamshire, UK) and 
three custom primers (Sigma-Genosys, Suffolk, UK):
1) The common forward primer: AGTCATGGTTTCGGGAGATG
2) The wild-type reverse primer: ACCATGATGTACACCGAGGAG
3) Adenosine A2A receptor knockout primer: AAGG A AGGGT G AG AAC AG AG
These were used to selectively amplify fragments of different sizes from the WT and 
adenosine A2A receptor knockout alleles. Primers 1 and 2 amplified a 229 base pair band 
from the WT allele, whereas primers 1 and 3 amplified a 572 base pair from the mutated 
allele. Heterozygous mice carrying a copy of both alleles resulted in 2 bands, enabling 
the identification of the 3 genotypes (Figure 4.1). A total volume of 25 pi per reaction 
was made up of 2 pi of each primer, 6 pi of DNA sample and 13 pi of double-autoclaved 
MilliQ water. The cycle parameters for the PCR were as follows:
1) Pre-cycle 2 minutes 94°C
2) Dénaturation 30 seconds 94°C
3) Annealing 1 minute 15 seconds 72°C
4) Elongation 1 minute 72°C
5) Post-cycle 5 minutes 72°C
This process was repeated for 40 cycles.
The PCR products were separated by gel electrophoresis using 2% agarose double comb 
e-gels (Invitrogen, Carlsbad, CA, USA) allowing the identification of the genotypes by 
comparison to the HyperLadder I DNA ladder (Bioline, London, UK); see Figure 4.1.
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Figure 4.1: Representative sample showing the separation of the PCR product of the 
genotyping reaction visualised by gel electrophoresis.
Lane 1: +/+ wild-type allele, 229 base-pairs (bp), Lane 2: +/- heterozygote, 229 and 572 bp. Lane 3: 
DNA Ladder, Lane 4: -/- À2a receptor knockout allele, 572 bp.
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4.2.2 Animals
Male, 8-12 week old CD-I wild-type and AiaR’^’ mice, derived from a heterozygous 
breeding programme were used in this study, as detailed in Section 4.2.1. Mice were 
singularly housed for a period of 7 days prior to the start of the study and throughout the 
whole study period. Mice were habituated to home cages and experimenter handling for 
one week before the start of experiment. The home cages were in a temperature- 
controlled environment and on a 12 hour light-dark cycle (lights on: 06:00am). Whilst 
in home cages, mice had access to food and water ad libitum. All experimental 
procedures were conducted in accordance with the UK Animal Scientific Procedures 
Act (1986).
4.2.3 Chronic steady-dose methamphetamine administration paradigm
Mice were randomly divided into four groups; chronic saline-treated WT and A2aR’^’ 
and chronic MAP-treated WT and A2aR' '^ treated animals. Chronic MAP-treated 
animals were injected i.p. for 10 days with MAP (1 mg/kg) (Sigma-Aldrich, Poole, UK), 
once per day (11:00), in accordance with small modifications of studies carried out by 
Liang et al., (2006). The chronic saline-treated group were administered with saline (4 
ml/kg, i.p.) for 10 days, once per day (11:00).
4.2.4 Autoradiographic binding of the adenosine A%A receptor
In order to confirm that the genotype of mice used had been correctly identified by 
PCR, autoradiographic binding of the adenosine A2A receptor was undertaken in all 
experimental mice used.
Sections were taken from the brains of all the experimental mice. Adjacent non-specific 
binding slides were not required to conduct qualitative confirmation of A2A receptor 
binding. Slides were defrosted thoroughly for 30 minutes and then pre-incubated at
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room temperature for 30 minutes in a 170 mM Tris-HCl buffer (pH 7.4) containing 1 
mM EDTA and 2U/ml adenosine deaminase (Sigma-Aldrich, Dorset, UK). The A2A 
receptor agonist [^H]-CGS 21680 (Amersham International pic., Buckinghamshire, UK) 
was used to label A2A receptors at a 10 nM concentration, 3-4 times Kd of ligand as 
previously described in the literature (Johansson and Fredholm, 1995, Bailey et al., 
2002b). Total binding was determined by incubating the sections with lOnM [^H]-CGS 
21680 in an incubation buffer solution (50 mM Tris-HCl and 10 mM MgCl2,pH 7.4 for 
2 hours at room temperature. The slides were then washed 3 times for 5 minutes in ice- 
cold rinse buffer (170 mM Tris-HCl, pH 7.4) followed by a 5 minute rinse in ice-cold 
distilled water. The slides were dried under a cold stream of air for 2 hours and stored in 
an airtight box with anhydrous calcium sulphate for 7 days at room temperature for 
further drying. Radioligand bound sections were apposed to film for a period of 3 weeks 
(at room temperature).
4.2.5 Autoradiographic binding of the oxytocin receptor
Tissue preparation, quantitative autoradiographic binding of the OTR and subsequent 
autoradiographic procedures were carried out as detailed in Section 2.2.4.1.
4.2.6 Statistical analysis
Three-way ANOVA for the factors treatment, genotype and brain region were used to 
compare receptor binding levels in saline- and MAP-treated, WT and adenosine A2aR’^ ’ 
animals. Moreover, two-way ANOVA was performed in each individual brain region 
for factors ‘treatment” and ‘genotype’. All statistical analyses were performed using 
Statistica 8.0 analysis program (StatSoft Inc., France). Where ANOVA yielded 
significant main effects (p<0.05), a Bonferroni post-hoc test was carried out. All the 
values are presented as mean ± SEM of 5-6 animals/group.
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4.3 Results
4.3.1 Autoradiographic binding of the adenosine A%A receptor for genotype 
confirmation in wild-type and adenosine A%A receptor knockout mice used 
in methamphetamine experiments
Sections from the brains of each experimental animal were bound with the radiolabelled
A2A receptor agonist [^H]-CGS 21680 to confirm that the genotype determined by the
PCR and DNA electrophoresis procedures were coiTect. Autoradiographic binding
confirmed genotyping was correct in all animals. Representative images showing the
presence (WT) and absence (A2AR ) of A2A receptors are shown in Figure 4.2.
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Figure 4.2: Representative computer-enhanced pseudocolour autoradiograms of adjacent 
coronal brain sections labelled with [^H]-CGS 21680 from wild-type and adenosine A?A 
receptor knockout mice.
Brain sections were incubated for 120 min in ['^H]-CGS 21680 (lOmM) to label A?A receptors. 
Sections presented are taken from the level of the striatum (Bregma 1.18mm and 0.62mm, first and 
second row respectively), at the level o f the globus pallidus (Bregma -1.22 mm, third row) and at the 
level of the thalamus (Bregma - 1.94 mm, fourth row).
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4.3.2 Chronic administration of methamphetamine induced region-specific 
alterations of [^ ^^ I]-OVTA binding following chronic methamphetamine 
treatment in both wild-type and A2A receptor knockout mice
High levels of OTR binding (1.17-1.46 fmol/mg) were observed within the olfactory
nuclei, moderate levels (0.33-0.85 fmol/mg) in the Pir, septum, Amy and Hyp, and low
levels (0.03-0.24 fmol/mg) in the cingulate cortex, thalamus, Acb, olfactory tubercle,
caudate-putamen in all treatment groups (Figure 4.3). Three way-ANOVA showed
significant ‘treatment’ effect ( F [ i , 2 7 3 ] = 1 3 . 2 2 , a n d  region effect (F[i4,2?3]=4.27,
p<0.001). No effect of ‘genotype’ (p>0.05) or ‘genotype’ x ‘treatment’ interaction
effects were observed (p>0.05). Two way-ANOVA for factors ‘treatment’ and
‘genotype’ in each individual brain region revealed a significant treatment effect in the
Amy (F[i,i9]=73.21, p<0.001) and the Hyp (F[ij9j=28.08, p<0.001) but no effect of
genotype was observed in any of these brain regions (p>0.05). Chronic MAP treatment
induced OTR up-regulation in both WT (78%) and A2aR’^ ' mice (54%) in the Amy and
52% (WT) and 55% (A2aR’^ ') in the Hyp (Figure 4.3). Chronic MAP administration
significantly increased OTR binding in both the Amy (p<0.00\) and the Hyp (p<0.001)
of WT and A2aR'^' mice compared with their saline controls (Bonferroni post-hoc
analysis). No other treatment or genotype effect was observed in any other brain regions
analysed (p>0.05).
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Figure 4.3: Region-specific up-regulation of [*^ '’I]-OVTA binding following chronic 
methamphetamine administration in wild-type and A%A receptor knockout mice.
Male WT and mice were treated with either saline or MAP with a 10-day steady-dose
paradigm ( 1 x 1  mg/kg, i.p. per day). (A) Computer-enhanced representative autoradiograms of 
adjacent coronal brain sections from chronic saline and MAP WT and A2aR  ^ mice at the level o f the 
olfactory nuclei (Bregma 2.46, first row), the caudate (Bregma 0.86mm, second row), the septum 
(Bregma 0.14, third row) and the thalamus (Bregma -2.06, fourth row). OTRs were labelled with 
[ '“^1]-0VTA (50pM). The colour bar illustrates a pseudo-colour interpretation o f black and white 
film images in fmol/mg tissue equivalent. Representative images for the non-specific binding (NSB) 
(50pM ['^^I]-OVTA in the presence o f 50pM unlabelled oxytocin) are shown for all the treatment 
groups. (B) Quantitative oxytocin receptor autoradiographic binding from WT and A2aR’^ ' mice 
treated with a chronic MAP administration paradigm. Data are expressed as mean ± SEM (n=5-6 
per group) specific binding of [’^^1]-0VTA (fmol/mg tissue) in left and right brain hemispheres.
***^<0.007 V.9 WT Saline; A2AR'^ ' Saline (Two-way ANOVA
followed by Bonferroni post-hoc test).Abbreviations: Acb, nucleus accumbens; Amy, amygdala; 
AOL, anterior olfactory nucleus-lateral; AOM, anterior olfactory nucleus-medial; AOV, anterior 
olfactory nucleus-ventral; CgCx, cingulate cortex; CPu, caudate-putamen; Hip, hippocampus; LS, 
lateral septum; MS, medial septum; Pir Cx, piriform cortex; Th, thalamus; Tu, olfactory tubercle; 
VDB, ventrical limb of the diagonal band of Broca; VMM, ventromedial hypothalamus.
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4.4 Discussion
This is the first study to demonstrate profound region-specific alterations of the OTR 
system in the brain following chronic MAP administration, which may be involved in 
the modulation of long-term behavioural and neurochemical adaptations taking place 
during and following chronic drug use. The present data show that in WT and A2aR’^ ’ 
mice, chronic MAP induces a 50-80% increase of OTR binding in the Hyp and Amy 
and also demonstrated that this dysregulation of the OTR system is not dependent on an 
A2A receptor-mediated mechanism.
Although dysregulation of the oxytocinergic system have been reported following acute 
or repeated alcohol (Kovacs et al., 1998), cocaine (Samyai, 1998, Samyai et al., 1992c), 
y-hydroxybutyric acid (GHB) (van Nieuwenhuijzen et al., 2010), MDMA (Thompson et 
al., 2007) and morphine (Kovacs et al., 1987a) administration in different brain regions 
of rodents, this is the first study to report any oxytocinergic neuroadaptations following 
chronic MAP administration. The up-regulation of the OTR following chronic MAP 
treatment was localised in the Amy and the Hyp, two regions involved in stress 
regulation. This is in agreement with van Nieuwenhuijzen et al., (2009, 2010), who also 
showed an increase in hypothalamic OTR and OT mRNA levels following repeated 
administration of other dmgs of abuse (GBH and MDMA respectively) in the rat; and 
an increase of OTR binding in the Amy following treatment with cocaine in rat dams 
(Johns et ah, 2004). In contrast to the present results, Jarrett et al., (2009) observed a 
reduction in OTR binding density in the ventromedial hypothalamus and failed to 
demonstrate an increase of OTR binding in the central nucleus of the Amy of 
postpartum rat dams repeatedly treated with cocaine. Nonetheless, the MAP-induced 
up-regulation observed in our study was profound (50 %) and was replicated in 
genetically modified A2aR'^' mice.
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The significance of this MAP-induced up-regulation of OTRs is yet to be determined. 
However, given the ability of OT to modulate MAP-induced hyperactivity (Carson et 
al., 2010a, Qi et al., 2008) and to attenuate MAP-induced CPP (Qi et al., 2009) and 
stress- and priming-induced reinstatement of MAP self-administration (Carson et al., 
2010a), or CPP (Qi et al., 2009), it is likely that this oxytocinergic alteration may 
underlie some behavioural consequences of chronic MAP use. Indeed, it has been 
suggested that based on the ability of OT to supress c-Fos activity in brain regions 
associated with motivation and reward such as subthalamic nucleus (STh) and the Acb 
(Carson et al., 2010b), and the ability of OT to reduce MAP-induced DA activity in Acb 
(Qi et al., 2008), OT may be involved in the modulation of the incentive motivational 
properties of MAP. Based on these observations, alterations of OTR would have been 
expected in the STh and the Acb following chronic MAP treatment. The reason why 
these alterations were not observed in these regions may be due to the relatively low 
expression of OTR in these regions in the CDl mouse used in the present study (Figure 
4.3). This does not, however, preclude the possibility that changes in OT release occur 
in these brain regions following chronic MAP administration, which may indeed lead to 
long-lasting morphological, functional and behavioural changes.
It is also important to highlight the possibility of OTR dysregulation taking place in the 
Amy in the present study, to influence DAergic neurotransmission in the Acb and thus 
motivation of MAP-seeking behaviour. A clear connection between the Acb and the 
Amy has been proposed to control limbic function and motivation. For instance, it has 
been suggested that the CeA affects tonic DAergic tone in the VTA, thereby regulating 
DAergic tone in the Acb and modulating the incentive value of environmental stimuli 
(Phillips et al., 2003). As a result the profound up-regulation of OTR system following
190
chronic MAP administration in the Amy may affect DA levels in the Acb in order to 
modulate its addictive-related behavioural effects.
The Amy is a limbic structure which is involved in a number of facets of emotional 
analysis (Phelps and LeDoux, 2005) and is a key component of social cognitive 
circuitry in both animals and humans (Rosenfeld et al., 2011). There is considerable 
evidence demonstrating abnormalities in the Amy following chronic MAP use (Kim et 
al., 2011, London et al., 2004), which are likely to be at least partly responsible for the 
development of anxiety, stress, depression (Dawe et al., 2009, Goeldner et al., 2011, 
Morley et al., 2001, Thompson et al., 2004) and social cognitive deficits (Dawe et al., 
2009, Volkow et al., 2011) following chronic drug use. As a result, it is possible that the 
up-regulation of amygdalar OTR following chronic MAP treatment might be involved 
in the modulation of the aforementioned behaviours. There is a growing body of 
evidence demonstrating the anxiolytic, antidepressant and stress relieving properties of 
OT partly due to its action in the Amy (see Debiec, 2005). In addition, the Amy is partly 
responsible for the pro-social behavioural enhancing properties of OT (Domes et al., 
2007a). It is not clear if the up-regulation of OTR in the Amy is a rebound consequence 
of a possible reduction of OT release in the brain following chronic MAP administration 
or if there is an independent mechanism involved. Nonetheless, the results clearly 
demonstrate an increased sensitivity of the OTR system in the Amy which may 
represent a compensatory homestatic mechanism to oppose the anxiogenic, stress- 
inducing and/or social deficit consequences of chronic MAP use. In support of this 
compensatory mechanism, OT release and OTR binding has been shown to be increased 
in brain regions, including the Amy, following chronic stress in rats (Ebner et ah, 2005, 
Landgraf and Neumann, 2004, Liberzon and Young, 1997) and OT'^' mice exhibit 
increased anxiety (see Baskerville and Douglas 2010); also see Section 1.6.4.
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Interestingly, the medial Amy is also strongly implicated in sexual behaviours and 
social bonding. These behaviours are strongly influenced by OT (see Baskerville and 
Douglas 2008). For instance, OT and MAP have been shown to act synergistically and 
there is some evidence that this synergistic interaction may enhance social and sexual 
responses (Holder et al., 2010). As a result the up-regulation of the OTR in the Amy 
may be involved in the sexual enhancing and pro-social properties of MAP. This is 
supported by Carson et al., (2010a) who suggested that exogenous OT treatement may 
be effective in decreasing MAP self-administration by enhancing the incentive salience 
value of social interactions relative to that provided by drug-related cues. In addition, 
Broadbear et al., (2011) recently demonstrated that the OT is involved in the pro-social 
effects of another psychostimulant drug, MDMA; however the pro-social effects of 
MDMA markedly depend on the activation of the oxytocinergic system (see McGregor 
et ah, 2008), while this is not the case with MAP-induced pro-social effects that need 
further investigation.
Moreover, chronic MAP administration also induced an up-regulation of OTR in the 
Hyp, another brain region associated with stress regulation. Although the 
behavioural/functional significance of this up-regulation is unclear, it may represent a 
compensatory mechanism to oppose the anxiogenic, stress-inducing, consequences of 
chronic MAP use. OT release in the Hyp is known to regulate HP A axis activity and 
thus stress. OT has been shown to have a marked anxiolytic, anti-aggressive and 
antidepressant effect in humans (when administered as an intranasal spray) 
(Baumgartner et ah, 2008, Kirsch et ah, 2005, Di Simplicio et ah, 2009) and in animal 
models (Dabrowska et ah, 2011, Windle et ah, 2004), primarily by inhibiting CRF 
release from the Hyp (see Neumann et ah, 2000b). As a result, the MAP-induced 
activation of the OTR system may be counterbalancing the stress and anti-social effects
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of MAP both by its action in the Hyp and in the Amy. This would imply that 
dysfunction of this MAP-induced oxytocinergic system regulation may lead to the 
release of the “brake”, thus triggering more severe anxiety, stress and social recognition 
deficits; however, this hypothesis remains to be explored.
Based on the evidence suggesting an involvement of central adenosine A2A receptors on 
the endogenous oxytocinergic function in the brain (Ponzio et al., 2006), we 
hypothesised that the neuroadaptations of the OTR system following chronic MAP 
administration may be mediated by an A2A receptor-dependent mechanism. However, as 
in WT mice, the profound up-regulation of OTR following chronic MAP administration 
was also observed in the Hyp and Amy of MAP-treated A2aR'^' mice clearly 
demonstrating a lack of A2A receptor involvement in this region-specific up-regulation. 
The reason that we did not observe any modulation of this MAP-induced up-regulation 
in A2aR’^’ mice might be due to the low expression of A2A receptors in these brain 
regions (Figure 4.2). Although, there is some evidence of A2A receptor expression in the 
Amy (Mak et al., 2012, Hume et al., 1996) and Hyp (Volkow et al., 2009, Kokoshka et 
al., 1998), our autoradiographic binding revealed that A2A receptors are almost entirely 
restricted to the striatum (Figure 4.2). As a result, the lack of A2A receptors in those low 
A2A receptor expressing regions is unlikely to influence OTR binding. This of course 
does not preclude the possibility of A2A receptors affecting oxytocinergic function by 
modulating OT release. Indeed, A2A receptors have been shown to be localised post- 
synaptically on SON neurons and activation of those receptors to cause depolarisation 
and excitation of OT-containing neurons (Ponzio et al., 2006). Therefore, it would be 
worth investigating if OT peptide release is affected by A2A receptor deletion in MAP- 
treated mice and whether A2A receptors are involved in the modulatory properties of OT 
on methamphtamine-induced behaviours, by modulating its release.
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It is important to point out here that, despite its significant contribution towards 
understanding the mechanisms underlying the effects of drugs of abuse, full 
developmental knockout mouse technology does not come without limitations (see Yoo 
et ah, 2012). One of the problems arising from studies in knockout mice is the 
emergence of compensatory adaptations of various systems in the mouse triggered by 
the gene deletion. For instance, an up-regulation of opioid receptors has been observed 
in preproenkephalin and preprodynorphin knockout mice (Clarke et ah, 2003). In the 
case of A2aR'^’ mice, we showed no compensatory changes in D2R, MOPr, DOPr, 
KOPr, a4p2 and a7 nAChR binding (Bailey et ah, 2004, Bailey et ah, 2002a, Campbell 
et ah, 2009). No change in OTR was also observed in saline-treated A2aR'^’ vs WT in 
the present study. As a result, we can conclude that it is unlikely that the up-regulation 
of OTR in chronically MAP-treated A2aR'^’ mice are caused by compensatory 
neuroadaptations induced by A2A gene deletion, but rather to the effect of the 
psychostimulant itself.
This is the first study to show profound alterations in the oxytocinergic system 
following MAP administration in specific brain regions. We showed that this MAP- 
induced up-regulation of OTR in the Hyp and Amy does not depend on the presence of 
A2A receptors. This has implications for the delineation of the role of endogenous 
oxytocinergic system in modulating a number of MAP effects including social 
behaviour, anxiety and addiction. Understanding the role of the oxytocinergic system 
may prove important for the development of drugs targeting the OTR as useful 
pharmacotherapy for treatment of MAP dependence.
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CHAPTER 5
General Discussion
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5.1 General Discussion
This thesis investigated the role of the neuropeptide oxytocin in psychostimulant and 
opioid addiction. Previous research has raised questions as to whether the oxytocinergic 
system is involved during chronic administration and withdrawal from addictive 
substances and whether it is implicated in the emergence of emotional impairment 
following prolonged abstinence from drug administration. The studies presented in this 
thesis provide clear evidence for critical alterations that occur in the oxytocinergic 
system during protracted withdrawal from drug administration that is accompanied by 
negative emotional symptoms and social deficits. Moreover, we show that an acute 
administration of an oxytocin analogue prevents the emotional impairment associated 
with long-term abstinence from opioid administration.
5.1.1 Oxytocin analogues: Novel pharmacotherapy to assist with relapse 
prevention
The present pre-clinical work demonstrated for the first time that oxytocin may be an 
effective therapeutic intervention to prevent emotional deficits during protracted 
abstinence from drugs of abuse and, thus, to assist with relapse prevention. Indeed, the 
presence of mental comorbidities (e.g. depression, anxiety, social phobia) among 
addicts is associated with poor treatment outcomes (Deas, 2006), and serve as a 
motivational trigger to re-take the drug and relapse during abstinence (Le Moal and 
Koob, 2007). The effectiveness of classic antidepressants in treating these comorbidities 
among opioid-abstinent individuals is limited (Nunes et al., 2004), therefore, novel 
pharmacotherapies are needed to assist with relapse prevention. The present work, not 
only adds to the existing evidence for an important role of the oxytocinergic system in 
opioid addiction but it also points towards the need for randomised double-blind control
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trials with opioid addicts undergoing detoxification to investigate the effects of 
intranasally administered OT in reducing comorbid emotional disorders and preventing 
relapse. In fact, we have recently shown that CBT is able to prevent stress-induced 
reinstatement to opioid-seeking following withdrawal, by using the conditioned-place 
preference paradigm in mice (unpublished data).
Furthermore, the present study is the first study to show that a single administration of 
an oxytocin analogue was able to restore social deficits associated with protracted 
opioid abstinence. This finding is of particular importance since prolonged use of drugs 
of abuse results in disintegration of the social lives of drug addicts and may lead to 
social isolation and poor decision making in their social domain at the expense of 
compulsive pre-occupation with the drug and its related cues (Dawe et ah, 2009, 
Volkow et ah, 2011). Impaired social behaviours have been linked with the propensity 
of addicts to relapse after long-term abstinence (see Section 1.5.3). Therefore, 
considering the therapeutic effects of social support programs (e.g. Alcoholics 
Anonymous) and the benefits of social rehabilitation and social reintegration in keeping 
addicts abstinent from the drug (Koemer, 2010, McGregor and Bowen, 2012), our 
findings may implicate the use of oxytocin agents as an adjunct to Cognitive 
Behavioural Therapy as a novel effective “psycho-biological therapy” for the 
prevention of relapse to drug-seeking. In support of this, there is clinical evidence for a 
possible beneficial role of OT in the treatment of other disorders characterised by social 
cognitive impairment including autistic spectrum disorders and schizophrenic patients 
(Carter, 2007, Heinrichs and Gaab, 2007).
Even though the present thesis clearly demonstrated the dysregulation of the 
oxytocinergic system at least at the receptor level following cocaine withdrawal it did
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not extend on the behavioural consequences of cocaine abstinence and the possible 
effects of the oxytocin analogues in preventing any emotional impairment. Therefore, 
future work must be focusing to investigate the behavioural effects of other drugs of 
abuse during abstinence and the effects of the activation of the oxytocinergic system at 
this time point. Although the present study clearly showed that acute administration of 
the oxytocin analogue carbetocin blocks emotional despair during protracted opioid 
withdrawal, one concern for studies looking at effects of exogenously administered OT 
is that OT has a very short plasma (3-5 min) and central (30 min) half-life (Ludwig and 
Leng, 2006, Uvnas-Moberg, 1998, Engstrom et al., 1998). However, intranasal 
administration of OT has been shown to induce more prolonged release of at least 80 
min (Burri et al., 2008) and has extended biological (endocrine and sexual) activity, 
even after a single dose in humans (Uvanas-Moberg et al., 2005). Moreover, 
intranasally administered oxytocin has been shown to cross the EBB and to exert central 
effects (Born et al., 2002, Chang et al., 2012, Pedersen et al., 2013). Nonetheless, the 
development of smaller non-peptide OT agonists with high specificity for central OTRs 
is undoubtedly desirable.
One important question that has yet to be addressed is whether long-term administration 
of oxytocin can cause any side effects. In fact, high doses of i.v. OT have been 
associated with severe cardiovascular side-effects including hypotension and 
myocardial ischemia (Dyer et al., 2011). Concerns also include the safety of oxytocin 
administration in females at different reproductive phases due to the peripheral effects 
of OT (i.e. milk ejection, labour induction). Also, chronic OT administration has the 
potential to cause electrolyte imbalances due to its structural similarity to arginine 
vasopressin and its effects in the kidneys (Rasmussen et al., 2004). Furthermore, it must 
be considered as to whether OT-based interventions are rewarding and/or have
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dependence liability. However, CBT, at least for the dose tested in this thesis (6.4 
mg/kg), was found to be neither rewarding, nor aversive, in mice.
5.1.2 Dysregulation of the oxytocinergic system; Common neurobiological 
mechanism underlying negative emotional symptoms of drug abstinence
The data presented in this thesis strongly suggest that the potential therapeutic effects of 
oxytocin analogues on the negative emotional symptoms induced by drug abstinence are 
mediated by alterations in the central oxytocinergic system and recognise the Amy as a 
potential site for this action. More specifically, we have demonstrated a hypo- 
oxytocinergic state as observed by decreased OT levels in Hyp and plasma, and a 
common up-regulation of OTR binding at the level of Amy following protracted 
withdrawal from opioids and an up-regulation of the OTR binding in the Amy following 
both cocaine and MAP administration, which in the case of cocaine it persistent after 
protracted withdrawal in mice.
Although the behavioural consequences of dysregulation of the oxytocinergic system 
during abstinence need further investigation, based on the findings of the present work 
it is highly likely to be involved in the modulation of withdrawal-associated anxiety, 
depression and social deficits. Given the anxiolytic, antidepressant and social enhancing 
effects of OT administration in humans when administered with an intranasal spray 
(Baumgartner et al., 2008, Kirsch et al., 2005, Di Simplicio et al., 2009), or in animal 
models when administered centrally or peripherally (Dabrowska et al., 2011, Windle et 
al., 2004), this dysregulation of the OTR system in the Amy may constitute a 
neurobiological mechanism to counteract the negative emotional state induced by 
chronic drug administration and abstinence. This hypothesis is further supported by the 
presence of a similar pattern of hypo-oxytocinergic state and OTR up-regulation in the 
Amy to that observed in other mental disorders characterised by emotional and social
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impairments, including schizophrenia (see Kring and Moran, 2008). For example, 
chronic administration of the NMDA receptor antagonist phencyclidine that induces 
similar behaviours to schizophrenia including social withdrawal (Sams-Dodd, 1999, 
Qiao et al., 2001), decreased OT mRNA expression in the Hyp and increased OTR 
binding in the CeA (Lee et al., 2005). In addition, direct OT infusion into the CeA 
restored the social behaviour of these animals to a level similar to the controls (Lee et 
al., 2005).
Clearly, further work is required to investigate the underlying neurobiological 
mechanisms underpinning the dysregulation of the oxytocinergic system in the Amy 
and the association of these alterations with emotional impairment during drug 
abstinence. Firstly, it would be of great interest to investigate whether abstinence from 
other addictive substances such as nicotine and alcohol induce similar dysregulation of 
the oxytocinergic system within the Amy. Moreover, microdialysis studies are needed 
to measure the exact OT release in several brain nuclei, especially the Amy, since an 
important limitation of the ELISA assay that has been used in the present study is that it 
can only detect peptide content and not release. In addition, the development of a 
knockout mouse model lacking the OTR gene specifically in the Amy and its 
behavioural phenotypic characterisation under basal and drug withdrawal conditions 
would be of particular importance. This model would potentially give an insight into the 
behavioural alterations induced by dysregulation of the OTR in the Amy. With regards 
to translational studies, directions for future research would be to measure Amy 
activation after an intranasal OT administration during protracted drug withdrawal by 
means of a double-blind placebo-controlled fMRI scanning trial in humans. In fact, OT 
administration has been shown to attenuate Amy activation to fear in humans (Kirsch et 
al., 2005), which further implicates the amygdalar oxytocinergic system in the
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modulation of emotional impairment. In addition, the development of PET ligands for 
the OTR may be important in the understanding of the changes taking place during drug 
administration and withdrawal in humans. However, the OTR levels in the brain are 
very low in humans (Loup et al., 1991) and the development of PET ligands remains a 
challenging area of research.
The current study also raises the question of whether people with oxytocin receptor 
gene polymorphisms have a differential propensity to develop emotional deficits and 
relapse during long-term withdrawal from drug-taking. There is recent evidence that the 
OTR polymorphism rs53576G rendered social support more effective in buffering 
against stress in humans (Chen et al., 2011). This is an important finding since 
psychosocial support has been shown to assist with the prolongation of a drug-free 
abstinent state in recovering addicts. Therefore, OTR polymorphisms in the Amy may 
predict the efficacy of psychosocial support in retaining abstinence from drug-taking.
5.1.3 Concluding remarks
Collectively, the results described in this thesis show that the central oxytocinergic 
system is involved in different phases of drug addiction and that the exogenous 
administration of an OT analogue is beneficial in preventing the negative psychological 
withdrawal symptoms of opioids during long-term abstinence (for a proposed 
mechanism see Figure 5.1). These results are supportive of the oxytocinergic system as 
a novel target for the treatment of addiction-mood disorders comorbidity, which could 
assist with relapse prevention. They also highlight the dysregulation of this system as an 
underpinning mechanism linking mood disorder comorbidity, at least during opioid 
abstinence. In light of the significant benefits that psychosocial support has in 
preventing relapse to drug-taking after abstinence, the combination of both social
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support and oxytocin administration might be proved a novel beneficial and effective 
“psycho-biological therapy” for the treatment of addiction.
Oxytocin analogues
©
Negative emotional 
state (depressitm, anxiety, 
social deficits)
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Drug-seeking
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Figure 5.1: Proposed mechanism for the modulation of the negative emotional symptoms of 
protracted opioid withdrawal by oxytocin.
Protracted abstinence from opioid administration brings about decreased oxytocin levels within the 
hypothalamus and negative emotional symptoms. A rebound up-regulation o f oxytocin receptor 
binding within the amygdala may act as a compensatory mechanism to counteract the negative 
emotional state o f opioid abstinence. Oxytocin analogues activate the oxytocinergic system, thereby 
blocking this negative “psychological” state and may be able to prevent relapse to opioid-seeking 
following abstinence. Dashed line indicates a hypothetical effect o f oxytocin analogues in reducing 
relapse to drug-seeking following abstinence.
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